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A B S T R A C T
The release and absorption profile of an oral medication is influenced by the physicochemical properties of the
drug and its formulation, as well as by the anatomy and physiology of the gastrointestinal (GI) tract. During drug
development the bioavailability of a new drug is typically assessed in early clinical studies in a healthy adult
population. However, many disease conditions are associated with an alteration of the anatomy and/or phy-
siology of the GI tract. The same holds true for some subpopulations, such as paediatric or elderly patients, or
populations with different ethnicity. The variation in GI tract conditions compared to healthy adults can directly
affect the kinetics of drug absorption, and thus, safety and efficacy of an oral medication.
This review provides an overview of GI tract properties in special populations compared to healthy adults and
discusses how drug absorption is affected by these conditions. Particular focus is directed towards non-disease
dependent conditions (age, sex, ethnicity, genetic factors, obesity, pregnancy), GI diseases (ulcerative colitis and
Crohn's disease, celiac disease, cancer in the GI tract, Roux-en-Y gastric bypass, lactose intolerance, Helicobacter
pylori infection, and infectious diseases of the GI tract), as well as systemic diseases that change the GI tract
conditions (cystic fibrosis, diabetes, Parkinson's disease, HIV enteropathy, and critical illness).
The current knowledge about GI conditions in special populations and their impact on drug absorption is still
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T
limited. Further research is required to improve confidence in pharmacokinetic predictions and dosing re-
commendations in the targeted patient population, and thus to ensure safe and effective drug therapies.
ABC ATP-binding cassette
AUC Area under the plasma concentration-time curve
BCRP Breast cancer resistance protein
BCS Biopharmaceutics Classification System
BMI Body-mass index
CD Crohn´s disease
CF Cystic fibrosis
CFTR Cystic fibrosis transmembrane conductance regulator
Cmax Maximum plasma concentration
CYP Cytochrome P450
FDA Food and Drug Administration
GI Gastrointestinal
GLP-1 Glucagon-like peptide 1
H. pylori Helicobacter pylori
HIV Human immunodeficiency virus
IBD Inflammatory bowel disease
ICH International Conference for Harmonization
OATP Organic anion transporting polypeptides
PARKD Parkinson's Disease
PBPK Physiologically-based pharmacokinetic
PEG Polyethylene glycol
P-gp P-glycoprotein
PK Pharmacokinetic
popPK Population pharmacokinetic
RYGB Roux-en-Y gastric bypass
T1DM Type-1 diabetes mellitus
T2DM Type-2 diabetes mellitus
Tmax Time to maximum plasma concentration
UC Ulcerative colitis
UGT 5′-diphospho-glucuronosyltransferase
1. Introduction
Oral dosing is the preferred route of administration as it is con-
venient and safe for most populations (Stewart et al., 2016). Upon oral
administration, the drug is passing through the stomach to the small
intestine where most of the drugs are absorbed. Poorly absorbed drugs,
or drugs in modified release formulations will pass to the colon, where
further absorption can occur. During the development of new medi-
cines, the absorption behaviour of oral compounds is usually studied in
healthy adults. However, the morphology and physiology of the gas-
trointestinal (GI) tract is influenced by multiple factors such as age, sex,
ethnicity, genome, or the disease state of the treated patient. These
factors can significantly alter the kinetics of drug absorption, as well as
the total amount of drug absorbed, thereby changing the pharmacoki-
netics of a drug and possibly its effect compared to the observed be-
haviour in healthy adults.
The main physiological parameters that are often altered in patients
compared to healthy populations are the gastric emptying rate and pH,
transit times across the different intestinal segments, intestinal surface
area, epithelial permeability, as well as intestinal enzyme and trans-
porter expression. Further differences may be observed with regard to
the volume and composition of luminal fluids and of the intestinal
microbiota (Fleisher et al., 1999; Bai et al., 2016; Effinger et al., 2019).
The possible interaction between co-administered drugs (poly-
pharmacy), between the drug and the excipients in its formulation, as
well as the drug-mediated effect on the GI tract physiology further add
to the complexity of drug absorption. An example is cyclosporine A,
which is known to inhibit cytochrome P450 (CYP) isoenzymes, parti-
cularly CYP 3A4, 2D6, and 2C19 (Niwa et al., 2007); however, it has
also shown a potential effect on the small intestinal transit time
(Buggins et al., 2007), suggesting a rather complex impact of cyclos-
porine A on the overall GI tract physiology.
The dosage forms are typically selected based on the biopharma-
ceutical behaviour anticipated in healthy adults and are in many cases
used in patients irrespective of the physiological differences between
these populations. These differences may strongly influence the drug
performance and result in large variability in exposure, which in turn
could result in reduced efficacy, higher incidence of adverse events,
and/or impaired compliance during clinical use. Thus, the character-
istics of the targeted population and possible differences in GI tract
physiology compared to healthy adults have to be considered from the
outset start of drug and formulation development.
During drug development physiologically based pharmacokinetic
(PBPK) modelling software tools are increasingly used for predicting
pharmacokinetic (PK) profiles or performance of dosage forms. The
strengths of these models lies in the possibility to include altered phy-
siological parameters to mechanistically predict drug disposition. A
major limitation of such models is, however, the lack of quantitative
data describing variation in all processes involved and the validation of
these models (Peters et al., 2016).
Recently, several reviews on the relation between drug absorption
and systemic diseases (Hatton et al., 2019) or GI diseases and disorders
(Effinger et al., 2019; Hatton et al., 2018), have been published and
provide a good overview of these areas. In contrast, this review aims to
cover changes in oral drug absorption in both non-disease and disease
related conditions that can influence the physiology of the GI tract, and
thereby absorption of drugs. After a short introduction to GI physiology
in the healthy adult, the present review is divided into three sections,
including non-disease dependent conditions, diseases in the GI tract,
and systemic diseases, all with the aim of providing a comprehensive
overview of the influence of different GI conditions on drug absorption.
2. GI tract physiology in healthy adults
The GI tract physiology in healthy adult subjects and its impact on
oral drug absorption has been extensively studied in the past decades
and comprehensive reviews can be found in the literature
(Bergstrom et al., 2014; Dressman and Reppas, 2010). A brief overview
of the main physiological parameters of the human GI tract is presented
here.
The pH of luminal fluids is acidic in the stomach (pH 1.5–3.5), and
increases to approximately pH 5-6 in the duodenum and pH 7-8 in the
distal jejunum and ileum, before dropping to pH 6 in the colon with
high interindividual variability (Evans et al., 1988; Koziolek et al.,
2015). The pH affects the degree of ionization of drug molecules, in-
fluencing their dissolution and permeation behaviour, as well as the
performance of some drug delivery systems, such as modified-release
formulations.
The gastric emptying time, measured by magnetic resonance ima-
ging as the time to get back to fasted gastric volumes, is approximately
45 min after a glass of water (240 mL) and more than 6 h after a
standardized Food and Drug Administration (FDA) high-caloric break-
fast (Koziolek et al., 2014; Mudie et al., 2014). The small intestinal
transit time has been reported to be relatively constant between 4.3 and
4.6 h, whereas the colonic transit time is very variable between ~18
and 34.2 h (Becker et al., 2014; Sarosiek et al., 2010; Maharaj and
Edginton, 2016).
Intestinal absorption can occur through passive permeation (para-
cellular or transcellular) or active uptake via intestinal transporters
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depending on both the physicochemical characteristics of the drug and
the properties of the intestinal membrane in different regions of the GI
tract. Polar molecules pass through the passive paracellular route de-
pending on their molecular size and charge, while more hydrophobic
molecules tend to be absorbed via the transcellular route. Since the
epithelial membrane composition, surface area, and pore size, are
varying along the GI tract, polar molecules tend to be absorbed in the
upper small intestine while hydrophobic molecules can penetrate across
the membrane throughout the intestine (Sarosiek et al., 2010).
Reviews of intestinal transporter expression and specificity have
been published recently (Drozdzik et al., 2014; Estudante et al., 2013).
Some uptake transporters (monocarboxylate transporter 1 and organic
cation transporter 1) are expressed along the whole GI tract
(Sjoberg et al., 2013) while others are located in a specific region:
peptide transporter protein 1 mainly in the jejunum and organic anion
transporting polypeptides 2B1 (OATP2B1) mainly in the colon
(Sjoberg et al., 2013). Overall the expression of efflux transporters, P-
glycoprotein (P-gp), breast cancer resistance protein (BCRP), and
multidrug-resistance-associated protein 2, increases from the proximal
to the distal small intestine (Peters et al., 2016; Gutmann et al., 2005;
Berggren et al., 2007), which is opposite to the expression of cyto-
chrome P450 enzymes being highest in the duodenum/jejunum
(Peters et al., 2016; Stappaerts et al., 2013).
The volume of GI fluids determines the local drug concentrations in
the GI tract, and thus, it affects the dissolution behaviour as well as the
driving force for permeation. Several studies using magnetic resonance
imaging can be found in the literature (Grimm et al., 2018; Mudie et al.,
2014; Perez de la Cruz Moreno et al., 2006; Schiller et al., 2005). In the
fasted stomach, resting gastric fluid volumes between 25 and 45 mL
have been reported with significant interindividual variability
(Grimm et al., 2018; Mudie et al., 2014; Schiller et al., 2006). In con-
trast, the volume in the fed state is dependent on the volume of the
ingested food, and the time after ingestion. In the small intestine the
fasted state volume has been reported to be 43 ± 14 mL (range
5−159 mL), which was non-evenly distributed in small pockets
(Mudie et al., 2014). In the ascending colon, mean fluid volumes of 7 to
22.3 mL were measured in the fasted state and 29.9 mL the fed state,
respectively (Murray et al., 2017; Diakidou et al., 2009).
The composition of bile salts and pancreatic enzymes can affect the
solubility and dissolution rate especially of hydrophobic drugs in the
gut. The overall composition of intestinal fluids changes during in-
testinal transit due to digestion and absorption processes, as well as the
secretion of bile and pancreatic fluids into the intestinal lumen. In the
fasted state, the concentration of bile salts ranges from 2.5 to 5.9 mM in
the duodenum and from 1.4 mM to 5.5 mM in the jejunum. Only few
studies have determined the regional bile salt level in the fed state, and
reported values between 3.6 and 24.0 mM in the duodenum and 4.5 and
8.0 mM in the jejunum. The large variability also reflects the effect of
different food types ingested (Bergstrom et al., 2014). In the fasted
state, the rank order of relative bile salt concentration in the duodenum
was reported as follows: taurocholic acid> glycocholate> glycoche-
nodeoxycholate> glycodeoxycholate> taurochenodeoxycholate>
taurodeoxycholate. The concentration of cholic acid, tauroursodeox-
ycholate, chenodeoxycholic acid, and deoxycholic acid was less than
1% of the total bile salts (Perez de la Cruz Moreno et al., 2006). Other
minor components of luminal fluids can be found in Diakidou et al.
(2009) and Perez de la Cruz Moreno et al. (2006). Interestingly, the
relative composition of bile salts is similar between fasted and fed state
in the upper GI tract as well as in the lower bowel (Diakidou et al.,
2009; Perez de la Cruz Moreno et al., 2006; Riethorst et al., 2016).
However, some disease states have been associated with erroneous
synthesis of bile acids resulting in different relative concentrations
compared to healthy subjects (Sundaram et al., 2008).
The healthy human gut is populated with billions of microbes, the
microbiome, that contributes to a dynamic relationship between im-
mune and metabolic function. The weight of the intestinal microbiome
amounts to around 1.8 kg in adults and every individual has a unique
mix of microbial species. The diversity of microbes within a given body
can be defined as the number and abundance distribution of distinct
types of organisms. An imbalance in this diversity has been linked to
several human diseases, such as obesity and inflammatory bowel dis-
ease (Human Microbiome Project Consortium, 2012). In addition, many
bacteria in the gut microbiome have been shown to metabolise drugs,
with potential consequences for the pharmacokinetics and effect of the
drug (Zimmermann et al., 2019). A large database on the human mi-
crobiome, including a variety of species for healthy and diseased hu-
mans can be found in the Human Microbiome Project Consortium re-
port (Human Microbiome Project, 2012).
3. Non-disease dependent conditions
3.1. Paediatric age groups
The paediatric population is a diverse ‘special’ population as it in-
cludes sub-populations including pre-term and term neonates, infants,
children and adolescents. The impact of age on drug absorption has
been reviewed recently for children (Guimaraes et al., 2019;
Johnson et al., 2018) and neonates (Neal-Kluever et al., 2019;
Somani et al., 2016). Both the rate and the extent of absorption of drugs
in children is different than in adults with the greatest differences from
the adult being observed in neonates (Batchelor et al., 2014). The dif-
ficulties of extrapolation of oral absorption data from adult data into
paediatric populations is further complicated by the dose adjustment
made for the population. For a long time, the standard approach for
dose adjustments was based on the weight or by body surface area of
the patient with no regard to the overall absorptive capacity of the
paediatric intestine and age-related changes of oral drug absorption
processes in the intestine. Since more recently, paediatric dose adjust-
ment based on allometric concepts and ontogeny is considered more
appropriate, but to date no final consensus on the suitability of different
methodologies for dose adjustment in children has been reached.
When dosing oral medicines it is important to recognise that most
oral processes are present from birth (rooting, lip, lateral tongue, mouth
opening, biting, and emerging chewing behaviours) (Sheppard and
Mysak, 1984). However, functionality is not fully matured: e.g., oral
syrups are incompletely swallowed when administered to neonates and
infants (Klingmann et al., 2018).
Key findings from recent reviews on the ontogeny of oral drug ab-
sorption processes are presented in summary here and, where available,
newer data is included (Mooij et al., 2012). In contrast to what has been
echoed in multiple reviews, the gastric pH is only high directly after
birth, likely due to buffering of remaining amniotic fluid, and rapidly
decreases to pH 1 to 3 in children of all ages (Mooij et al., 2012).
Collection of paediatric gastric fluids have shown pH values ranges
from 2.0 to 2.7 in neonates and typically <3 in children and adoles-
cents (Van Den Abeele et al., 2018). The postprandial buffering effect of
a milk-based diet in frequently-fed neonates results in a higher per-
centage of time at higher gastric pH.
The paediatric gastric emptying time is highly variable in children
younger than 6 months and paracetamol absorption kinetics have re-
vealed delayed gastric emptying in the first few days of life. Intestinal
transit time is also slower in neonates and infants yet reaches adult
values by the age of 2 years (Bonner et al., 2015).
To study the effect of age and feeding in vitro, simulated paediatric
fasted- and fed-state gastric and intestinal fluids have been developed
based on literature data to inform their composition, although the
evidence-base is limited (Maharaj et al., 2016). The solubility of six
drugs were evaluated in these new paediatric media and compared to
values from adult simulated media; key differences in solubility were
found for neonatal media where milk was a component. Typically, the
differences in solubility were outside the nominal 80–125% bioequi-
valence criteria for neonatal media compared to adults (Maharaj et al.,
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2016). Very recent work has shown that the total bile salt concentration
in gastric fluids collected from neonates and infants was low with 31.2
and 9.2 µM, respectively; whereas higher values were found in children
(99.5 µM) and adolescents (763.6 µM) (Van Den Abeele et al., 2018).
Small intestinal pH has only been studied in older children and showed
adult values; bile acid concentrations are reported to reach adult values
around the age of 4 years. Pancreatic function appears to be sufficient
in healthy neonates, independent of gestational age (Zoppi et al., 1972).
Drug absorption in the intestine may be affected by age-related
changes in intestinal permeability, as well as activity of drug metabo-
lizing enzymes and membrane transporters. Intestinal permeability is
reported to be higher in neonates compared to adults with factors re-
lating to the three-dimensional shape of the intestinal mucosal surface
as well as the high nutritional need of this sub-population
(Bezerra et al., 1990). The ontogeny of intestinal and hepatic drug
metabolizing enzymes and transporters, both impacting oral bioavail-
ability, shows age-dependent and transporter-specific profiles
(Brouwer et al., 2015; Mooij et al., 2016a; Mooij et al., 2016b;
Mooij et al., 2016c; Cheung et al., 2019; van Groen et al., 2018). For
example, hepatic ATP-binding cassette B1 (ABCB1) expression appears
low at birth as compared to adults, but stable in the intestine. In con-
trast to the stable intestinal ABCB1 expression, OATP2B1 expression in
the intestine appears higher in neonates than in older children and
adults. By combining the existing physiological data from children
across the paediatric life span and PK data of oral and intravenous
administration, physiology based (population) PK studies aimed to
elucidate the relative contribution of intestinal and hepatic drug me-
tabolism during growth and maturation (Brussee et al., 2018a;
Brussee et al., 2018b). While very informative, these models are still
hampered by limited data on age-related physiological parameters,
including intestinal drug metabolizing enzyme and transporter ex-
pression (Kodidela et al., 2017).
The impact of food and nutrition can influence the absorption of
drugs as the diet particularly in neonates and infants with milk-based
feeding is different to that in adults (Batchelor et al., 2018;
Karkossa et al., 2017). Not only buffering of gastric pH by milk, as
discussed above, but dietary conditions, may also change drug meta-
bolizing enzyme and maybe transporter maturation, as for example CYP
1A2 and CYP 3A4 activity appears to be higher in formula fed than in
breast-milk fed neonates (Blake et al., 2006). However, it is not yet
clear if this is caused by the presence of an inducer in formula or an
inhibitory factor in breast milk. In young children, manipulations with
drugs (i.e., crushing, dissolving tablets) or co-administering with food
to enhance ingestion by children may affect drug bioavailability.
In conclusion, gaps in knowledge are related to the composition and
volume of fluids present in the small intestine, the expression of in-
testinal transporters and metabolizing enzymes, and methods to un-
derstand permeability in paediatric intestine and pathways relevant to
intestinal wall metabolism. Major knowledge gaps were identified in
the most vulnerable groups of neonates and infants under 6 months of
age. In addition, there is a critical need for PK data from these young
populations to better understand the implications of GI differences on
the absorption of drugs.
3.2. Advanced age
As age advances, the GI tract undergoes a variety of morphological
and functional changes that result in a general decline in bodily func-
tion. The complex deterioration of normal GI parameters can therefore
compromise effective drug absorption in the elderly population, who is
often subject to polypharmacy. The impact of advanced age on GI
physiological factors including GI transit, pH, expression of metabo-
lising enzymes and membrane transporters, permeability and the mi-
crobiome are limited (Khan and Roberts, 2018), but studies have de-
monstrated minor differences when compared with healthy adults
(Brogna et al., 1999; Carríon, 2017; Fakhoury et al., 2005; Holt, 2018;
Russell et al., 1993).
There is an important interaction between drug absorption and
nutritional practice prevalent in the older population. For example, the
limited fluid intake in the geriatrics in particular has the potential to
influence the intestinal absorption process. In addition, the thirst sen-
sation is diminished in elderly (Carríon, 2017; Kenney and Chiu, 2001).
The consequence of the reduced fluid intake in the longer term, how-
ever, may be associated with the impaired drug absorption. Further
research is required to generate evidence-based data to understand: (i)
whether the alteration in thirst physiology is associated with changes in
intestinal absorption and (ii) if it is associated, which drugs are subject
to altered absorption profiles in older people with diminished thirst.
Nutritional intake is also subject to change at advanced age. Fibre-
based enteral nutrition is often administered to improve bowel function
in the elderly. Hence, age-related motility changes as a result or in
combination with these formulations may elicit varying intestinal drug
absorption profiles. More importantly, the geriatric population is the
main user of thickening agents to manage dysphagia. The administra-
tion of a drug product mixed with thickening agents may present an
unforeseen reason for changes in the bioavailability profile
(McKinley et al., 2006).
Drug absorption in the GI tract should be investigated thoroughly in
the presence of disease. The incidence of disease is higher in the elderly
although this factor is rarely considered as the primary cause of
variability in drug absorption as drug bioavailability may further be
perturbed due to advanced age or a combination of both. Therefore, it is
more complicated to understand the intestinal absorption profile of a
drug in an older individual with a clinical condition.
Polypharmacy may further contribute to varied absorption in the
intestine, for example due to drugs that increase the risk of constipa-
tion. As multi-morbidity, and consequently polypharmacy, is pre-
dominant in the elderly, the use of drugs with an effect on the GI pat-
tern is more frequent than in younger subjects (Cichero, 2013;
Petrini et al., 2019).
Overall, there is a lack of consensus regarding the independent ef-
fects of ageing on intestinal absorption due to: (i) the challenge in in-
vestigating the aged intestine that is free of disease; (ii) the lack of
harmonisation in the applied methods and tools to study drug absorp-
tion from the intestine at old age and; (iii) the scattered approach in
reporting the GI physiology related factors as the main drivers for drug
absorption. Clinical studies including healthy elderly subjects should be
encouraged to understand GI tract physiology and drug absorption in
this population.
3.3. Sex differences
Men and women respond differently to medicines. These sex dif-
ferences, however, have largely been neglected in the drug develop-
ment arena. Many pharmaceutical scientists can attest that for decades,
the default human model subject was a “70 kg Caucasian male”
(Beery et al., 2011; Yoon et al., 2014). With the effort to overcome the
disparity between sexes in biomedical research, the FDA and the Na-
tional Institues of Health mandated for the inclusion of women in
clinical trials in the U.S. in 1993. Nonetheless, following the review of
ten drugs that were withdrawn from the market from 1997 to 2000, it
was found that withdrawal of eight of the ten drugs were due to greater
risks of adverse effects in women (GAO, 2001). In addition, out of 67
new molecular entities approved by the U.S. FDA between 2000 and
2002, 25 compounds demonstrated significant sex-specific differences
in PK and efficacy (Yang, 2009). Ignoring female participants in clinical
trials has backfired and has resulted in the significant implications in
women directly related to drug use. For example, only identified during
post-market drug surveillance, women were more susceptible to next-
day effects following the administration of the sedative zolpidem as
drug elimination was slower in women than in men. The FDA subse-
quently recommended that immediate-release and extended-release
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products were to reduce the dose from 10 mg to 5 mg and 12.5 mg to
6.25 mg respectively for women (Norman et al., 2017). In addition,
women are also at a greater risk (50–70%) of experiencing adverse side
effects (Rademaker, 2001), which may be directly linked to distinct GI
physiological differences between the sexes.
Drug dissolution is often the rate limiting step in drug absorption,
however, it was identified that fluid volumes in the stomach and small
intestine (following the normalisation of body weight) were higher in
men than in women (Gotch et al., 1957; Soldin and Mattison, 2009). In
terms of gastric pH, the fasted state pH is higher in females than in
males (2.79 ± 0.18 and 2.16 ± 0.09, respectively), which may be
attributed to reduced acid secretion and smaller sized female stomach
(Feldman and Barnett, 1991; Phan et al., 2015). Lowered gastric acid
secretion may influence drug ionisation and solubility of pH-sensitive
drugs, thereby impairing absorption and consequently, oral drug
bioavailability (Lahner et al., 2014).
With regards to motility, pre-menopausal women have a sig-
nificantly longer gastric emptying time when compared with their male
counterparts for solids and calorific liquids, however, in post-meno-
pausal women, gastric emptying time decreases and becomes similar to
that in men (Bennink et al., 1998). Variabilities in drug PK can be at-
tributed to differences in gastric emptying time as a shorter absorption
lag time of an enteric-coated aspirin tablet was demonstrated in males
than females (Mojaverian et al., 1988; Fischer and Fadda, 2016). Co-
lonic transit time is also significantly longer in women than in males
(ascending colon: 13.3 ± 1.6 h; 8.9 ± 1.1 h and transverse colon:
13.7 ± 2.1 h; 8.7 ± 1.5 h; descending colon: 11.8 ± 1.6 h;
13.0 ± 1.7 h in women and men respectively) (Metcalf et al., 1987;
Rao et al., 2009). The increased total intestinal transit time in women
would have significant implications to oral drug bioavailability. The
longer GI residence time for sustained-release dosage forms may facil-
itate enhanced drug absorption in women as demonstrated with the PK
profile of an extended-release formulation of diltiazem, which was
demonstrated to be sensitive to GI transit time (Zimmermann et al.,
1999). This, however, may further be implicated by the regulation of
intestinal membrane transporters and metabolising enzymes located in
the GI mucosa.
CYP enzymes are responsible for the metabolism of a number of
drug substrates of which CYP2C and 3A are most commonly expressed
in the small intestine. For example, the oral bioavailability of verapamil
(a CYP3A substrate) was higher in women than in men (Krecic-
Shepard et al., 2000) due to higher intestinal CYP3A expression and
activity (Tamargo et al., 2017). P-gp, the most studied efflux membrane
transporter in the GI tract, has been shown to differentially affect oral
drug absorption in males and females in the presence of so called
“inert” excipients. A human study firstly identified that when co-for-
mulated with 0.5 g polyethylene glycol 400 (PEG 400), the bioavail-
ability of ranitidine (a P-gp substrate) significantly increased by 63% in
males. In females, however, ranitidine bioavailability decreased by 8%
when compared with the control (Ashiru et al., 2008). As aforemen-
tioned, the National Institute of Health mandated for women to be in-
cluded in clinical trials in 1993. No such initiatives, however, have been
implemented to investigate sex differences in pre-clinical research, i.e.,
cell and animal models. As early drug development often uses rats as
animal models, the sex differences at a rodent physiological level can
translate the oral drug performance in humans. A rat study was sub-
sequently developed to explore the levels of P-gp along the gastro-
intestinal tract. Afonso-Pereira et al. identified that female rats dis-
played significantly higher relative P-gp expression levels than male
rats throughout the small intestine (Afonso-Pereira et al., 2018). Ex-
cipients have since been identified to directly interact with the gene and
protein expression of P-gp differently between males and females
(Mai et al., 2017). The presence of PEG 400 and its potential interaction
with P-gp was assessed for its gene and protein expression in the pre-
sence of a P-gp substrate (ranitidine and ampicillin), a non-P-gp sub-
strate (metformin) and a P-gp inhibitor (cyclosporine A) in male and
female rats. The study showed that the bioavailability of ampicillin
significantly increased (p < 0.05) in the presence of PEG 400 in male,
but not female, rats. No sex differences were reported in the bioavail-
ability of metformin in the presence of PEG 400. When formulated with
a P-gp inhibitor (cyclosporine A), the bioavailability of ampicillin and
ranitidine increased in males to a greater extent but showed no influ-
ence on metformin bioavailability. There is, therefore, a potential sex-
specific effect of PEG 400 on the bioavailability of certain drugs due to
the interaction of PEG 400 with the P-gp efflux transporter (Mai et al.,
2018a). A recent study established an in vitro permeation model for the
prediction of the in vivo sex-related influence of PEG 400 mediated by P-
gp. The study identified a good in vivo-in vitro correlation for the in-
fluence of PEG 400 on the absorption of ranitidine in different segments
of the small intestine which can predict drug bioavailability in human
subjects (Mai et al., 2018b).
Advancements in the research has since revealed that the sex-spe-
cific influence of excipients on drug bioavailability is not limited to PEG
400 alone. Other solubilising excipients including PEG 2000,
Cremophor RH 40, Poloxamer 188 and Tween 80 have shown to sig-
nificantly increase ranitidine bioavailability, although this was only
apparent in males but not in female rats (Mai et al., 2019). The effect of
Span 20 was also studied on the oral bioavailability of ranitidine; al-
though this solubilising agent was able to significantly increase raniti-
dine bioavailability, its effects were in a non-sex dependent manner.
Consequently, sex-specific effects may be attributed to the presence of a
polyoxyethylated group in PEG 2000, Cremophor RH 40, Poloxamer
188 and Tween 80, but not for Span 20.
Food intake has recently been discovered to affect the intestinal
expression of P-gp in males and females. Dou et al. identified that re-
lative P-gp levels decreased in all segments of the intestine (bar duo-
denum) in male rats following food intake. A fundamentally different
outcome, however, was observed in female rats where the fed state
resulted to a significant increase in P-gp expression in the small intes-
tine. Specifically, a six-fold increase in jejunal P-gp expression occurred
from the fasted to fed state in female rats. As such, intestinal permea-
tion studies in an Ussing chamber showed that ganciclovir and raniti-
dine (both P-gp drug substrates) exhibited a sex difference in intestinal
permeability from the fasted to fed state (Dou et al., 2018).
Adding further to the complexity of varying drug response between
the sexes may be governed by the intestinal microbiome. The increasing
number of microbiome studies have revealed the importance of the gut-
brain axis namely the microbiota and the endocrine system with bac-
teria being able to produce hormones (e.g., serotonin and dopamine),
respond to host hormones (e.g., oestrogen) and regulate the home-
ostasis of host hormones by inhibiting gene transcription (e.g., pro-
lactin) (Edwards et al., 2018). A study demonstrated that women ap-
pear to have significantly higher levels of faecal bifidobacteria and
Bilophila than men (Cross et al., 2018; Haro et al., 2016). The diversity
seen in the gut microbiota between the sexes may have a dominant role
in defining the sex-specific response to medications or provide the
foundation to understanding the pathology of disease.
Although men are subject to higher mortality rates, the prevalence
of morbidity is higher in women (Singh-Manoux et al., 2008). The onset
of disease has also recently been identified to affect normal gut phy-
siology and function between the sexes which consequently alter drug
absorption and bioavailability (Freire et al., 2011). For example, the
erratic gastric emptying of levodopa in Parkinson's disease patients can
reduce the dissolution time of the tablets in the stomach resulting in
delayed and incomplete absorption (Deleu et al., 1991). A study showed
that a significantly higher bioavailability of levodopa was found in all
female patients with Parkinson's disease (PARKD) where the area under
the curve was almost 1.6 times higher than in their male counterparts
(Kumagai et al., 2014). The study did not investigate further into why
sex differences were found, but hypothesised the potentially negative
influence of oestrogen in patients with PARKD. Although the under-
lying mechanism of PARKD is still unclear, the effects of oestrogen on
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PARKD symptoms that are mediated by the modulation of the basal
ganglia have been shown to exacerbate classic parkinsonism disorders
in human PARKD patients (Van Hartesveldt et al., 1986;
McEwen, 2014).
Research invested in to understanding the differences between the
sexes in the main site of drug absorption continue to be very limited. It
is clear that males and females differently respond to medicines due to
the dynamic interplay of GI fluid volumes, luminal pH, transit time,
expression of membrane transporters, the microbiome and the onset of
disease. As such, drug development is required to invest in specialised
sex-specific studies to fully understand the mechanism of the gut and to
maximise effective oral drug bioavailability.
3.4. Ethnic and genetic factors
Ethnicity can be considered as an important demographic variable
that may contribute to significant interindividual variability in PK and
pharmacodynamics of several drugs. Regulatory authorities are ex-
pecting a sponsor developing a medicine for a new geographical region
to consider how to “deal with the possibility that ethnic factors could
influence the effects (safety and efficacy) of medicines and the risk/
benefit assessment in different populations” (ICH, 1998). Ethnic var-
iation in drug absorption may be attributed to intrinsic factors such as
variation in the genetics or physiology, or to extrinsic factors such as
socioeconomic background, culture and environment with major dif-
ferences in the diet (Chen, 2006; ICH, 1998; Johnson, 1997).
When considering passive processes in intestinal absorption, ethnic
differences as such are not anticipated (Johnson, 1997). However, with
drugs undergoing active transport and metabolism in the gut there is
more potential for differences. An example is the active calcium ab-
sorption with fractional absorption of calcium in premenarchal girls of
African origin being significantly higher compared to Caucasian girls
(Johnson, 1997). Apart from CYP3A4, also CYP2C9 and CYP3A5 are
considerably expressed along the GI tract (Drozdzik et al., 2018).
CYP3A4 is known to have largely variable expression between subjects,
but limited information is available comparing the CYP3A4 expression
or activity in different ethnic groups. Further, little evidence is avail-
able regarding clinically significant polymorphisms in the CYP3A4
gene. However, polymorphism in the CYP3A5 gene can make a sig-
nificant contribution to the variability in drug absorption in different
ethnic groups, particularly for substrates with preferential metabolism
by CYP3A5 over CYP3A4, such as tacrolimus (Zanger and
Schwab, 2013). The ethnic differences in tacrolimus PK were suggested
to be related to intestinal metabolism rather than hepatic elimination,
and thus the CYP3A5 genotype can affect absorption profiles of ex-
tended-release and immediate-release oral formulations (Chen and
Prasad, 2018). The most studied polymorphism is CYP3A5*3, and those
with homozygous condition are considered as non-expresser. This
polymorphism is less frequent in populations of African origin as
compared to Caucasians (Chen and Prasad, 2018). Indeed, the pre-
scribing information of orally dosed tacrolimus capsules advice African
American patients to receive a higher dose to attain comparable plasma
trough concentrations compared to Caucasian patients (FDA, 1994).
For the efflux transporter P-gp, many polymorphisms in the ABCB1
gene have been associated with altered expression of P-gp, potentially
leading to changes in drug PK (Wolking et al., 2015). One of the most
common variants, 3435 C>T, shows remarkable interethnic variability,
and people of African origin due to their lower allele frequency could be
expected to have higher plasma concentrations for P-gp substrates than
other ethnic groups, such as East Asians, Indians, and Caucasians.
However, the clinical significance remains inconsistent and equivocal
(Cascorbi, 2006; Wolking et al., 2015).
In addition to P-gp, BCRP, another efflux transporter expressed in
the GI tract, can have a clinically significant effect on drug absorption.
For the gene coding for BCRP, ABCG2, a much studied single nucleotide
polymorphism, Q141K (421C>A), has been shown to decrease BCRP
expression and activity, and this polymorphism has a highly variable
frequency depending on ethnicity (Heyes et al., 2018). It is common in
Asian populations, where about one third of Japanese and Chinese
subjects are affected, while more rare in Caucasian, Sub-Saharan, or
African American populations (Heyes et al., 2018). As BCRP is ex-
pressed in many tissues, including the intestine, it is complicated to
interpret the role of the transporter on the PK. Examples where altered
PK is considered to be due to tissue-specific BCRP interaction is ator-
vastatin and rosuvastin, where a change in absorption parameters has
been observed, but no effect on the elimination half-life (Heyes et al.,
2018; Li and Barton, 2018). The FDA label of rosuvastatin states “PK
studies have demonstrated an approximate 2-fold increase in median
exposure to rosuvastatin in Asian subjects when compared with Cau-
casian controls” (FDA, 2003c). Consequently, a lower rosuvastatin dose
is suggested for Asian subjects. What complicates the assessment of the
precise mechanism for this ethnic difference is that not only the poly-
morphism of ABCG2, but also that of SLCO1B1, a gene coding a hepatic
transporter OATP1B1, can have an effect on rosuvastatin PK (Li and
Barton, 2018; Wu et al., 2017).
Even though there is limited evidence for clinically meaningful
ethnic disparities in gastric pH, emptying, intestinal motility, transit
time or mucus properties, ethnicity may be associated to these prop-
erties through extrinsic factors such as the diet. For example, some
ethnic groups may have more vegetarians than others. Vegetarians,
compared with non-vegetarians, are expected to have more rapid GI
transit time, thus impacting the residence time of the dosage form in the
intestine (Chen, 2006). However, ethnic differences in gastric pH can
exist as lower gastric acidity has been found in the Japanese population
(Tamboli et al., 2010). Implications of specific pharmaceutical product
designs on the PK of drugs prescribed for various ethnic groups and
genetic variants need to be considered, especially for the drugs that
exhibit active processes in absorption and have narrow therapeutic
index. More mechanistic studies are needed for detailing the con-
tribution of various factors. Especially, the interrelationship between P-
gp and CYP3A, with a highly variable interindividual expression, and
potential food-drug interactions, makes it difficult to elucidate the
precise ethnic differences in drug absorption.
3.5. Diet
The interaction between food ingestion and drug absorption is well
described in several recent review papers (Deng et al., 2017;
Mouly et al., 2017; Peter et al., 2017; Van Orten-Luiten, 2017;
Witkamp and van Norren, 2018). The postprandial effect of food intake
in the GI tract is complex and includes increased viscosity of luminal
contents, delay in gastric emptying, elevation of gastric pH, enhance-
ment of splanchnic blood flow and stimulation of bile secretion
(Deng et al., 2017). The interaction between food components and
drugs mainly takes place in the GI tract before absorption and thus can
affect the PK profile of the drug. The effect on a specific drug is de-
pendent of the physico-chemical characteristics of the drug and also the
nature of the food. For lipophilic drugs, a positive food effect, i.e., in-
creased absorption upon ingestion of, especially, a high-fat meal, is
most prevalent (Deng et al., 2017). Postprandially, the ingested food
will react directly or indirectly with drugs through changes in the GI
tract. Deng and colleagues made a distinction between different food
categories, drug categories and dosage regimens; within the food ca-
tegories (i.e., different composition of food) a distinction is made be-
tween high-fat, high-protein, high-fibre, metal-rich, purine-rich and
high-carbohydrate food (Deng et al., 2017). The high-fat diet, which is
reflected in the U.S. FDA test meal (FDA, 2002) delays gastric emptying,
induces bile secretion, stimulates the intestinal lymphatic transport
pathway, inhibits epithelial efflux transporters and may induce diar-
rhoea. A high-protein diet (although not clearly defined) can inhibit
intestinal amino/peptide transporters, stimulate intestinal transporter
systems and hepatic enzyme activity. A high-fibre meal is recognised for
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its postprandial adsorption of bile acids and stimulation of fermentation
in the gut lumen, influencing the gut microbiota. High-carbohydrate
food, like high-fat meals, retards the gastric emptying. Thus, Deng and
colleagues conclude that one food item or a specific diet can interact
through different mechanisms, thus having diverse effect on different
drugs (Deng et al., 2017).
Food components can also impact drug absorption via metabolising
enzymes and transporters (Won et al., 2012). The most well-known
specific interaction here is the inhibition of intestinal CYP3A expression
and activity by grapefruit juice (Mouly et al., 2017). Similar interaction
is assumed with P-gp transporters, which were shown to be inhibited by
citrus juices in vitro (Soldner et al., 1999), but the in vivo relevance has
not been fully demonstrated (Becquemont et al., 2001).
Moreover, the gut microbiome and postprandially produced meta-
bolites can affect the absorption of nutrients and pharmaceutical
compounds. (Zimmermann et al., 2019) describe that the gut micro-
biota can modify drug absorption and drugs biotransformation and
suggest to take the role of the gut microbiota into account when con-
sidering bioavailability and efficacy of drugs. The gut microbiota does
not only modify drug absorption, but can be a therapeutic target as
well. Food components and diet influence the composition of the gut
microbiota and therefore will interact with drug absorption
(Falony et al., 2019). Nevertheless, the clinical relevance of all these
interactions could be questioned and are often not clear and unexpected
interactions could occur (Witkamp and van Norren, 2018).
3.6. Obesity
The prevalence of obesity is increasing and it is now estimated that
more than six million adults in Europe are obese (Webber et al., 2014).
Obesity is associated with co-morbidities that include type 2 diabetes
mellitus (T2DM), ischaemic heart disease, cancer, depression and hy-
pertension, all of which require therapy (Brandt, 2013). Previous work
exploring the impact of obesity on drug PK have focused on distribu-
tion, metabolism, and elimination aspects rather than absorption
(Hanley et al., 2010; Smit et al., 2018). There have also been reviews
describing the impact of GI surgery as a treatment for obesity, for ex-
ample bariatric surgery and Roux-en-Y gastric bypass
(Santamaría et al., 2018). Obesity is associated with GI complications
which are further described in a recent review (Camilleri et al., 2017).
Obesity has been reported to increase the prevalence of oesophageal
disorders; there is a documented link between gastroesophageal reflux
disease and obesity in adults, which is likely due to the increased
pressure on the stomach and oesophagus due to excess weight
(Zacchi et al., 1991). Abdominal obesity has been linked to increased
intra-abdominal pressure in subjects whose body mass index (BMI) had
a mean value of = 49 ± 10 kg/m2. However, in an alternative study
there was only a weak positive correlation between intragastric pres-
sure and both BMI and waist circumference (El-Serag et al., 2006);
(Varela et al., 2009).
The maximum gastric capacity was compared in normal
(BMI = 23.6 ± 2.0 kg/m2) and obese women (BMI = 40.3 ± 6.8 kg/
m2). Although the total volumes for each subject group was not re-
ported, the statistical analysis demonstrated no significant differences
between the two groups (Geliebter and Hashim, 2001). Two further
studies compared gastric volume in lean and obese participants: values
in lean and obese were 26 ± 8 mL in lean compared to 26 ± 13 mL in
obese reported by (Juvin et al., 2001) showing no statistically sig-
nificant difference. In contrast, a study that investigated risk factors for
aspiration during anaesthesia compared the gastric volume and pH in
lean patients (BMI 18–25 kg/m2) versus obese patients
(BMI = ≥35 kg/m2) and reported larger gastric volumes in the obese
(26.9 ± 14.6 mL) compared to lean (6.3 ± 7.4 mL) (Mahajan et al.,
2015). Those studies reporting gastric volumes also reported gastric pH
with values of 2.8 and 4.3 in lean participants and values of 2.3 and 3.5
in obese participants by Juvin et al. (2001) and Mahajan et al. (2015),
respectively.
The impact of obesity on gastric emptying is complex with some
studies showing no difference (Buchholz et al., 2013; Zahorska-
Markiewicz et al., 1986), some showing slower (Jackson et al., 2004)
and others showing faster gastric emptying in obese subjects
(BMI = 45.3–58.0 kg/m2) compared to controls (BMI = 20.3–24.8 kg/
m2) (Tosetti et al., 1996).
Intestinal transit has been measured in obese (BMI = 34.0–43.6 kg/
m2) and normal-weight subjects (BMI = 20.0–26.6 kg/m2) and similar
intestinal transit times have been reported (Wisen and
Johansson, 1992). However, the same study showed that the obese
population absorbed 74 ± 4% of the total liquid test meal compared to
50± 5% absorbed in the lean control group. This increased energy
uptake may be related to the need for energy transfer to the relatively
larger organs present in the obese subjects (Wisen and
Johansson, 1992).
The total bile acid concentration was comparable between normal
weight (mean BMI = 23.2 kg/m2) and obese populations (mean
BMI = 47.2 kg/m2) in the fasted state (Diakidou et al., 2009). How-
ever, the postprandial concentrations of bile salts were much reduced in
obese compared to control populations (Glicksman et al., 2010).
Intestinal transporter expression was investigated in obese com-
pared to non-obese subjects and the following differences were re-
ported: decreased glucose transporter 5 expression (Deal et al., 2018),
reduced amino acid nutrient transporter expression (Irving et al.,
2016), increased short-chain fatty/monocarboxylate acid transporter
expression (Irving et al., 2016), increased levels of CYP1A2 and glucose
transporter 4 (Miyauchi et al., 2016).
The above differences in GI physiology between normal weight and
obese, can indicate potential differences in drug absorption. However,
to date there are no reports on the impact of obesity on drug absorption,
whereas there are several studies reporting on the distribution and
clearance of drugs in obese patients (e.g., Abdussalam et al., 2018;
Greenblatt et al., 2018; van Rongen et al., 2018).
3.7. Pregnancy
The effect of pregnancy on drug absorption has been studied using
clinical pharmacological tools (i.e., by studying the PK of drugs that are
metabolized or transported by a specific enzyme or transporter, and can
therefore serve as probe substrates to reflect the activities of the in-
volved enzyme/transporter), as well as via physiological measurements
of relevant mechanistic determinants of the absorption process. In
terms of gastric acid secretion, several previous reviews report in-
creased gastric pH during pregnancy (Costantine, 2014; Pariente et al.,
2016). However, looking back to several original studies, which ad-
dressed heartburn during pregnancy, learns that there are also reports
of no major changes in gastric pH taking place between the different
trimesters of pregnancy and the non-pregnant situation. In these studies
also no significant effect of pregnancy on basal and peak acid outputs
could be found, suggesting that changes in gastric acidity may not be
that prominent (O'Sullivan and Bullingham, 1984; Van Thiel et al.,
1977). In terms of gastric emptying, it has been demonstrated using
ultrasound studies that gastric emptying time for fluids does not appear
to be affected by pregnancy (Chiloiro et al., 2001). In line with this, it
was found that the absorption of acetaminophen (maximum plasma
concentration (Cmax), time to Cmax (Tmax)), was not altered by preg-
nancy over the trimesters and compared to non-pregnant women
(Whitehead et al., 1993). The authors reasoned that due to the very
rapid absorption of this drug from the small intestine, gastric emptying
will be absorption-limiting. Hence, the fact that no differences occur in
absorption profile also led them to conclude that gastric emptying times
are not very different between trimesters. Nevertheless, overall GI
transit time was found to be longer in the third trimester, indicative of
an overall lower intestinal motility (Chiloiro et al., 2001). Conse-
quently, intestinal absorption may be delayed during pregnancy
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possibly resulting in slower Tmax and lower Cmax values for drugs in
which the intestinal transit time is the rate-limiting step.
The ultimate bioavailability of drugs is also determined by enteric
first pass metabolism, the extent of which can be affected by changes in
the expression of drug metabolizing enzymes. The same holds true for
compounds that are subject to active transport. The changes in ex-
pression of metabolizing enzymes and transporters are in many cases
secondary to changes in hormone levels, such as progesterone, oestro-
gens or cortisol. Substrates of CYP3A4 (e.g., midazolam), CYP2D6 (e.g.,
fluoxetine), CYP2C9 (e.g., glibenclamide), as well as UGT1A1 (labe-
talol) and UGT1A4 (lamotrigine), experience increased enzyme activity
during pregnancy, which may result in lower bioavailabilities. In con-
trast, activity of CYP1A2 (caffeine) and CYP2C19 (proguanil) decline
during pregnancy, hence an opposite effect may be expected
(Fischer et al., 2014; Hebert et al., 2008; Hebert et al., 2009;
Heikkinen et al., 2003; Knutti et al., 1981; McGready et al., 2003;
Ohman et al., 2008; Wangboonskul et al., 1993). However, as overall
oral bioavailability is also determined by hepatic first pass metabolism,
it remains difficult to delineate to which extent the changes in PK are
the result of changes in enzyme expression occurring in the gut. Al-
though limited direct data is available on the expression of drug me-
tabolising enzymes and transporters in the intestine during pregnancy,
changes in activity may be derived from clinical PK studies that have
investigated drug disposition after oral administration during preg-
nancy and the non-pregnant situation (Broe et al., 2014;
Deligiannidis et al., 2014; Leke et al., 2018; van der Galiën et al., 2019).
Quantitative proteomic analysis of the expression levels of transporter
and different CYP and uridine 5′-diphospho-glucuronosyltransferase
(UGT) enzymes in the intestine of pregnant women will help to address
this question further (Groer et al., 2014; Miyauchi et al., 2016).
An improved understanding of quantitative changes in the expres-
sion levels of enzymes and drug transporters or the availability of useful
probe substrates or endogenous markers that reflect enzyme and
transporter activity would further improve our understanding of the
impact of pregnancy on drug absorption. At the same time, this type of
mechanistic information is useful to build better in silico PBPK models
for prediction of oral absorption and bioavailability in this specific
patient population, as reviewed in Section 6 of this paper and by others
(Abduljalil et al., 2012; Ke et al., 2018).
4. Diseases in the GI tract
4.1. Inflammatory bowel disease
Inflammatory bowel disease (IBD) is an umbrella term for in-
flammatory conditions that affect the GI tract, mainly the small intes-
tine and the colon. The aetiology of IBD is not fully understood
(Bilsborough et al., 2016). IBD includes two major inflammatory con-
ditions of unknown aetiology, Crohn´s disease (CD) and ulcerative co-
litis (UC). Both are associated with a variety of intestinal and extra-
intestinal features. Extra-intestinal manifestations are usually related to
intestinal disease activity and may precede or develop concurrently.
However, the GI areas that are affected can be quite different in CD and
UC (Hendrickson et al., 2002).
Fig. 1. Components of the mucosal barrier in healthy gut (left) and inflammatory bowel disease (IBD) (right). For detailed explanation, please refer to (Michielan and
D'Incà, 2015). The basic structure of tight junctions and other junctional complexes are shown in the bottom-right box. JAM: junctional adhesion (copied from
(Michielan and D'Incà, 2015) with permission).
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Numerous review and research articles on the pathology, clinical
presentation and treatment of CD and UC can be found in the literature.
The major treatment goals of current therapies are to decrease the in-
flammatory reaction, minimize symptoms, improve quality of life, and
minimize progression and complications of disease (Sairenji et al.,
2017). Even though in many patients it is possible to induce and
maintain phases of remission, in both diseases, chronic inflammatory
changes of the intestinal epithelium dominate epithelial histology.
CD is a chronic transmural inflammation, i.e., it can affect the entire
thickness of the bowel wall, and also any segment of the GI tract from
mouth to anus. The inflammation pattern is usually discontinuous with
inflamed segments and so called “skip areas” of healthy tissue. The
initial location of CD is most commonly in the distal ileum and the
earliest mucosal lesions often appear over Peyer's patches (Xavier and
Podolsky, 2007). Approximately half of the patients suffer from in-
flammations that are localized in the distal ileum and proximal colon.
The inflammatory reaction can also appear in the proximal parts of the
small intestine and/or the colon and, in some patients, also the upper GI
tract can be involved. Inflammation can decrease the functional surface
area of the intestines, but results from various studies indicate that it
also can increase intestinal tight junction permeability (Michielan and
D'Incà, 2015). Increasing the pore size of intestinal tight junctions
contributes to an increased tight junction permeation of larger mole-
cules, but also bacteria. According to Michielan and D'Incà, CD patients
display several defects in the many specialized components of mucosal
barrier that regulate paracellular permeability (Michielan and D'Incà,
2015). A schematic comparison of the components of the mucosal
barrier in the gut of a healthy subject and an IBD patient is given in
Fig. 1 (Michielan and D'Incà, 2015).
UC shows a continuous distribution in the intestinal mucosa and is
generally confined to the colon (Stein et al., 1999). It includes diffuse
mucosal inflammation that extends proximally from the rectum to a
varying degree (Xavier and Podolsky, 2007). Occasionally, it extends
into the terminal ileum (Haskell et al., 2005). Histologically, UC in-
volves the innermost lining of the colon. In conjunction with severe
inflammation, an extensive superficial mucosal ulceration can be ob-
served (Xavier and Podolsky, 2007). Due to the presence of a significant
number of neutrophils within the lamina propria and the crypts, micro-
abscesses are formed and another common feature is the depletion of
goblet cell mucin (Xavier and Podolsky, 2007). Even though the in-
flammation is mainly restricted to the colon, there is evidence for some
functional small intestinal abnormalities as well. Mourad et al. reported
that small intestinal dysfunction is a common feature in UC patients
(Mourad et al., 2017). With the intention of better understanding the
impairment of small intestinal function in UC, they screened the re-
levant literature for case studies focusing on intestinal dysfunction in
UC and summarized that even though the pathophysiology of the dys-
function has not been elucidated, there is evidence for a decrease in
fluid, electrolyte, amino acid, fat, and carbohydrate absorption, as well
as for a deranged intestinal motility (Xavier and Podolsky, 2007).
Oral drug absorption in IBD patients is altered due to impaired
mucosal barrier function. The type, pattern and severity of the disease is
likely to determine whether the reduced total absorptive surface area,
or the increased tight junction permeability, also referred to as “leaky-
gut-syndrome”, will be the major determinant of the plasma profile of
orally administered drugs. However, gut wall permeability is only one
factor to consider when discussing oral drug exposure. GI parameters
that affect rate, timing and site of in vivo drug release are of equal
importance. Surprisingly, even though numerous articles and guidelines
have been published on various aspects of diagnosing and treating IBD,
a systematic review of how IBD affects GI parameters relevant to oral
drug exposure is not available.
One of the major GI symptoms in both CD and UC is diarrhoea.
Patients often present with severe and chronic diarrhoea. Consequently,
GI transit in these patients can significantly differ from that in healthy
patients. However, in CD patients, constipation is also a common
symptom. It results from a so-called stricture resulting from thickening
of the intestinal wall. Stricture involves narrowing of a small intestinal
section and in the worst case can block the flow of digestive contents. GI
transit of the luminal contents and dosage forms in IBD patients can
thus be significantly different from healthy subjects.
In the recent past, several review and research articles on GI moti-
lity in IBD patients have been published. Bassotti et al. reviewed results
from studies focusing on colonic motility in UC patients and summar-
ized that UC patients present colonic motor abnormalities, including a
lack of contractility and an increase in propulsive contractile waves
(Bassotti et al., 2014). Yung et al. assessed GI pH, transit, and motility
in 12 patients with known or suspected CD using a wireless-motility
capsule (Yung et al., 2016). The motility index in stomach, SI and colon
was significantly lower in patients with CD. Since this was the very first
study with a wireless-motility capsule in CD patients, at this stage, these
observations can only indicate a potential trend, but with the wireless-
motility capsule technology, it should be possible to gain a much better
insight into GI motility and transit in IBD patients in the near future.
Nugent et al. reviewed the literature with regard to intestinal lu-
minal pH in IBD and concluded that some data indicate that colonic pH
is reduced in UC patients, particularly in active disease (Nugent et al.,
2001). They could not draw a definite conclusion on intraluminal pH in
CD patients, but overall, pH conditions reported in the articles reviewed
by Nugent et al. were quite similar to those in healthy controls.
There is currently next to no information available on small in-
testinal fluid properties and composition in IBD patients (Barkas et al.,
2013). A bit more information is already available on colonic fluid
properties. With the aim of characterizing the fluid composition in the
ascending colon of fasted UC patients in relapse and in remission,
Vertzoni et al. analysed the properties of ascending colonic fluid of
twelve UC patients (Vertzoni et al., 2010). Of potential relevance for
drug absorption, the pH was lower and the buffer capacity higher in IBD
patients compared with healthy subjects. More recently, Müllertz et al.
presented results from a study on assessing ascending colonic fluid
composition, which indicate the presence and structure of some rem-
nants of lipolytic products in the ascending colon of UC patients
(Müllertz et al., 2013). However, as for the small intestine, there are
still a lot of knowledge gaps to be filled and the same is true for gastric
conditions.
In summary, it is obvious that IBD can affect oral drug absorption
significantly, but there is a need to fill several essential knowledge gaps.
When designing experiments for assessing essential GI parameters, the
large inter-and intraindividual variability in pattern and severity of the
inflammation in both CD and UC will require particular attention.
Moreover, the increasing number of paediatric and adolescent patients,
in whom IBD is often following a more complicated and aggressive
course than in adult onset (Grover et al., 2017; Rosen et al., 2015),
should be properly addressed.
4.2. Cancer in the GI tract
The GLOBOCAN statistic report for 2018 predicted a total of 18.1
millions newly diagnosed cases of cancer, together with expected 9.6
millions cancer-related deaths worldwide (Bray et al., 2018). Out of
those numbers, colorectal cancer and gastric cancer rank third (10.2%)
and fifth (5.7%) in total cancer incidence, respectively, while they are
positioned as second (9.2%) and third (8.2%) cause of death among
cancer patients (with pancreatic cancer causing 4.5% of deaths glob-
ally).
Primary treatments for GI cancer include surgical removal of the
tumor tissue, chemotherapy, radiotherapy and targeted therapy
(Gulbake et al., 2016; Orditura et al., 2014). Usual intravenous ad-
ministration of chemotherapeutics causes various side effects like
nausea, vomiting, neutropenia, hematological disorders, and general
fatigue (Lin et al., 2015) due to unspecific activity of drugs on both
cancer and healthy cells. In order to avoid these effects, targeted
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delivery of drugs to the GI tract could offer a much-needed replace-
ment, also with the convenience of patients in mind (Amidon et al.,
2015; Banerjee et al., 2017; Derakhshankhah et al., 2017). Well-de-
signed oral chemotherapy can result in low plasma drug concentrations,
and concomitantly achieve a prolonged drug exposure to the cancerous
cells in the GI tract, resulting in better efficacy and fewer side effects
than an intermittent parenteral chemotherapy (Joshi et al., 2014).
Gastric cancer causes changes in physiological function of the sto-
mach manifested as delayed gastric emptying. While delayed gastric
emptying has been reported as one of the features of gastric cancer
(Tatsuta et al., 1990), it is also one of the most common postoperative
syndromes of (partial) gastrectomy, which is a treatment for gastric
cancer. As reported in several studies (Kim et al., 2017; Pradhan et al.,
2017) delayed gastric emptying develops in 7% to 52% of patients that
underwent distal gastrectomy, with this time declining in the post-
operative period. However, a study by Chang et al. including 28 pa-
tients with non-obstructive gastric cancer, showed no difference in
water gastric emptying time compared to control group (15.51 +/-
2.21 and 16.82 +/- 2.13 min, respectively) (Chang et al., 2004). De-
layed gastric emptying represents burden for the patients, but also an
important fact for the physicians in determining the medication dosage.
The gastric pH has been found to be as high as pH 6–7 in gastric
cancer patients (n = 89) (Lu et al., 2010). This increase in the pH of
gastric juices is explained by gastric atrophy, which results in reduction
of parietal cell mass and cause reduction or absence of detectable
gastric acid (Ghosh et al., 2011). Human gastric cancer cell lines were
found to have an increased expression of membrane transporters be-
longing to ABC and the family of efflux proteins, such as multidrug-
resistance-associated protein 1 (Obuchi et al., 2013). Inhibition of these
and other efflux carriers (e.g., reduced folate carrier 1, multidrug-re-
sistance-associated protein 5, monocarboxylate transporter 4) re-
presents an option to increase cancer cell susceptibility to locally acting
cancer drugs (Lee et al., 2016). Other potential targets of drug action,
besides efflux transporters, are proposed in reviews by Yu and Xie
(2016) and Kang et al. (2004). Drug absorption studies with gastric
cancer tissue is highly recommended to assess the drug absorption
characteristics of a therapeutic compound as performed by
Hultman et al. (2014).
Drug absorption changes in cancer types affecting other GI segments
and accessory organs of digestion, such as aggressive pancreatic cancer,
hepatic cancer or the very rare small intestine carcinoma, remain
poorly studied. In the case of pancreatic cancer, the altered function of
the gland leads to decreased exocrine secretions, changes in in-
traluminal pH, motility disorders and bacterial overgrowth in the in-
testine (Feig et al., 2012; Ma et al., 2019; Olesen et al., 2013). These
effects directly influence drug absorption from the GI tract, especially in
the case of lipophilic drugs whose dissolution is decreased with lowered
exocrine function of pancreas. Drug resistance is also seen in pancreatic
cancer, most likely related to the increased expression of mono-
carboxylate transporter 4 and solute carrier 1A5 (Grasso et al., 2017).
Further research is needed to understand the mechanism of drug sen-
sitivity and resistance through ABC carriers in pancreatic carcinoma as
proposed by Adamska and Falasca (2018). Pathological changes in
small intestinal tissue can potentially affect the absorption process, but
since typically only a small area of the total small intestinal surface is
affected, the impact on the overall absorption is limited.
As mentioned above, colon transit time in the general population is
characterized by large inter-individual differences (Becker et al., 2014;
Sarosiek et al., 2010). Unfortunately, no data on colorectal cancer effect
on colon transit time could be found. Although bowel motility changes
have been widely accepted as one of the signs of colon cancer, findings
from the epidemiological studies are giving inconsistent results
(Park et al., 2009; Simons et al., 2010). No effect on the transit time
through the upper GI tract was noticed after colorectal resection as
therapy of colon cancer (Matsuoka et al., 2011). As with the colon
transit time, previous studies have shown no differences in intraluminal
pH at patients diagnosed with colorectal cancer (McDougall et al.,
1993; Pye et al., 1990). Further analysis in terms total colonic fluid
volume and composition in colorectal cancer patients are required since
very scarce data are available for these properties, which will affect
drug transit and absorption.
Colorectal cancer starts with epithelial changes in the colon by
formation of adenomatous polyps (Simon, 2016), which can affect the
absorption process through the colonic epithelium. The absorption of
some drugs depends on membrane transporters, which are present to a
greater extent on the surface of colonic epithelial cells compared to
other parts of the GI tract (Calcagno et al., 2006). The expression of
membrane transporters in the GI tract is influenced by pathophysiolo-
gical processes such as cancer. Various studies have identified modified
expression of membrane transporters in intestinal cancer cells, in par-
ticular for members of the ABC or solute carrier group of proteins
(Cui et al., 2017; Devriese et al., 2017; Lozoya-Agullo et al., 2015;
Pinheiro et al., 2008; Trumpi et al., 2015). Several comprehensive re-
cent reviews on variation of the transporter expression on cancer cell
membranes in different stages of the disease, as well as in different
colorectal cancer cell lines, are available (Da Silva et al., 2015;
Gonçalvesa and Martel, 2016). For the purpose of testing intestinal drug
absorption, model systems such as the Caco-2 cell line (Calcagno et al.,
2006; Devriese et al., 2017; Tannergren et al., 2009) and murine cell
models (Kim et al., 2012) have been used. Caco-2 cells appear to be
more similar to healthy small intestinal tissue than to cancerous col-
orectal tissue (Calcagno et al., 2006). Thus there is a need for colon
cancer cell lines to study the absorption properties of cancer cells. These
model systems should preferably be accompanied with tests on ex vivo
tissue samples, as suggested by Calcagno et al. (2006) and Collett et al.
(2008). Increased expression of drug efflux transporters (P-gp, BCRP,
multidrug-resistance-associated protein) in colorectal cancer cells
(Hu et al., 2016) accompanied with increased glycosylation of the
transporters and other molecules on the cancer cell membrane
(Very et al., 2018) has been reported. The expression of certain drug
transporters also correlates with the progression of the disease
(Gotanda et al., 2013; Hlavata et al., 2012). In vitro models of drug
absorption in cancer have been developed based on the expression of
transporters in cancer cells in order to predict the absorption of drugs
dosed in combination therapies (Bekusova et al., 2018).
Bekusova et al. found that the paracellular permeability (opening of
tight junctions) in colorectal cancer varies depending on the tumour
location. The tumour tissues were less permeable than the intact in-
testinal membrane, while the tumour-adjacent tissues exhibited an in-
creased paracellular permeability (Bekusova et al., 2018). Passive
transcellular absorption of drugs is also affected by neoplastic changes
of the colonic cells. Changes in the properties of the transcellular
transport systems in cancer cells should be considered when designing
the new molecular entities intended for treatment of colon cancer.
As presented, cancer pathologies of the GI tract do affect drug ab-
sorption through the alteration of the GI tract physiology, in particular
the modification or damage of the GI epithelium. These alterations
require careful consideration when patients are treated with oral
therapeutics to treat the disease itself or associated comorbidities such
as diabetes or hypertension.
4.3. Roux-en-Y gastric bypass
The prevalence of obesity is growing (see above), and it is associated
with an increased demand for bariatric surgery; especially Roux-en-Y
gastric bypass (RYGB, Fig. 2) and sleeve gastrectomy are gaining
ground. With a sleeve gastrectomy, there is only a restriction of the size
of the stomach by creating a gastric tube (Neff and le Roux, 2014).
When performing a RYGB, a small gastric pouch is formed and the
proximal part of the small intestine is bypassed. The gastric remnant
and bypassed biliary limb is reconnected to the intestine 75 to 150 cm
distal to the anastomosis between the gastric pouch and distal part of
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the jejunum. These anatomical and physiological changes of the GI tract
including changes in volume of the stomach, gastric pH, gastric emp-
tying, inlet of bile acids, surface area for absorption and transit time,
can all affect the intestinal drug absorption. This can result in altered
drug disposition, namely decreased (Gesquiere et al., 2016), increased
(Padwal et al., 2011) or comparable (Gesquiere et al., 2015) bioavail-
ability after RYGB. A good insight into these changes is important as
they can result in potentially dangerous over- or under-dosing. In this
section, we focus on the changes following RYGB.
Gastric mixing promotes disintegration, which is required for drug
absorption. Gastric mixing, and thus disintegration, may be reduced as
the stomach volume is reduced after RYGB (Padwal et al., 2010). To
avoid the need for disintegration, drugs can be administered as a liquid
formulation, crushing/chewing solid formulation or as an or-
odispersible formulation, if this is available for the drug involved.
A small gastric pouch, which is separated from the native stomach,
is created in patients with a gastric bypass. In the study of Smith et al.
(patients with RYGB: n = 10; controls: n = 15), the gastric acid se-
cretion from the gastric pouch was markedly reduced compared to the
gastric acid secretion from the total stomach of age- and sex-matched
control subjects (Smith et al., 1993). This was the case for both the
basal secretion (mean± Standard error of the mean:
0.01 ± 0.01 mEq/h post-RYGB vs. 4.97 ± 0.66 mEq/h in the control
group) and the pentagastrin-based stimulated secretion
(0.08 ± 0.04 mEq/h post-RYGB vs. 12.11 ± 1.34 mEq/h in the
control group) (Smith et al., 1993). These findings were confirmed by
Behrns et al. (Behrns et al., 1994), indicating that the gastric acid se-
cretion after gastric bypass is negligible as most of the parietal cells
(i.e., acid-producing cells) are bypassed. This results in an elevated
gastric pH, which will have an impact on the solubility of drugs as it
influences the ionization (De Smet et al., 2013). Basic drugs will have a
decreased solubility after RYGB as there is less ionization, and acidic
drugs will have an increased solubility, as there is more ionization. In
modelling studies, an average pH of 6.6 was set to simulate the gastric
pouch after RYGB in fasted state (Darwich et al., 2012; Seaman et al.,
2005). An in vitro analysis of the dissolution of psychiatric medications
after RYGB showed that the dissolution of 10 out of 22 drugs was sig-
nificantly reduced, while two drugs had significantly greater dissolution
in a post-RYGB environment in comparison with a control environment
(Seaman et al., 2005). The level of dissolution gives no direct in-
formation on the therapeutic effect of drugs, but it provides already an
indication of the level of absorption since the absorption of drugs is
often limited by the dissolution rate.
Gastric content, hormones and neural influences regulate gastric
emptying. It has been shown by different methods (e.g., D-xylose test,
paracetamol test and scintigraphic measurements) that gastric emp-
tying for liquids is accelerated after RYGB (Dirksen et al., 2013;
Horowitz et al., 1982; Morinigo et al., 2006; Näslund and
Beckman, 1987; Wang et al., 2012). Oral administration of a liquid drug
may therefore result in faster absorption and in a shorter time to reach
Cmax. The influence of RYGB on gastric emptying for solids is more
controversial, as Horowitz et al. have shown that the gastric emptying
for solids is slower postoperatively, while Dirksen et al. have shown
that it is faster (Dirksen et al., 2013; Horowitz et al., 1982).
RYGB is associated with alterations of the anatomical structure of
the upper intestinal tract, which could affect the enterohepatic re-
circulation of bile acids. The inlet of bile acids and pancreatic juices in
the small intestine is delayed, thus the interaction between these
compounds and food/drugs is delayed (Neff et al., 2013). These
changes have mainly an impact on lipophilic drugs as they depend on
bile acids for their dissolution/solubility. Furthermore, lipophilic drugs
often undergo enterohepatic recirculation, influencing its steady-state
concentration (Padwal et al., 2010). Patti et al. showed that, in in-
dividuals who had undergone a RYGB 2–4 years before (n = 9), the
serum concentration of bile acids was more than twofold higher than in
overweight (n = 10) or severely obese individuals (n = 5) without
bariatric surgery (Patti et al., 2009). This was the same for the in-
dividual bile salts taurodeoxycholic, glycocholic, glycochenodeoxy-
cholic, and glycodeoxycholic acids. This has been confirmed by Si-
monen et al. (n = 30) (Simonen et al., 2012), who have also shown that
the total serum bile acid concentration in fasted state was twofold in-
creased post-RYGB. However, the increased secretion of bile acids may
not be sufficient to compensate the delayed inlet as it has been shown
that the absorption of fat is reduced after RYGB, as mentioned before
(Carswell et al., 2014; Kumar et al., 2011; Odstrcil et al., 2010).
Dirksen et al. have studied the small intestinal transit time after a
meal by a scintigraphic technique in 17 patients who had undergone a
RYGB more than a year before and in 9 healthy control subjects. They
have shown that the small intestinal transit time was longer in patients
with RYGB compared to control subjects (Dirksen et al., 2013). This
does not entirely correspond with the findings of Morinigo et al., who
observed that, by performing a lactulose breath test, the oro-caecal
transit time was shorter in RYGB-patients. However, the oro-caecal
transit includes pouch emptying and small intestinal transit, so it re-
flects not only the intestinal transit time (Morinigo et al., 2006). Cars-
well et al. have also measured the oro-caecal transit time using sul-
phasalazine. In this study, RYGB had no impact on the oro-caecal transit
time (Carswell et al., 2014). Dirksen et al. have also determined the
colonic transit time, which was unaltered after RYGB (Dirksen et al.,
2013).
By performing a RYGB, a part of the stomach and the proximal small
intestine is bypassed resulting in a reduction of the functional GI length
(Neff et al., 2013). Moreover, the proximal small intestine has the lar-
gest surface area of the GI tract by the presence of villi and microvilli. A
bypass of the duodenum and the proximal part of the jejunum results in
a large reduction of the surface area for absorption (Miller and
Smith, 2006; Spak et al., 2010). This can have an impact on the bioa-
vailability of drugs, especially since most of the orally administered
drugs are maximally absorbed in the small intestine (Padwal et al.,
2010). Besides, Spak et al. have shown that the appearance of the
mucosa of the Roux-limb is altered 6–8 months after the surgery
(Spak et al., 2010). They showed that the height of the villi was de-
creased after RYGB, which also contributes to the reduction of the
surface area. However, cell proliferation was increased, which might be
a compensatory mechanism for the loss of cells at the tips of the villi.
The influence of drug metabolism and drug efflux may vary over
distinct parts of the intestine (Padwal et al., 2010). The expression of P-
gp increases from the proximal to the distal small intestine, while the
expression of CYP450 enzymes is the highest in the duodenum and
jejunum and decreases to more distal sites (Stappaerts et al., 2013).
Bypassing parts of the small intestine with a high abundance of CYP450
isoenzymes can therefore lead to alterations in oral drug bioavailability
as there will be less metabolism and may thus increase the relative
influence of P-gp. The majority of drugs enter into the systemic circu-
lation by passive diffusion from the GI tract, provided that they are non-
Fig. 2. Schematic representation of Roux-en-Y gastric bypass (RYGB).
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ionized. Ionized drugs often require active transport for absorption.
However, receptors and transporters are not homogenously distributed
throughout the small intestine; hence, bypassing the proximal part of
the small intestine can be associated with bypassing receptors or
transporters. This can influence the bioavailability of drugs that need
these transporters for absorption (Smith et al., 2011).
4.4. Celiac disease
Celiac disease is an autoimmune disorder occurring in genetically
predisposed individuals, in whom the ingestion of gluten, a protein
from wheat, barley and rye, leads to an immune reaction in the small
intestine. Celiac disease generally affects around 1% of the population
worldwide (Lebwohl et al., 2018). The occurrence has increased over
the past 50 years, and is higher in some countries, e.g., Finland, than in
others, e.g., Germany (Lebwohl et al., 2018; Mustalahti et al., 2010). It
is estimated that more than two million Americans with celiac disease
are not diagnosed and can be at risk for long-term health complications.
Prolonged gluten intake in undiagnosed patients can lead to an increase
in the incidence of autoimmune diseases such as T1DM, IBD, auto-
immune thyroiditis, and also an increased mortality rate
(Ludvigsson et al., 2015; Rubio-Tapia and Murray, 2010). The current
treatment of celiac disease is a gluten-free diet, and hereby most
symptoms, but not all, can be alleviated (Lebwohl et al., 2018; Rubio-
Tapia and Murray, 2010; Samsel and Seneff, 2013).
The classical symptoms of celiac disease include chronic diarrhoea
and weight loss, but also symptoms like bloating, constipation, chronic
fatigue, headache, abdominal pain, and osteoporosis are prevalent
(Downey et al., 2015). Celiac disease is manifested in the small intestine
as an increased number of intraepithelial lymphocytes, crypt hyper-
plasia, and villous atrophy (Lebwohl et al., 2018; Rubio-Tapia and
Murray, 2010). Most often, villous atrophy is found in the duodenum,
but it can also affect more distal parts of the small intestine. The areas
of villous atrophy tends to be patchy and are dispersed between regions
of normal mucusa (Ciaccio et al., 2016). Villous atrophy results in a
flattening of the microvilli, which in turn gives a decreased absorptive
surface area in the intestine, which can impair the ability to absorb
nutrients (Ciaccio et al., 2016; Samsel and Seneff, 2013). Accordingly,
celiac disease is associated with deficiencies in iron, vitamin D3, mo-
lybdenum, selenium, and cobalamin (Samsel and Seneff, 2013). It is
therefore possible that intestinal drug absorption will also be negatively
affected. However, it is also well accepted that the intestinal perme-
ability is increased, in part due to opening of tight junctions, which can
potentially increase drug absorption (Heyman et al., 2012;
Kuitunen and Savilahti, 1996; Vilela et al., 2008).
Details on other changes in the small intestine in untreated celiac
disease are scarce. A single study has examined the pH on the jejunal
surface in untreated patients and compared it with the pH of patients on
a gluten-free diet. The study showed a significantly higher pH in un-
treated celiac disease patients, which also might impact absorption of
ionizable drugs (Kitis et al., 1982). Another study by Lang et al. (1996)
found that the activity of CYP3A4 was decreased in adult untreated
patients, compared to healthy subjects, and Johnson et al. found the
same for paediatric celiac disease patients (Johnson et al., 2001). This is
likely to be related to the villus atrophy, as the CYP enzymes are pri-
marily located in the apex of the enterocytes, in a band just below the
microvillar border (Lang et al., 1996). This decrease in CYP3A4 is
normalized when patients where on a gluten-free diet (Lang et al.,
1996; Samsel and Seneff, 2013).
Celiac disease is associated with delayed gall bladder emptying and
decreased pancreatic secretions (Benini et al., 2012). The fasting gall
bladder volume and the post prandial residual volume are significantly
higher in celiac disease patients compared to controls. These symptoms
are reversible and disappear when celiac disease patients get on a
gluten free diet. Unfortunately, the intestinal bile salt concentrations
have not been determined in any of these patient groups (Benini et al.,
2012; Usai-Satta et al., 2018).
In general, the mouth-to-caecum transit time has been reported to
be slower in untreated celiac disease patients, compared to healthy
controls, but the literature does not agree as to whether this is nor-
malized when patients are on a gluten-free diet (Benini et al., 2012;
Chiarioni et al., 1997). The gastric emptying time is prolonged in un-
treated celiac disease patients, but is normalized upon intake of a
gluten-free diet (Benini et al., 2012; Elli and Bardella, 2005; Perri et al.,
2000). In addition, the transit time of a meal through the small intestine
is delayed in celiac disease patients, probably due to functional al-
teration of small intestinal motility, whereas there are no changes in the
colonic transit time (Benini et al., 2012; Usai-Satta et al., 2018). An
abnormal gastrointestinal motor activity, indicating a neuropathic dis-
order, in untreated celiac disease patients has been observed and this is
persisting in most adult celiac disease patients also during a gluten free
diet (Bassotti et al., 2008; Benini et al., 2012). The mechanism involved
in this remains unclear, but there might be a low-grade mucosal in-
flammation even on a gluten-free diet. This in turn has recently been
connected to an intestinal sensorimotor dysfunction (Usai-Satta et al.,
2018).
The microbiota in celiac disease patients has been shown to be al-
tered, as compared to healthy subjects. Often reduced levels of the
commensal bacteria Enterococcus, Bifidobacteria and Lactobacillus are
found, together with an overgrowth of pathogenic gram-negative bac-
teria (Di Cagno et al., 2011; Sanz et al., 2011). A gluten-free diet will
change the microbiome, but this is also the case in healthy individuals.
Drug absorption studies in treated and untreated celiac disease pa-
tients mostly date back to the 70ties and 80ties and all involve a rather
low number of patients (up to 14), and often lack proper controls. In
these studies, many drugs showed a higher absorption in celiac disease
patients, as compared to control subjects (propranolol, cephalexin,
clindamycin, sulfamethoxazole, trimethoprim and methyldopa),
whereas paracetamol and practolol displayed a lower absorption
(Tran et al., 2013). Thus, a conclusion on the impact of celiac disease on
drug absorption cannot be drawn on this point. However, the physio-
logical changes described above make it possible that drug absorption is
altered, but more clinical studies in untreated celiac disease patients are
needed.
4.5. Lactose intolerance
Lactose intolerance is the consequence of decreased or absent lac-
tase activity in the brush border of the small intestinal epithelium re-
sulting in malabsorption of lactose in the small intestine and fermen-
tation of it in the large intestine. The primary effect concerning drug
absorption is related to the osmotic effect of the non-absorbed lactose
that also results in diarrheal symptoms. The prevalence of lactase de-
ficiency has been described in most regions of the world and in people
with diverse ethnic backgrounds. However, the prevalence of lactose
malabsorption and lactose intolerance is unclear due to methodological
limitations. The lowest prevalence was seen in Europeans and European
Americans and higher prevalence in African Americans, Hispanics,
Asians, Asian Americans, and Native Americans (Suchy et al., 2010).
Particularly, Asian populations present higher prevalence of lactose
intolerance, which originates from the high prevalence of lactase dec-
ifiency in these populations (Goh et al., 2018).
The effect of lactose intolerance has most extensively been in-
vestigated in patients undergoing thyroid hormone replacement
therapy. Lactose intolerance can cause malabsorption of levothyroxine:
eliminating lactose from the diet leads to decreased values of thyroid-
stimulating hormone in the serum of patients with both Hashimoto
thyroiditis and lactose intolerance, indicating less effective absorption
of the drug (Asik et al., 2014; Cellini et al., 2014; Munoz-Torres et al.,
2006). Therefore, in patients resistant to levothyroxine therapy, lactose
intolerance should be considered as a cause. The most recent advance
concerning levothyroxine therapy is the development of a novel oral
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liquid preparation that has been shown to overcome different malab-
sorption conditions (Fallahi et al., 2017).
Another study investigated the absorption of isoflavones, which
have preventive effects against loss of bone mass and cardiovascular
diseases. Serum isoflavone metabolites were measured in participants
with and without evidence for lactose malabsorption. Interestingly, the
lower absorption of isoflavone glucosides induced by low lactase ac-
tivity was compensated by bacterial deglycosylation in the large in-
testine in humans. Therefore, the effect of lactose intolerance on drug
absorption depends on the chemical properties of the drug in question,
as well as the extent to which the colon participates in drug assimilation
processes (Tamura et al., 2008).
4.6. Infectious diseases of the gastrointestinal tract
GI tract infections include acute and chronic disorders of the di-
gestive apparatus induced by viruses, bacteria, and parasites. Most GI
tract infections are self-limiting and exhibit acute symptoms lasting 5 to
7 days. However, in some cases the symptoms can persist over a longer
period of time and result in a prolonged, persistent, or even chronic
disease state. Typical symptoms comprise diarrhoea, nausea, vomiting,
abdominal cramping, fever, and/or dysentery. Nausea is typically as-
sociated with an increased stomach emptying time. In case of diarrhoea
the intestinal motility is often increased which results in a shorter in-
testinal transit time (Higgs et al., 1975; Spiller, 2006). The overall stool
volume is increased and the viscosity of intestinal contents decreased
compared to a healthy gut (Schiller, 1999). Finally, GI tract infections
can also result in the damage of the intestinal membrane barrier
(Barnes and Townley, 1973; Ford et al., 1985) and are often linked to
the disruption of the intestinal microbiota system (Aebischer et al.,
2006; Kuehl et al., 2005; Sekirov and Finlay, 2009).
The impact of the pathophysiology of GI tract infections on oral
drug absorption largely depends on the type, severity, and duration of
symptoms. The increased stomach emptying time, associated with
nausea and vomiting, delays the onset of action of medications and may
result in uncontrolled or sub-therapeutic plasma concentrations. The
selection of appropriate dosage forms, such as sublingual or orally
disintegrating tablets, suppositories, or parenteral formulations is
therefore particularly important in the treatment of patients exhibiting
nausea or concomitant diseases.
The decrease in intestinal transit time can significantly affect the
absorption of drugs exhibiting an absorption window or pre-systemic
metabolism as observed with tacrolimus and cyclosporine. Tacrolimus
is rapidly absorbed in the duodenum and jejunum. The absorption is
limited by the efflux-transporter P-gp, and tacrolimus undergoes ex-
tensive pre-systemic metabolism by CYP3A4 in the gut wall, which both
reduce the oral bioavailability to approximately 20%. In gastroenteritis
patients, P-gp-mediated efflux and pre-systemic metabolism are re-
duced due to impaired enterocytes. This results in significantly higher
tacrolimus trough levels (Eades et al., 2000; Hochleitner et al., 2001).
The opposite effect is observed with cyclosporine A. Cyclosporine A is
subject to an absorption window in the small intestine, and the re-
sidence time in this segment was shown to be an important determinant
of oral cyclosporine exposure (Drewe et al., 1992). In gastroenteritis
patients, the increased GI motility and reduced residence time in the gut
was shown to significantly reduce the oral cyclosporine exposure.
The impact of membrane damage on oral exposure is difficult to
predict and can result in either an increase or a decrease in drug ab-
sorption. The loss in mucosal integrity results in an increased permea-
tion of compounds, while villous shortening reduces the absorptive
surface area and thus may reduce the total absorption of compounds
(Ford et al., 1985). This severe condition directly influences the ab-
sorption of oral compounds exhibiting permeability-limited exposure or
which are intended for local activity, such as vancomycin (Oami et al.,
2017). Such damage typically occurs in case of prolonged symptoms or
massive diarrhoea, and therefore, it must be kept in mind that a specific
drug may show different absorption behaviour depending on the length
and severity of the GI tract infection (Bolme and Margareta, 1975;
Nelson John et al., 1972). Little is known about the impact of GI tract
infections on the expression and activity of membrane transporters. The
intestinal gut membrane typically regenerates within 2-4 weeks and the
absorption of oral compounds may still be altered after the recovery
from clinically evident GI tract symptoms.
The microbial imbalance occurring during GI tract infections is
critical for drugs that are activated or inactivated by the intestinal
microbiome (Li et al., 2016), as reported for several compounds in-
cluding immunosuppressant, antineoplastic, and cardiovascular medi-
cines (Enright et al., 2016). The impact of the intestinal microbiota
system on oral drug absorption is particularly critical for low solubility
and/or low permeability compounds, as well as for extended release
formulations, which are subject to long residence time in the gut and
may therefore interact with the intestinal microbiome.
The impact of infectious GI tract diseases on oral drug absorption is
very variable and difficult to predict a priori. It does not only depend on
the type, severity, and duration of GI symptoms, but also the specific
biopharmaceutical properties of the compound and its dosage form. In
the absence of predictive biopharmaceutical methods simulating such
altered GI tract conditions, a good mechanistic understanding of the
absorption behaviour of the drug (e.g., absorption window, perme-
ability- vs. solubility-limited absorption etc.) is key for estimating the
impact of GI tract infections on oral exposure. Attention must be di-
rected towards medicines with a narrow therapeutic index, for which
careful plasma concentration monitoring should be considered to en-
sure safety and efficacy.
4.7. Helicobacter pylori infection
Helicobacter pylori (H. pylori) is a highly prevalent pathogen causing
a chronic inflammation of the gastric mucosa. The clinical outcome
ranges from an asymptomatic gastritis to serious conditions such as
peptic ulcer or gastric cancer.
H. pylori infection is known to induce alterations in some physio-
logical functions of the stomach, particularly affecting gastric acid se-
cretion and GI motility. The impact on gastric acidity depends on the
severity of the infection and distribution of the affected tissue in the
stomach. Inflammation in the antral region is associated with increased
production of gastrin, which in turn increases acid secretion in the
gastric corpus. However, if the corpus is affected by severe inflamma-
tion, the response to gastrin is greatly reduced, resulting in reduced
capacity to secrete acid (El-Omar, 2006). Thus, H. pylori positive sub-
jects can exhibit either increased or decreased stomach acidity. Be-
tween 25 and 40% of patients also exhibit antral hypomotility and a
delayed gastric emptying (Mearin et al., 1995; Miyaji et al., 1999;
Thor et al., 1996). Furthermore, there is increasing evidence that H.
pylori infection affects the GI functions indirectly by influencing the
brain-gut axis (Budzynski and Klopocka, 2014). This may have an im-
pact on the pathophysiology of other organs than the stomach, and
generate disturbances in permeability, motility and secretion along the
entire GI tract (Budzynski and Klopocka, 2014; Gerards et al., 2001;
Su et al., 2000).
The physiological changes induced by H. pylori infection can have a
significant impact on the drug absorption process and thus important
clinical implications as highlighted in several systematic reviews
(Fiorini et al., 2015; Lahner et al., 2009; Lahner et al., 2014). Particu-
larly, oral compounds and formulations with pH-dependent solubility
need careful evaluation when administered to H. pylori positive pa-
tients, as observed with thyroxine (Centanni et al., 2006), L-dopa
(Pierantozzi et al., 2006; Pierantozzi et al., 2001), and delaviridin
(Shelton et al., 2000; Shelton et al., 2003). However, more research is
needed to capture the pathophysiology of H. pylori infections, its impact
on the function of the entire GI tract, and thus, the clinical implications
on oral drug absorption.
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5. Systemic diseases that change GI conditions
5.1. Parkinson's disease
Parkinson's disease (PARKD) is a progressive neurodegenerative
disease that is classically diagnosed after the manifestation of visible
motor symptoms such as rigidity, bradykinesia, tremor and postural
instability. However, there is a growing body of evidence supporting
the hypothesis that non-motor features, especially a variety of GI
symptoms could be considered as early biomarkers since they are pre-
valent among confirmed patients and occur much earlier than the
cardinal signs of PARKD, i.e., the motor symptoms (Pfeiffer, 1998;
Poirier et al., 2016).
A thorough understanding of the broad spectrum of clinical mani-
festations of PARKD is essential for a proper diagnosis of the disease.
There is evidence that pathological processes that lead to PARKD could
be initiated in the enteric nervous system before spreading to the cen-
tral nervous system. This would be an explanation for the early oc-
currence of GI symptoms, but to date the pathophysiology of the enteric
nervous system component in the aetiology of PARKD is not completely
understood (Poirier et al., 2016). According to numerous review articles
on GI dysfunctions in PARKD patients published in the recent past, a
more detailed picture of the presence and extent of GI dysfunction in
PARKD is emerging and over the last decades many abnormalities or
disturbances in function at virtually all levels of the GI system have
been identified (Fasano et al., 2015; Jost, 2010; Kim and Sung, 2015;
Pfeiffer, 2011; Poirier et al., 2016; Su et al., 2017).
A detailed understanding of how and to which extent the GI system
is affected in which state of the disease would be essential for devel-
oping better oral PARKD medications. It would improve the estimation
of how dosing regimens for orally administered drug might be affected
by the stage of the disease (Wollmer and Klein, 2017) and the devel-
opment of appropriate experimental models when the aim is to predict
drug release and absorption in PARKD patients using in vitro and in silico
tools.
With the aim of better predicting in vivo drug release and absorption
of orally administered drugs in PARKD patients, Wollmer and Klein
recently reviewed the literature for a reliable set of PARKD -specific GI
parameters (Wollmer and Klein, 2017). They found that the level of
detail of information available is limited and that reports focus on the
discussion of general GI symptoms rather than specific GI parameters.
Typical PARKD-related GI symptoms range from oral issues, in-
cluding drooling, swallowing problems, nausea, vomiting, early satiety,
bloating and weight loss to constipation which is regarded as one of the
most common symptoms (Fasano et al., 2015; Pfeiffer, 2011; Su et al.,
2017). These symptoms are, however, just indicators of serious phy-
siological alterations of several GI parameters including a reduced
salivary secretion rate and an impaired motility of oesophagus, sto-
mach, and the intestines amongst others. An altered GI environment
and transit time may seriously affect PK of orally administered drugs.
To date, this issue has been mainly discussed for orally administered
PARKD drugs (Fasano et al., 2015; Pfeiffer, 2011), but is of equal im-
portance for all other oral medications taken by a PARKD patient, not
only in an advanced stage of the disease, but particularly in early
phases, when motor symptoms are not yet developed and the patient is
sometimes not even diagnosed with PARKD.
Based on their literature review Wollmer and Klein concluded that
even though there is quite a reasonable set of data available on para-
meters, such as salivary secretion, oropharyngeal and oesophageal
passage and gastric emptying, there is still a big lack in knowledge that
would be required for addressing all parameters that might be relevant
for drug release and absorption during a GI passage in a PARKD patient.
The latter is particularly true for contractile motility patterns and
pressures in the entire GI tract as well as for the small intestinal transit
time. Moreover, it seems that to date next to no attention has been
given to potential disease-related changes in GI fluid composition
(Wollmer and Klein, 2017). With the availability of novel non-invasive
diagnostic options, such as for instance the wireless motility capsule
and magnetic resonance imaging and a proper test design, it will
hopefully be possible to gather the required information in the near
future.
5.2. Cystic fibrosis
Cystic fibrosis (CF) is an autosomal genetic disorder, caused by
mutations in the CF transmembrane conductance regulator (CFTR) gene
(Gelfond and Borowitz, 2013). World-wide, around 70-80.000 people
suffer from CF. In the past, life expectancy for a CF patient was 15-20
years and it was therefore considered a fatal paediatric disease. How-
ever, in the last decades life expectancy has increased to 40-50 years,
especially in developed countries (Bowen and Hull, 2015;
Elborn, 2016). This is partly caused by prophylactic use of oral anti-
biotics to avoid pulmonary infections (Elborn, 2016).
The CFTR protein is responsible for ion transport across the epi-
thelium, i.e., the lungs and the GI tract, including the pancreatic and
hepatobiliary systems (Gelfond and Borowitz, 2013). Mutations in the
Fig. 3. Schematic illustration of the transporter defects leading to cystic fibrosis (copied from Kumar, 2014 with permission).
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CFTR protein results in an abnormal chloride and bicarbonate transport
across the apical membrane of the epithelial cells. This in turn leads to
the formation of thick, viscous mucus secretions in, e.g., the lungs and
the GI tract (Fig. 3) (Bowen and Hull, 2015; Elborn, 2016; Gelfond and
Borowitz, 2013). Most CF patients also have pancreatic insufficiency, as
well as GI dysmotility disorders, such as gastroesophageal reflux, distal
intestinal obstruction syndrome, and chronic constipation (Corral et al.,
2016; Gelfond and Borowitz, 2013). Corral and co-workers recently
reviewed gastric emptying and incidence of gastroparesis in CF pa-
tients. In general, a more rapid gastric emptying was seen in younger
patients, whereas the overall CF population had a gastroparesis fre-
quency of 38%, and this was higher for patients >18 years, and espe-
cially patients with diabetes (Corral et al., 2016).
The impaired pancreatic and intestinal bicarbonate secretion can
lead to a decreased duodenal and jejunal pH, which influences the ef-
fect of the enterocoated pancreatic enzyme supplements, taken by CF
patients to improve food digestion (Tang et al., 2009). The decreased
duodenal and jejunal pH can therefore lead to low and variable ab-
sorption of drugs dosed in enterocoated formulations. All in all, the GI
symptoms of CF patients often lead to poor nutrient and fat absorption
(Duffield, 1996; Elborn, 2016), which in turn could be associated with a
reduced absorption of orally dosed drugs, however, this is not clear
from the literature. For example, lower and more variable drug ab-
sorption for lung transplanted CF patients, compared to non-CF lung
transplanted patients has been observed for tacrolimus (Saint-
Marcoux et al., 2005), whereas no difference in oral absorption com-
pared to healthy volunteers was found for doxycycline (Beringer et al.,
2012). Often studies of oral drug pharmacokinetics in CF patients are
carried out without proper control groups (Touw et al., 2000), thus
better controlled studies are needed in order to conclude if CF patients
in general have impaired drug absorption.
5.3. Diabetes mellitus
Diabetes mellitus is a significant issue with approximately 8.5% of
the adult population being affected (Sarwar et al., 2010). There are two
main types of diabetes: Type 1 (T1DM), an autoimmune disease, where
the body is unable to produce insulin, and Type 2 (T2DM) where insulin
secretion is deficient or there is insulin resistance. T2DM is the domi-
nant form in adults and is strongly linked to obesity.
Several authors have recently reviewed gastric emptying in T1DM
and T2DM (Chang et al., 2010; Kashyap and Farrugia, 2010;
Marathe et al., 2013). Delayed gastric emptying (diabetic gastroparesis)
is observed in 30-50% of diabetic patients, with a similar prevalence
between T1DM and T2DM. However, in some diabetic subjects, ab-
normally rapid gastric emptying can also occur (Chang et al., 2010;
Marathe et al., 2013). Alterations in plasma glucose levels also have an
impact on gastric emptying: severe hyperglycaemia slows gastric
emptying of solids and liquids, whereas insulin-induced hypoglycaemia
increases the gastric emptying rate, even in subjects with an underlying
delay in gastric emptying (Chang et al., 2010). An increase in gastric pH
is associated with diabetic gastroparesis (Hasler et al., 2008).
Wegener et al. investigated GI transit in insulin-treated diabetic
patients (Wegener et al., 1990). Three aspects of GI transit were stu-
died, i.e., gastric emptying (using scintigraphy), oro-caecal transit time
(using a hydrogen breath test), and whole gut transit time (using ap-
pearance of indigocarmine in the stool). Both T1DM and T2DM patients
were enrolled in the study, which was performed in the fed state.
Gastric emptying was significantly delayed in diabetic patients com-
pared to healthy controls. While the difference in median % gastric
retention at 60 min was modest (approximately 69% vs. 72% in healthy
controls), 35% of diabetic patients had a % retention at 60 min that was
higher than the upper limit of the normal range. For oro-caecal and
whole gut transit time, there was no significant overall increase in the
diabetic group, although the proportion of subjects with prolonged oro-
caecal transit time (>135 min) or prolonged whole gut transit time
(>29 h) was higher in the diabetic group than in the control group
(23.0% vs. 3.6% for oro-caecal, and 25.6% vs. 3.0% for whole gut
transit time). This remained significant when patients with prolonged
gastric emptying time were removed from the analysis. No patient had
abnormal transit times in all three compartments reported (gastric,
small intestinal, and mouth to caecum), suggesting that there was an
impact on specific segments of the intestine rather than an overall effect
on the whole GI tract. The presence of autonomic neuropathy corre-
lated significantly with delayed gastric emptying, although there was
no significant difference in oro-caecal or whole gut transit time in pa-
tients with or without autonomic neuropathy. This is in contrast to the
work of Scarpello et al., who reported a significant prolongation of oro-
caecal transit time in diabetic patients with autonomic neuropathy
versus patients without autonomic neuropathy or healthy volunteers
(hydrogen appearance time 140.2 min compared to 69.8 or 70.8 min,
respectively) (Scarpello et al., 1976). This study was performed in the
fasted state.
Increased intestinal permeability has been reported in patients with
T1DM and T2DM and in animal models of the disease, as assessed by
sugar permeability tests (Vaarala et al., 2008; Zhong et al., 2016). This
is attributed to a more permeable mucosal barrier (‘leaky gut’), due to
intestinal inflammation and altered interepithelial tight junctions
caused by hyperglycaemia (Thaiss et al., 2018).
Chronic diarrhoea is a common symptom of diabetes, occurring in
10–22% of patients. 43% of patients presenting chronic diarrhoea show
evidence of small intestinal bacterial overgrowth (Virally-Monod et al.,
1998). Cuoco et al. demonstrated that treatment of small intestinal
bacterial overgrowth with antibiotics accelerated oro-caecal transit
time in the majority of diabetic patients (62%) (Cuoco et al., 2002).
There is growing evidence that the composition of the intestinal mi-
croflora in T2DM patients is different compared to healthy controls,
e.g., a lower amount of butyrate-producing bacteria is reported
(Tilg and Moschen, 2014). Disbiosys of the microflora caused by, e.g.,
antibiotic therapies and low-fibre diet, results in reduced production of
short-chain fatty acids, which impacts the pathogenesis of T2DM
(Aw and Fukuda, 2018).
Antidiabetic agents can also have a significant impact on GI con-
ditions. Metformin is widely prescribed in T2DM, and up to 25% of
subjects suffer from GI side effects (McCreight et al., 2016). Its effects
on the GI tract were recently reviewed by McCreight et al. (2016); key
mechanisms of interest form a biopharmaceutics perspective are briefly
summarised here. Metformin increases intestinal glucose uptake, which
is the basis of an interaction with the imaging agent F-18-fluordeox-
yglucose. However, the mechanism by which metformin increases
glucose uptake is currently unclear. Metformin was also shown to in-
crease glucagon-like peptide 1 (GLP-1) concentration in mice and in
humans, probably through an increase in GLP-1 secretion. GLP-1 can
slow down gastric emptying (Marathe et al., 2013), although there do
not appear to be any reports that directly make this link for metformin.
Metformin has structural similarities to 5-hydroxytryptamine agonists,
and stimulates the intestinal release of 5-hydroxytryptamine in vitro. 5-
hydroxytryptamine release in the intestine is associated with nausea,
vomiting and diarrhoea, and it is hypothesised that this could be one
mechanism responsible for the GI side effects observed with metformin.
Finally, metformin increases the concentration of bile acids in the small
intestine by reducing their ileal absorption and it alters the gut mi-
crobiome in mouse and human.
GLP-1 agonists used to treat T2DM, such as exenatide, have GI side
effects including nausea and diarrhoea. These agents can slow down
gastric emptying through their pharmacological action on GLP-1 re-
ceptors (Marathe et al., 2013). Exenatide administered twice daily de-
lays gastric emptying in a dose-dependent manner; the half-emptying
time for the solid component of a test meal was increased by 1.9- and
2.8-fold for 5 µg and 10 µg exenatide doses, respectively, and for the
liquid meal components increased by 2.6- and 3.4-fold, respectively
(Linnebjerg et al., 2008). The impact of long-acting GLP-1 agonists on
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gastric emptying appears to diminish with time, whereas this is not the
case for short-acting GLP-1 agonists (Marathe et al., 2013).
In summary, several aspects of GI conditions can differ between
diabetic patients and healthy subjects, which could impact drug pro-
duct performance in this patient group. Delayed gastric emptying could
lead to reduced or delayed Cmax. The longer time spent in the gastric
environment could alter dissolution for drugs with pH-dependent so-
lubility, increasing the time available for dissolution of basic com-
pounds in an acidic environment where they are more soluble, and
delaying the arrival of weakly acid drugs in the small intestine where
the majority of dissolution will occur for these compounds. There could
also be an increase in degradation of drugs which are unstable in an
acidic environment. Increased rate and extent of absorption may be
observed for compounds that normally exhibit permeability-limited
absorption. For drugs which are subject to bacterial metabolism (either
for activation or clearance), the presence of small intestinal bacterial
overgrowth could result in increased bacterial degradation, and oc-
curring at an earlier site in the small intestine before significant ab-
sorption has occurred, and the potentially altered microbiome compo-
sition could result in different metabolic profiles. The side effects of
antidiabetic medications can also affect several aspects of GI functions,
representing an additional source of absorption variability in this pa-
tient population.
5.4. HIV enteropathy
Patients infected with human immunodeficiency virus (HIV) or
patients who develop acquired immunodeficiency syndrome (AIDS)
have reduced immune response that often leads to other comorbidities.
The most common ones are of GI origin, including symptoms such as
diarrhoea, weight loss, vomiting, nausea, and dysphagia (Lim et al.,
1993; Malebranche et al., 1983). In addition, patients with HIV/AIDS
develop certain types of cancer, among which GI malignancies, more
often compared to non-HIV infected patients (Coghill et al., 2015).
HIV enteropathy is a condition characterized by persistent diar-
rhoea, without a pathogen isolated in the stool (Slavik, 2012). Many
theories have been formulated to explain the possible cause(s) of
diarrhoea in HIV patients, however it remains unclear.
As previously shown, HIV affects the mucosal immune system of the
GI tract mostly during the acute infection period, but then again the
influence of HIV on lamina propria immune cells in later stages of the
disease is also confirmed (Dikman et al., 2015). Consequently, the
number of mucosal CD4+ lymphocytes is reduced as compared with
peripheral CD4+ cells in the early stage of HIV infection, and the im-
mune response to usual pathogens decreases (Mehandru et al., 2004).
The number of CD4+ T cells correlates well with GI symptoms
(Thompson et al., 2012). Mucosal CD4+ cells are more susceptible to
depletion in contrast to peripheral CD4+ cells because of the expres-
sion of the specific co-receptor CCR5 (Brenchley and Douek, 2008;
Poles et al., 2001). Inflammation and damaged epithelium (villous
atrophy and blunting and crypt hyperplasia) altogether increase in-
testinal permeability (Batman et al., 2007; Brenchley and Douek, 2008;
Sharpstone et al., 1999). Hence, studies have shown that HIV-positive
patients have vitamin B12 deficiency due to the reduced permeation in
intestines and steatorrhea as a result of decreased fat absorption
(Ehrenpreis et al., 1994). Likewise, the changes in intestinal absorption
can reduce the AUC or Cmax of some antituberculosis drugs, as tu-
berculosis represents a common comorbidity in HIV-positive patients
(Gurumurthy et al., 2004; McIlleron et al., 2012). On the other hand, in
HIV-positive patients without chronic diarrhoea, no significant change
in plasma concentrations of antituberculosis drugs was observed
(van Oosterhout et al., 2015). In addition, proton pump inhibitors or H2
antagonists, often administered to HIV positive patients, can decrease
the absorption of antiretroviral agents by changing gastric pH, and
consequently drugs solubility (Hughes et al., 2015).
Altered absorption in HIV infected patients may also be caused by
the changes in the microbiota. Recent research suggests that microbiota
can be considered as an organ, and as such it has its own pathology that
can influence the functioning of other systems (Baquero and
Nombela, 2012). HIV causes a decrease in certain types of gut bacteria
such as Bacteroides, Lactobacillus and Clostridia. On the other hand,
pathogenic bacteria like Prevotella and Proteobacteria are abundant
resulting in an imbalance in the gut flora. Furthermore, the altered
microbiota induces inflammation that affects the GI mucosa
(Zevin et al., 2016). These can potentially lead to changes in drug ab-
sorption.
5.5. Critical illness
Critically ill patients often depend on pharmacotherapy, however,
they are in a condition in which drug disposition might have changed
and pharmacotherapy might become erratic. Although oral drug ad-
ministration is generally not the preferred route especially for life-
saving drugs, there are nevertheless several reasons for selecting oral
medications, i.e., absence of intravenous access, higher occurrence of
side-effects with intravenous administration, absence of appropriate
intravenous formulations (especially for the paediatric population).
Roberts and Hall reviewed drug absorption considerations in criti-
cally ill adults and identified mesenteric hypoperfusion, increased in-
testinal permeability, decreased functional absorptive capacity, and
delayed gastric emptying leading to significant changes in oral drug
absorption with higher and lower bioavailability (Kar et al., 2015;
Roberts and Hall, 2013).
As inflammation has shown to alter drug metabolism and transport
in the liver, it can be expected that this is also the case for the intestine
(Aitken et al., 2006; Evers et al., 2018; Vet et al., 2016). Indeed, in vitro
studies also show mostly a decrease in transporter gene and protein
expression with inflammatory states as proinflammatory cytokine-in-
duction, high altitude or response to enteropathogenic bacteria
(Evers et al., 2018). At the same time, the complexity and interplay of
drug metabolizing enzymes and transporters make it difficult at this
time to predict the effect on drug bioavailability.
When drugs are given orally to sedated and non-sedated critically ill
patients they are most often administered through gastric or duodenal
feeding tubes. This might impose problems for some drugs, as the need
to be crushed and suspended or dissolved, potentially can reduce sta-
bility or induce chemical characteristics resulting in sticking to tubes.
Enteral administration and the alteration of the drug product may also
significantly modify the rate and/or extent of drug release and ab-
sorption causing wide variability in serum concentrations, as described
for different antibiotics (Roberts and Hall, 2013). A change in pheny-
toin plasma levels was found in patients after starting or discontinuing
enteral feeding compared to normal oral administration, exposing them
to increased risk of seizures. This observation suggests an interaction
with enteral feeding, although the mechanism is not fully understood
(Au Yeung and Ensom, 2000).
Besides the processes specific to oral absorption, other processes
involved in drug disposition (i.e., distribution, metabolism, elimina-
tion) may be altered in the critically ill due to, e.g., body fluid shifts,
alteration in protein binding or pH, renal or hepatic failure, or the need
for life-sustaining measures as extracorporeal membrane oxygenation
or dialysis (Thakkar et al., 2017). Polypharmacy is common in the In-
tensive Care Unit and further contributes to possible changes in oral
drug absorption, e.g., by delaying gastric emptying, altering gastric and
enteric pH, or inducing drug-drug interactions.
In summary, altered oral drug absorption has been observed in
critically ill patients in the past. For these patients there are several
disease-, co-medication-, and medical care-related factors that may af-
fect oral exposure. This complexity represents a major challenge in
predicting drug absorption or making dosing recommendations in this
group of patients.
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6. Physiologically based and population pharmacokinetic
modelling in special populations
Knowledge of a drug's PK and pharmacodynamics and the re-
lationship between them is required to guide appropriate drug dosing
(Standing, 2017). Both of these factors can differ between populations
of healthy individuals and patients and in particular, differences in GI
physiological function can affect a drug's PK profile and consequently
affect drug therapy. Therefore, model informed approaches represent a
valuable tool for drug development in special populations (Suri et al.,
2015).
PBPK models are mathematical representations of the body, para-
meterized based on known physiological data such as tissue composi-
tion, tissue volumes and blood flows (Jones et al., 2015). PBPK models
integrate this physiological description with drug specific data to si-
mulate the time-course of drug concentrations in plasma and tissues.
PBPK models can also describe the processes of drug absorption with
mechanistic absorption models. Commercial implementations of me-
chanistic absorption models (Agoram et al., 2001; Jamei et al., 2009)
are now routinely used in the pharmaceutical industry to address
questions around intrinsic and extrinsic factors influencing oral ab-
sorption such as formulation, and both the FDA (FDA, 2018) and the
European Medicines Agency (EMA, 2016) have recently produced
guidance documents on appropriate use of PBPK models.
Since PBPK models follow a systems pharmacology approach, they
include both system specific and drug specific data where system spe-
cific data refers to the physiology being simulated. When sufficient
knowledge on the influence of disease or non-disease-related conditions
on the GI physiology exists, this may be integrated into the models and
the effects predicted. To verify an initially developed PBPK model and
its assumptions, predictions should be confirmed with in vivo data from
early clinical phases and in this context, a population PK (popPK) model
which describes these data well, can be useful to refine a PBPK model
(Kostewicz et al., 2014). In addition, when clinical data are available,
verification of the special population-based PBPK model predictions can
be performed (Suri et al., 2015).
PopPK modelling is a statistical approach, typically applied to de-
scribe the sources of PK variability in in vivo data obtained in clinical
studies in both healthy individuals and patients. Although popPK is
usually considered a non-mechanistic approach, some physiological
parameters can be incorporated in the models such as body size, age or
organ function (Schlender et al., 2018). Furthermore, efforts are being
undertaken to increase the physiological knowledge included in popPK
models to describe the extent and rate of absorption. Due to ethical and
practical considerations, patients representing special populations are
often underrepresented in clinical trials. Nevertheless, a popPK ap-
proach can be applied to optimize study design to obtain optimal PK
data.
Several examples of simulations in special populations have been
published. Perhaps the most studied is the paediatric population where
reviews of the development and maturation of GI physiology have been
published and implemented into commercial software platforms
(Johnson et al., 2018; Samant et al., 2015). These paediatric absorption
models provide an invaluable tool to guide formulation development in
children although large gaps in understanding the underlying phy-
siology still exist and verification of the model performance is still
limited (Kohlmann et al., 2017; Villiger et al., 2016). Other areas where
oral absorption models are being applied is for modelling the influence
of food (Tistaert et al., 2019) although effects of different diets is not
well explored currently. The effect of changed GI pH on the absorption
of ionisable drugs with pH dependent solubility is also studied and
existing absorption models can account for these changes which could
be relevant in elderly populations, as well as in those taking acid re-
ducing agents as co-medication (Cristofoletti et al., 2017), which is
often the case for oncology patients. Within the commercial software
tools, specific disease related PBPK models exist for hepatic and renal
impairment (Hsueh et al., 2018; Wagner et al., 2017) and for different
ethnicities (Barter et al., 2011), but these models include little to no
information on differences in absorption between these populations.
Publications have also reported PBPK models incorporating specific
pathophysiological changes to capture drug-disease PK interactions
(Rasool et al., 2015), but there is little done on diseases of the GI tract.
For a more thorough review of applications of PBPK to enable perso-
nalized medicine a recent paper from Hartmanshenn is recommended
(Hartmanshenn et al., 2016).
PBPK and popPK modelling are complementary methods for char-
acterizing and predicting the impact of intrinsic and extrinsic factors on
drug exposure. In order to describe and/or predict drug effects and
inform special population-based drug dosing, the extension of popPK
and PBPK models with a pharmacodynamic component is required
(Fig. 4) (Kostewicz et al., 2014; Standing, 2017).
7. How are special populations considered in regulatory
guidance?
Typical drug development requires clinical testing of medicines in a
general population and can exclude special populations. For example,
typical exclusion criteria in phase 1 and 2 trials include: adults aged
Fig. 4. Schematic illustration of the role of physiologically based and popula-
tion pharmacokinetic/ pharmacodynamics (PBPK/PD and popPK/PD) models
towards guiding drug dosing in special populations.
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<18 or >65 years; a BMI greater than 30 kg/m2; pregnancy; hepatic
dysfunction (Tamboli et al., 2010). Phase 3 trials can have broader
recruitment with increased age; increased divergence in ethnicity and
inclusion of patients with co-morbidities. Regulatory guidance on spe-
cial populations has related to differences in PK broadly, yet there is
limited focus on the GI and absorption parameters within this re-
cognition. The importance of non-clinical safety studies to support
clinical testing in special populations is detailed in the ICH M3 guidance
document (ICH, 2008). Clinical testing in special populations is detailed
in ICH E8 guidelines (ICH, 1997) and a recent review on special po-
pulations in clinical research (Grimsrud et al., 2015).
Regulatory guidance on biopharmaceutics classification system
(BCS) based biowaivers do not mention any special populations or al-
lude to any additional risk mitigation; this may cause particular risks
for certain special populations (FDA, 2017). In addition, bioequivalence
studies are likely to be undertaken in a small population of males aged
18-40 years of the same ethnicity (Western), with a BMI < 30 kg/m2
and healthy volunteers (FDA, 2014). Despite regulations stating that a
mixture of males and females should be included in bioequivalence
studies, there are issues in identifying what proportion of women are
involved in some key studies (McGregor et al., 2017). There are dif-
ferences in the requirements for bioequivalence testing in Japan due to
the lower gastric acidity reported in this population (Tamboli et al.,
2010). Also the dose number, which is defined as the ratio of drug
concentration in the administered volume to its saturation solubility in
water, is calculated using a 150 mL volume in Japan rather than the
250 mL volume used in the rest of the world (Takagi et al., 2006). This
lower volume accounts for the lower volume of co-administered water
in Japanese bioequivalence studies (Kuribayashi et al., 2016).
The paediatric decision tree that was first presented within FDA
Guidance on exposure-response relationships (FDA, 2003a) provides a
decision tree that might be used also for other special populations in
terms of extrapolation of PK data from a healthy adult population. In-
creasingly, the use of in vitro and in silico tools to mitigate risks in
special populations has been highlighted for paediatric (Batchelor et al.,
2013), elderly (Thompson et al., 2009), obese (Ghobadi et al., 2011)
and pregnant (Dallmann et al., 2018) populations. These tools are in-
creasingly supported by the regulators to support dose finding for trials
or even replace clinical trials in special populations (FDA, 2018).
Table 1 describes the guidance available that mention the inclusion
of special populations in clinical testing and the timeline for the in-
troductions is shown in Fig. 5.
8. Conclusions
The process of oral drug absorption is complex and influenced by
many compound- and GI physiology-related factors. The present review
evidences how different demographic and clinical conditions can in-
fluence the environment in the GI tract, and thus, modify the kinetics of
drug release and absorption when compared to the situation in a
healthy adult (Fig. 6). Consideration of these alterations in GI tract
physiology is key to ensure safe and effective use of oral medications.
Patient-specific PBPK models and biorelevant in vitro tests, which can
account for these changes in GI tract physiology, are extremely useful to
anticipate oral drug exposure in patient populations. Such predictive
tools can support dose finding, formulation selection, as well as the
design and conduct of clinical studies. If sufficient confidence in a
compound-specific PBPK model is given, it may even be used to waive
clinical studies, for example to show bioequivalence between different
formulations.
Although multiple studies have already addressed some aspects of
GI tract alterations in specific clinical conditions and have highlighted
how these changes can impact oral exposure, there still exist significant
knowledge gaps in this area. The relevant parameters for oral absorp-
tion, such as the volume and composition of GI fluids or the expression
level of enzymes and transporters, are often insufficiently characterised,Ta
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which is limiting, for example, the development of disease-specific
PBPK models. Moreover, a clinical condition often implies a particular
setting in terms of medication and diet, such as co-medications,
crushing of tablets, or co-administration of fibre-rich nutrition in el-
derly patients, which increases the complexity for anticipating the im-
pact on bioavailability.
Further research is therefore required using new methods and di-
agnostic tools to generate physiological reference data and improve
biopharmaceutics tools to ensure safe and efficacious drug therapies in
the targeted patient population.
Fig. 5. Timeline of regulations (listed in Table 1) introduced to provide guidance on special populations.
Fig. 6. Overview of the main GI parameters influencing oral drug absorption (black) and the corresponding disease and non-disease related conditions that are
known to alter these physiological properties (blue) [RYGB: Roux-en-Y gastric bypass; H. pylori: Helicobacter pylori; PARKD: Parkinson's disease; CF: Cystic fibrosis;
CD: celiac disease; IBD: irritable bowel syndrome; HIV: human immunodeficiency virus].
C. Stillhart, et al. European Journal of Pharmaceutical Sciences 147 (2020) 105280
20
Credit author statement
All authors contributed equally to this review.
In addition, Cordula Stillhart and Anette Müllertz were responsible
for putting the individual parts together and revising the manuscript.
Declarations of Competing Interest
None.
Acknowledgements
This article is based upon work from COST Action UNGAP
(CA16205), supported by COST (European Cooperation in Science and
Technology).
References
Abduljalil, K., Furness, P., Johnson, T.N., Rostami-Hodjegan, A., Soltani, H., 2012.
Anatomical, physiological and metabolic changes with gestational age during normal
pregnancy: a database for parameters required in physiologically based pharmaco-
kinetic modelling. Clin. Pharmacokinet. 51, 365–396.
Abdussalam, A., Al-Agili, M., Al Nebaihi, H.M., Mayo, P.R., Gabr, R.Q., Brocks, D.R.,
2018. Dietary-induced obesity and changes in the biodistribution and metabolism of
amiodarone in the rat. J. Pharm. Sci. 107, 2938–2945.
Adamska, A., Falasca, M., 2018. ATP-binding cassette transporters in progression and
clinical outcome of pancreatic cancer: What is the way forward? World J.
Gastroenterol. 24, 3222–3238.
Aebischer, T., Fischer, A., Walduck, A., Schlötelburg, C., Lindig, M., Schreiber, S., Meyer,
T., Bereswill, S., Göbel, U., 2006. Vaccination prevents Helicobacter pylori‐induced
alterations of the gastric flora in mice. FEMS Immunol. Med. Microbiol. 46, 221–229.
Afonso-Pereira, F., Dou, L., Trenfield, S.J., Madla, C.M., Murdan, S., Sousa, J., Veiga, F.,
Basit, A.W., 2018. Sex differences in the gastrointestinal tract of rats and the im-
plications for oral drug delivery. Eur. J. Pharm. Sci. 115, 339–344.
Agoram, B., Woltosz, W.S., Bolger, M.B., 2001. Predicting the impact of physiological and
biochemical processes on oral drug bioavailability. Adv. Drug Deliv. Rev. 50 (1),
S41–S67 Suppl.
Aitken, A.E., Richardson, T.A., Morgan, E.T., 2006. Regulation of drug-metabolizing en-
zymes and transporters in inflammation. Annu. Rev. Pharmacol. Toxicol. 46,
123–149.
Amidon, S., Brown, J.E., Dave, V.S., 2015. Colon-targeted oral drug delivery systems:
design trends and approaches. AAPS PharmSciTech 16, 731–741.
Ashiru, D.A., Patel, R., Basit, A.W., 2008. Polyethylene glycol 400 enhances the bioa-
vailability of a BCS class III drug (ranitidine) in male subjects but not females. Pharm.
Res. 25, 2327–2333.
Asik, M., Gunes, F., Binnetoglu, E., Eroglu, M., Bozkurt, N., Sen, H., Akbal, E., Bakar, C.,
Beyazit, Y., Ukinc, K., 2014. Decrease in TSH levels after lactose restriction in
Hashimoto's thyroiditis patients with lactose intolerance. Endocrine 46, 279–284.
Au Yeung, S.C., Ensom, M.H., 2000. Phenytoin and enteral feedings: does evidence
support an interaction? Ann. Pharmacoth. 34, 896–905.
Aw, W., Fukuda, S., 2018. Understanding the role of the gut ecosystem in diabetes
mellitus. J. Diabetes Investig. 9, 5–12.
Bai, J.P.F, Burckart, G.J., Mulberg, A.E., 2016. Literature review of gastrointestinal
physiology in the elderly, in pediatric patients, and in patients with gastrointestinal
diseases. J. Pharm. Sci. 105 (2), 476–483.
Banerjee, A., Pathak, S., Subramanium, V.D., G, D., Murugesan, R., Verma, R.S., 2017.
Strategies for targeted drug delivery in treatment of colon cancer: current trends and
future perspectives. Drug Discov. Today 22, 1224–1232.
Baquero, F., Nombela, C., 2012. The microbiome as a human organ. Clin. Microbiol. Inf.
18 (4), 2–4 Suppl.
Barkas, F., Liberopoulos, E., Kei, A., Elisaf, M., 2013. Electrolyte and acid-base disorders
in inflammatory bowel disease. Ann. Gastroenterol. 26, 23–28.
Barnes, G.L., Townley, R.R.W., 1973. Duodenal mucosal damage in 31 infants with gas-
troenteritis. Arch. Dis. Child. 48, 343.
Barter, Z., Yeo, R., Tucker, G., 2011. Prediction of differences in pharmacokinetics be-
tween chinese and caucasian populations using a mechanistic physiologically-based
pharmacokinetic model. In: 4th Asian Pacific Regional International Society for the
Study Of Xenobiotics Meeting.
Bassotti, G., Antonelli, E., Villanacci, V., Baldoni, M., Dore, M.P., 2014. Colonic motility
in ulcerative colitis. United European Gastroenterol. J. 2, 457–462.
Bassotti, G., Villanacci, V., Mazzocchi, A., Mariano, M., Incardona, P., Clerici, C., Morelli,
A., 2008. Antroduodenojejunal motor activity in untreated and treated celiac disease
patients. J. Gastroenterol. Hepatol. 23, e23–e28.
Batchelor, H., Kaukonen, A.M., Klein, S., Davit, B., Ju, R., Ternik, R., Heimbach, T., Lin,
W., Wang, J., Storey, D., 2018. Food effects in paediatric medicines development for
products co-administered with food. Int. J. Pharm. 536, 530–535.
Batchelor, H.K., Fotaki, N., Klein, S., 2014. Paediatric oral biopharmaceutics: key con-
siderations and current challenges. Adv. Drug Deliv. Rev. 73, 102–126.
Batchelor, H.K., Kendall, R., Desset-Brethes, S., Alex, R., Ernest, T.B., 2013. Application of
in vitro biopharmaceutical methods in development of immediate release oral dosage
forms intended for paediatric patients. Eur. J. Pharm. Biopharm. 85, 833–842.
Batman, P.A., Kotler, D.P., Kapembwa, M.S., Booth, D., Potten, C.S., Orenstein, J.M.,
Scally, A.J., Griffin, G.E., 2007. HIV enteropathy: crypt stem and transit cell hyper-
proliferation induces villous atrophy in HIV/Microsporidia-infected jejunal mucosa.
Aids 21, 433–439.
Becker, D., Zhang, J., Heimbach, T., Penland, R.C., Wanke, C., Shimizu, J., Kulmatycki,
K., 2014. Novel orally swallowable IntelliCap((R)) device to quantify regional drug
absorption in human GI tract using diltiazem as model drug. AAPS PharmSciTech 15,
1490–1497.
Becquemont, L., Verstuyft, C., Kerb, R., Brinkmann, U., Lebot, M., Jaillon, P., Funck-
Brentano, C, 2001. Effect of grapefruit juice on digoxin pharmacokinetics in humans.
Clin. Pharmacol. Ther. 70 (4), 311–316.
Beery, A.K., Zucker, I., 2011. Sex bias in neuroscience and biomedical research. Neurosci.
Behav. Res. 35, 565–572.
Behrns, K.E., Smith, C.D., Sarr, M.G., 1994. Prospective evaluation of gastric acid secre-
tion and cobalamin absorption following gastric bypass for clinically severe obesity.
Dig. Dis. Sci. 39, 315–320.
Bekusova, V.V., Falchuk, E.L., Okorokova, L.S., Kruglova, N.M., Nozdrachev, A.D.,
Markov, A.G., 2018. Increased paracellular permeability of tumor-adjacent areas in
1,2-dimethylhydrazine-induced colon carcinogenesis in rats. Cancer Biol. Med. 15,
251–259.
Benini, F., Mora, A., Turini, D., Bertolazzi, S., Lanzarotto, F., Ricci, C., Villanacci, V.,
Barbara, G., Stanghellini, V., Lanzini, A., 2012. Slow gallbladder emptying reverts to
normal but small intestinal transit of a physiological meal remains slow in celiac
patients during gluten-free diet. Neurogastroenterology and Motility. 24 (100-107),
e179–e180.
Bennink, R., Peeters, M., Van den Maegdenbergh, V., Geypens, B., Rutgeerts, P., De Roo,
M., Mortelmans, L., 1998. Comparison of total and compartmental gastric emptying
and antral motility between healthy men and women. Eur. J. Nucl. Med. 25,
1293–1299.
Berggren, S., Gall, C., Wollnitz, N., Ekelund, M., Karlbom, U., Hoogstraate, J., Schrenk, D.,
Lennernäs, H., 2007. Gene and protein expression of P-glycoprotein, MRP1, MRP2,
and CYP3A4 in the small and large human intestine. Mol. Pharm. 4 (2), 252–257.
Bergstrom, C.A., Holm, R., Jorgensen, S.A., Andersson, S.B., Artursson, P., Beato, S.,
Borde, A., Box, K., Brewster, M., Dressman, J., Feng, K.I., Halbert, G., Kostewicz, E.,
McAllister, M., Muenster, U., Thinnes, J., Taylor, R., Mullertz, A., 2014. Early
pharmaceutical profiling to predict oral drug absorption: current status and unmet
needs. Eur. J. Pharm. Sci. 57, 173–199.
Beringer, P.M., Owens, H., Nguyen, A., Benitez, D., Rao, A., D'Argenio, D.Z., 2012.
Pharmacokinetics of doxycycline in adults with cystic fibrosis. Antimicrob. Agents
Chemother. 56, 70–74.
Bezerra, J.A., Thompson, S.H., Morse, M., Koldovsky, O., Udall, J.N., 1990. Intestinal
permeability to intact lactose in newborns and adults. Biol. Neonate. 58, 334–342.
Bilsborough, J., Targan, S.R., Snapper, S.B., 2016. Therapeutic targets in inflammatory
bowel disease: current and future. Am. J. Gastroenterol. 3, 27 Supplements.
Blake, M.J., Abdel-Rahman, S.M., Pearce, R.E., Leeder, J.S., Kearns, G.L., 2006. Effect of
diet on the development of drug metabolism by cytochrome P-450 enzymes in
healthy infants. Pediatr. Res. 60, 717–723.
Bolme, P., Margareta, E., 1975. Influence of diarrhea on the oral absorption of penicillin V
and ampicillin in children. Scand. J. Infect. Dis. 7, 141–145.
Bonner, J.J., Vajjah, P., Abduljalil, K., Jamei, M., Rostami-Hodjegan, A., Tucker, G.T.,
Johnson, T.N., 2015. Does age affect gastric emptying time? A model-based meta-
analysis of data from premature neonates through to adults. Biopharm. Drug Dispos
36, 245–257.
Bowen, S., Hull, J., 2015. The basic science of cystic fibrosis. J. Paediatr. Child Health 25,
159–164.
Brandt, L, E.F., 2013. The prevalence and growth of obesity and obesity related illnesses
in Europe. European Center for International Political Economy, Geneva.
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A., Jemal, A., 2018. Global
cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide
for 36 cancers in 185 countries. CA:Cancer J. Clin. 68, 394–424.
Brenchley, J.M., Douek, D.C., 2008. HIV infection and the gastrointestinal immune
system. Mucosal Immunol. 1, 23–30.
Broe, A., Pottegard, A., Lamont, R.F., Jorgensen, J.S., Damkier, P., 2014. Increasing use of
antibiotics in pregnancy during the period 2000-2010: prevalence, timing, category,
and demographics. BJOG 121, 988–996.
Brogna, A., Ferrara, R., Bucceri, A.M., Lanteri, E., Catalano, F., 1999. Influence of aging
on gastrointestinal transit time. An ultrasonographic and radiologic study. Invest.
Radiol. 34, 357–359.
Brouwer, K.L.R., Aleksunes, L.M., Brandys, B., Giacoia, G.P., Knipp, G., Lukacova, V.,
Meibohm, B., Nigam, S.M, Rieder, M., Wildt, S.D., 2015. Human ontogeny of drug
transporters: review and recommendations of the pediatric transporter working
group. Clin. Pharmacol. Ther. 98, 266–287.
Brussee, J.M., Yu, H., Krekels, E.H.J., de Roos, B., Brill, M.J.E., van den Anker, J.N.,
Rostami-Hodjegan, A., de Wildt, S.N., Knibbe, C.A.J., 2018a. First-pass CYP3A-
mediated metabolism of midazolam in the gut wall and liver in preterm neonates.
CPT Pharmacometrics Syst. Pharmacol. 7, 374–383.
Brussee, J.M., Yu, H., Krekels, E.H.J., Palic, S., Brill, M.J.E., Barrett, J.S., Rostami-
Hodjegan, A., de Wildt, S.N., Knibbe, C.A.J., 2018b. Characterization of intestinal and
hepatic CYP3A-mediated metabolism of midazolam in children using a physiological
population pharmacokinetic modelling approach. Pharm. Res. 35, 182.
Buchholz, V., Berkenstadt, H., Goitein, D., Dickman, R., Bernstine, H., Rubin, M., 2013.
Gastric emptying is not prolonged in obese patients. Surg. Obes. Relat. Dis. 9,
714–717.
Budzynski, J., Klopocka, M., 2014. Brain-gut axis in the pathogenesis of Helicobacter
pylori infection. World J. Gastroenterol. 20, 5212–5225.
C. Stillhart, et al. European Journal of Pharmaceutical Sciences 147 (2020) 105280
21
Buggins, T.R., Dickinson, P.A., Taylor, G., 2007. The effects of pharmaceutical excipients
on drug disposition. Adv. Drug Deliv. Rev. 59, 1482–1503.
Calcagno, A.M., Ludwig, J.A., Fostel, J.M., Gottesman, M.M., Ambudkar, S.V., 2006.
Comparison of drug transporter levels in normal colon, colon cancer, and Caco-2
cells: impact on drug disposition and discovery. Mol. Pharm. 3, 87–93.
Camilleri, M., Malhi, H., Acosta, A., 2017. Gastrointestinal complications of obesity.
Gastroenterology 152, 1656–1670.
Health Canada., 2013. Guidance document: considerations for inclusion of women in
clinical trials and analysis of sex differences. https://www.canada.ca/en/health-
canada/services/drugs-health-products/drug-products/applications-submissions/
guidance-documents/clinical-trials/considerations-inclusion-women-clinical-trials-
analysis-data-sex-differences.html(accessed 11. September 2019).
Carríon, S., Clavé, P., 2017. Gastrointestinal disease in the older population. In: Michel,
J.P., Beattie, B.L., Martin, F.C., Walston, J. (Eds.), Oxford Textbook of Geriatric
Medicine, 3rd ed. Oxford University Press, Oxford, United Kingdom, pp. 1110.
Carswell, K.A., Vincent, R.P., Belgaumkar, A.P., Sherwood, R.A., Amiel, S.A., Patel, A.G.,
le Roux, C.W., 2014. The effect of bariatric surgery on intestinal absorption and
transit time. Obes. Surg. 24, 796–805.
Cascorbi, I., 2006. Role of pharmacogenetics of ATP-binding cassette transporters in the
pharmacokinetics of drugs. Pharmacol. Therapeut. 112, 457–473.
Cellini, M., Santaguida, M.G., Gatto, I., Virili, C., Del Duca, S.C., Brusca, N., Capriello, S.,
Gargano, L., Centanni, M., 2014. Systematic appraisal of lactose intolerance as cause
of increased need for oral thyroxine. J. Clin. Endocrinol. Metab. 99, E1454–E1458.
Centanni, M., Gargano, L., Canettieri, G., Viceconti, N., Franchi, A., Delle Fave, G.,
Annibale, B., 2006. Thyroxine in goiter, Helicobacter pylori infection, and chronic
gastritis. N. Engl. J. Med. 354, 1787–1795.
Chang, F.Y., Chen, C.Y., Lu, C.L., Luo, J.C., Jiun, K.L., Lee, S.D., Wu, C.W., 2004.
Undisturbed water gastric emptying in patients of stomach cancer. Hepato-
Gastroenterology 51, 1219–1224.
Chang, J., Rayner, C.K., Jones, K.L., Horowitz, M., 2010. Diabetic gastroparesis and its
impact on glycemia. Endocrin Metabol. Clin. 39, 745–762.
Chen, L., Prasad, G.V.R., 2018. CYP3A5 polymorphisms in renal transplant recipients:
influence on tacrolimus treatment. Pharmacogenomics Pers. Med. 11, 23–33.
Chen, M.L., 2006. Ethnic or racial differences revisited: impact of dosage regimen and
dosage form on pharmacokinetics and pharmacodynamics. Clin. Pharmacokinet. 45,
957–964.
Cheung, K.W.K., Van Groen, B.D., Burckart, G.J., Zhang, L., de Wildt, S.N., Huang, S.M.,
2019. Incorporating ontogeny in physiologically based pharmacokinetic modeling to
improve pediatric drug development: What we know about developmental changes in
membrane transporters. J. Clin. Pharm. 59, S56–S69.
Chiarioni, G., Bassotti, G., Germani, U., Battaglia, E., Brentegani, M.T., Morelli, A.,
Vantini, I., 1997. Gluten-free diet normalizes mouth-to-cecum transit of a caloric
meal in adult patients with celiac disease. Digest. Dis. Sci. 42, 2100–2105.
Chiloiro, M., Darconza, G., Piccioli, E., De Carne, M., Clemente, C., Riezzo, G., 2001.
Gastric emptying and orocecal transit time in pregnancy. J. Gastroenterol. 36,
538–543.
Ciaccio, E.J., Bhagat, G., Lewis, S.K., Green, P.H., 2016. Recommendations to quantify
villous atrophy in video capsule endoscopy images of celiac disease patients. World J.
Gastrointest. Endosc. 8, 653–662.
Cichero, J.A., 2013. Thickening agents used for dysphagia management: effect on bioa-
vailability of water, medication and feelings of satiety. Nutr. J. 12, 54.
Coghill, A.E., Shiels, M.S., Suneja, G., Engels, E.A., 2015. Elevated cancer-specific mor-
tality among HIV-Infected patients in the United States. J. Clin. Oncol. 33,
2376–2383.
Collett, A., Stephens, R.H., Harwood, M.D., Humphrey, M., Dallman, L., Bennett, J.,
Davis, J., Carlson, G.L., Warhurst, G., 2008. Investigation of regional mechanisms
responsible for poor oral absorption in humans of a modified release preparation of
the alpha-adrenoreceptor antagonist, 4-amino-6,7-dimethoxy-2-(5-methanesulfona-
mido-1,2,3,4 tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline (UK-338,003): the
rational use of ex vivo intestine to predict in vivo absorption. Drug Metab. Dispos. 36,
87–94.
Corral, J.E., Dye, C.W., Mascarenhas, M.R., Barkin, J.S., Salathe, M., Moshiree, B., 2016.
Is gastroparesis found more frequently in patients with cystic fibrosis? A systematic
review. Scientifica 2016, 2918139.
Costantine, M.M., 2014. Physiologic and pharmacokinetic changes in pregnancy. Front.
Pharmacol. 5, 65.
Cristofoletti, R., Patel, N., Dressman, J.B., 2017. Assessment of bioequivalence of weak
base formulations under various dosing conditions using physiologically based
pharmacokinetic simulations in virtual populations. Case examples: ketoconazole and
posaconazole. J. Pharm. Sci. 106, 560–569.
Cross, T.L., Kasahara, K., Rey, F.E., 2018. Sexual dimorphism of cardiometabolic dys-
function: Gut microbiome in the play? Mol. Metab 15, 70–81. https://doi.org/10.
1016/j.molmet.2018.05.016.
Cui, H., Zhang, A.J., McKeage, M.J., Nott, L.M., Geraghty, D., Guven, N., Liu, J.J., 2017.
Copper transporter 1 in human colorectal cancer cell lines: Effects of endogenous and
modified expression on oxaliplatin cytotoxicity. J. Inorg. Biochem. 177, 249–258.
Cuoco, L., Montalto, M., Jorizzo, R.A., Santarelli, L., Arancio, F., Cammarota, G.,
Gasbarrini, G., 2002. Eradication of small intestinal bacterial overgrowth and oro-
cecal transit in diabetics. Hepato-Gastroenterology 49, 1582–1586.
Da Silva, C.G., Honeywell, R.J., Dekker, H., Peters, G.J., 2015. Physicochemical proper-
ties of novel protein kinase inhibitors in relation to their substrate specificity for drug
transporters. Expert Opin. Drug Metab. Toxicol. 11, 703–717.
Dallmann, A., Solodenko, J., Ince, I., Eissing, T., 2018. Applied concepts in PBPK mod-
eling: how to extend an open systems pharmacology model to the special population
of pregnant women. CPT: Pharmacometr. Syst. Pharmacol. 7, 419–431.
Darwich, A.S., Pade, D., Ammori, B.J., Jamei, M., Ashcroft, D.M., Rostami-Hodjegan, A.,
2012. A mechanistic pharmacokinetic model to assess modified oral drug bioavail-
ability post bariatric surgery in morbidly obese patients: interplay between CYP3A
gut wall metabolism, permeability and dissolution. J. Pharm. Pharmacol. 64,
1008–1024.
De Smet, J., Van Bocxlaer, J., Boussery, K., 2013. The influence of bypass procedures and
other anatomical changes in the gastrointestinal tract on the oral bioavailability of
drugs. J. Clin. Pharmacol. 53, 361–376.
Deal, R.A., Tang, Y., Fletcher, R., Torquati, A., Omotosho, P., 2018. Understanding in-
testinal glucose transporter expression in obese compared to non-obese subjects.
Surg. Endosc. 32, 1755–1761.
Deleu, D., Ebinger, G., Michotte, Y., 1991. Clinical and pharmacokinetic comparison of
oral and duodenal delivery of levodopa/carbidopa in patients with Parkinson's dis-
ease with a fluctuating response to levodopa. Eur. J. Clin. Pharmacol. 41, 453–458.
Deligiannidis, K.M., Byatt, N., Freeman, M.P., 2014. Pharmacotherapy for mood disorders
in pregnancy: a review of pharmacokinetic changes and clinical recommendations for
therapeutic drug monitoring. J. Clin. Psychopharmacol. 34, 244–255.
Deng, J., Zhu, X., Chen, Z., Fan, C.H., Kwan, H.S., Wong, C.H., Shek, K.Y., Zuo, Z., Lam,
T.N., 2017. A review of food-drug interactions on oral drug absorption. Drugs 77,
1833–1855.
Derakhshankhah, H., Izadi, Z., Alaei, L., Lotfabadi, A., Saboury, A.A., Dinarvand, R.,
Divsalar, A., Seyedarabi, A., Barzegari, E., Evini, M., 2017. Colon cancer and specific
ways to deliver drugs to the large intestine. Anticancer Agents Med. Chem. 17,
1317–1327.
Devriese, S., Van den Bossche, L., Van Welden, S., Holvoet, T., Pinheiro, I., Hindryckx, P.,
De Vos, M., Laukens, D., 2017. T84 monolayers are superior to Caco-2 as a model
system of colonocytes. Histochem. Cell Biol. 148, 85–93.
Di Cagno, R., De Angelis, M., De Pasquale, I., Ndagijimana, M., Vernocchi, P., Ricciuti, P.,
Gagliardi, F., Laghi, L., Crecchio, C., Guerzoni, M.E., Gobbetti, M., Francavilla, R.,
2011. Duodenal and faecal microbiota of celiac children: molecular, phenotype and
metabolome characterization. BMC Microbiol. 11, 219.
Diakidou, A., Vertzoni, M., Goumas, K., Soderlind, E., Abrahamsson, B., Dressman, J.,
Reppas, C., 2009. Characterization of the contents of ascending colon to which drugs
are exposed after oral administration to healthy adults. Pharm. Res. 26, 2141–2151.
Dikman, A.E., Schonfeld, E., Srisarajivakul, N.C., Poles, M.A., 2015. Human im-
munodeficiency virus-associated diarrhea: still an issue in the era of antiretroviral
therapy. Dig. Dis. Sci. 60, 2236–2245.
Dirksen, C., Damgaard, M., Bojsen-Moller, K.N., Jorgensen, N.B., Kielgast, U., Jacobsen,
S.H., Naver, L.S., Worm, D., Holst, J.J., Madsbad, S., Hansen, D.L., Madsen, J.L.,
2013. Fast pouch emptying, delayed small intestinal transit, and exaggerated gut
hormone responses after Roux-en-Y gastric bypass. Neurogastroenterol. Motil. 25,
346–e255.
Dou, L., Mai, Y., Madla, C.M., Orlu, M., Basit, A.W., 2018. P-glycoprotein expression in
the gastrointestinal tract of male and female rats is influenced differently by food.
Eur. J. Pharm. Sci. 123, 569–575.
Downey, L., Houten, R., Murch, S., Longson, D., 2015. Recognition, assessment, and
management of coeliac disease: summary of updated NICE guidance. BMJ 351,
h4513.
Dressman, J.B., Reppas, C., 2010. Oral Drug Absorption: Prediction and Assessment,
second ed. CRC Press.
Drewe, J., Beglinger, C., Kissel, T., 1992. The absorption site of cyclosporin in the human
gastrointestinal tract. Br. J. Clin. Pharm. 33, 39–43.
Drozdzik, M., Busch, D., Lapczuk, J., Muller, J., Ostrowski, M., Kurzawski, M., Oswald, S.,
2018. Protein abundance of clinically relevant drug-metabolizing enzymes in the
human liver and intestine: a comparative analysis in paired tissue specimens. Clin.
Pharmacol. Ther. 104, 515–524.
Drozdzik, M., Groer, C., Penski, J., Lapczuk, J., Ostrowski, M., Lai, Y., Prasad, B.,
Unadkat, J.D., Siegmund, W., Oswald, S., 2014. Protein abundance of clinically re-
levant multidrug transporters along the entire length of the human intestine. Mol.
Pharm. 11, 3547–3555.
Duffield, R.A., 1996. Cystic fibrosis and the gastrointestinal tract. J. Pediatr. Health Care.
10, 51–57.
Eades, S., Boineau, F., Christensen, M., 2000. Increased tacrolimus levels in a pediatric
renal transplant patient attributed to chronic diarrhea. Pediatr. Transplant. 4, 63–66.
Edwards, M., Dai, R., Ahmed, S.A., 2018. Our Environment Shapes Us: The Importance of
environment and sex differences in regulation of autoantibody production. Front.
Immunol. 9, 478.
Effinger, A., O'Driscoll, C.M., McAllister, M., Fotaki, N., 2019. Impact of gastrointestinal
disease states on oral drug absorption - implications for formulation design - a
PEARRL review. J. Pharm. Pharmacol. 71, 674–698.
Ehrenpreis, E.D., Carlson, S.J., Boorstein, H.L., Craig, R.M., 1994. Malabsorption and
deficiency of vitamin B12 in HIV-infected patients with chronic diarrhea. Dig. Dis.
Sci. 39, 2159–2162.
El-Omar, E.M., 2006. Mechanisms of increased acid secretion after eradication of
Helicobacter pylori infection. Gut 55, 144–146.
El-Serag, H.B., Tran, T., Richardson, P., Ergun, G., 2006. Anthropometric correlates of
intragastric pressure. Scand. J. Gastroenterol. 41, 887–891.
Elborn, J.S., 2016. Cystic fibrosis. Lancet 388, 2519–2531.
Elli, L., Bardella, M.T., 2005. Motility disorders in patients with celiac disease. Scand. J.
Gastroenterol. 40, 743–749.
EMA, 2005a. Evaluation of the pharmacokinetics of medicinal products in patients with
impaired hepatic function. https://www.ema.europa.eu/documents/scientific-
guideline/guideline-evaluation-pharmacokinetics-medicinal-products-patients-
impaired-hepatic-function_en.pdf (accessed 11 September 2019).
EMA, 2005b. Gender considerations in the conduct of clinical trials. https://www.ema.
europa.eu/documents/scientific-guideline/ich-gender-considerations-conduct-
clinical-trials-step-5_en.pdf (accessed 11 September 2019).
C. Stillhart, et al. European Journal of Pharmaceutical Sciences 147 (2020) 105280
22
EMA, 2007. Role of pharmacokinetics in the development of medicinal products in the
paediatric population. https://www.ema.europa.eu/documents/scientific-guideline/
guideline-role-pharmacokinetics-development-medicinal-products-paediatric-
population_en.pdf (accessed 11 September 2019).
EMA, 2009. Guideline on the investigation of medicinal products in the term and preterm
neonate. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-
investigation-medicinal-products-term-preterm-neonate-first-version_en.pdf (ac-
cessed 29 September 2019).
EMA, 2016a. Evaluation of the pharmacokinetics of medicinal products in patients with
decreased renal function. https://www.ema.europa.eu/documents/scientific-
guideline/guideline-evaluation-pharmacokinetics-medicinal-products-patients-
decreased-renal-function_en.pdf (accessed 11 September 2019).
EMA, 2016b. Guideline on the qualification and reporting of 4 physiologically based
pharmacokinetic (PBPK) modelling and simulation. https://www.ema.europa.eu/
documents/scientific-guideline/guideline-qualification-reporting-physiologically-
based-pharmacokinetic-pbpk-modelling-simulation_en.pdf (accessed 11 September
2019).
EMA, 2017. ICH E11(R1) guideline on clinical investigation of medicinal products in the
pediatric population. https://www.ema.europa.eu/en/documents/scientific-
guideline/ich-e11r1-guideline-clinical-investigation-medicinal-products-pediatric-
population-revision-1_en.pdf (accessed 29 September 2019).
Emerging Risk Factors Collaboration,Sarwar, N., Gao, P., Seshasai, S.R., Gobin, R.,
Kaptoge, S., Di Angelantonio, E., Ingelsson, E., Lawlor, D.A., Selvin, E., Stampfer, M.,
Stehouwer, C.D., Lewington, S., Pennells, L., Thompson, A., Sattar, N., White, I.R.,
Ray, K.K., Danesh, J., 2010. Diabetes mellitus, fasting blood glucose concentration,
and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies.
Lancet 375, 2215–2222.
Enright, E., Gahan, C.M., Joyce, S., Griffin, B., 2016. The impact of the gut microbiota on
drug metabolism and clinical outcome. Yale J. Biol. Med. 89, 375–382.
Estudante, M., Morais, J.G., Soveral, G., Benet, L.Z., 2013. Intestinal drug transporters: an
overview. Adv. Drug Del. Rev. 65, 1340–1356.
Evans, D.F., Pye, G., Bramley, R., Clark, A.G., Dyson, T.J., Hardcastle, J.D., 1988.
Measurement of gastrointestinal pH profiles in normal ambulant human subjects. Gut
29, 1035–1041.
Evers, R., Piquette-Miller, M., Polli, J.W., Russel, F.G.M., Sprowl, J.A., Tohyama, K.,
Ware, J.A., de Wildt, S.N., Xie, W., Brouwer, K.L.R., International Transporter, C.,
2018. Disease-associated changes in drug transporters may impact the pharmacoki-
netics and/or toxicity of drugs: a white paper from the international transporter
consortium. Clin. Pharmacol. Ther. 104, 900–915.
Fakhoury, M., Litalien, C., Medard, Y., Cave, H., Ezzahir, N., Peuchmaur, M., Jacqz-
Aigrain, E., 2005. Localization and mRNA expression of CYP3A and P-glycoprotein in
human duodenum as a function of age. Drug Metab. Dispos. 33, 1603–1607.
Fallahi, P., Ferrari, S.M., Marchi, S., De Bortoli, N., Ruffilli, I., Antonelli, A., 2017.
Patients with lactose intolerance absorb liquid levothyroxine better than tablet le-
vothyroxine. Endocrine 57, 175–178.
Falony, G., Vandeputte, D., Caenepeel, C., Vieira-Silva, S., Daryoush, T., Vermeire, S.,
Raes, J., 2019. The human microbiome in health and disease: hype or hope. Acta
Clin. Belg. 74, 53–64.
Fasano, A., Visanji, N.P., Liu, L.W., Lang, A.E., Pfeiffer, R.F., 2015. Gastrointestinal
dysfunction in Parkinson's disease. Lancet Neurol 14, 625–639.
EMA, 2018. Reflection paper on investigation of pharmacokinetics and pharmacody-
namics in the obese population. . https://www.ema.europa.eu/documents/scientific-
guideline/reflection-paper-investigation-pharmacokinetics-pharmacodynamics-
obese-population_en.pdf (accessed 11 September 2019).
FDA, 1989. Guideline for the study of drugs likely to be used in the elderly. https://www.
fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/
UCM072048.pdf (accessed 11 September 2019).
FDA, 1993. Guideline for the study and evaluationof gender differences in the clinical
evaluation of drugs. https://www.fda.gov/downloads/ScienceResearch/
SpecialTopics/WomensHealthResearch/UCM131204.pdf (accessed 11 September
2019).
FDA, 1994. Prograf® (tacrolimus) capsules. FDA prescribing information. https://www.
accessdata.fda.gov/drugsatfda_docs/label/2012/050709s031lbl.pdf (accessed 11
September 2019).
FDA, 2019. Population Pharmacokinetics.https://www.fda.gov/downloads/Drugs/
GuidanceComplianceRegulatoryInformation/Guidances/UCM072137.pdf(accessed
11 September 2019).
FDA, 2002. Guidance for Industry - Food-effect bioavailability and fed bioequivalence
studies. https://www.fda.gov/media/70945/download(accessed 11 September
2019).
FDA, 2003a. Exposure-Response Relationships — Study Design, Data Analysis, and
Regulatory Applications. https://www.fda.gov/downloads/Drugs/
GuidanceComplianceRegulatoryInformation/Guidances/UCM072109.pdf(accessed
11 September 2019).
FDA, 2003b. Pharmacokinetics in Patients with Impaired Hepatic Function: Study Design,
Data Analysis, and Impact on Dosing and Labeling. https://www.fda.gov/
downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/
UCM072123.pdf(accessed 11 September 2019).
FDA, 2003c. CRESTOR (rosuvastatin calcium) tablets. FDA prescribing in-
formationhttps://www.accessdata.fda.gov/drugsatfda_docs/label/2010/
021366s016lbl.pdf(accessed 11 September 2019).
FDA, 2004. Pharmacokinetics in Pregnancy — Study Design, Data Analysis, and Impact
on Dosing and Labeling. https://www.fda.gov/downloads/Drugs/
GuidanceComplianceRegulatoryInformation/Guidances/UCM072133.pdf(accessed
11 September 2019).
FDA, 2005. Clinical Lactation Studies - Study Design, Data Analysis, and
Recommendations for Labelinghttps://www.fda.gov/downloads/Drugs/
GuidanceComplianceRegulatoryInformation/Guidances/UCM072097.pdf(accessed
11 September 2019).
FDA, 2010. Pharmacokinetics in Patients with Impaired Renal Function - Study Design,
Data Analysis, and Impact on Dosing and Labeling. https://www.fda.gov/
downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/
UCM204959.pdf(accessed 11 September 2019).
FDA, 2014. General Clinical Pharmacology Considerations for Pediatric Studies for Drugs
and Biological Productshttps://www.fda.gov/downloads/Drugs/
GuidanceComplianceRegulatoryInformation/Guidances/UCM425885.pdf(accessed
11 September 2019).
FDA, 2014Bioavailability and Bioequivalence Studies Submitted in NDAs or INDs —
General Considerationshttps://www.fda.gov/downloads/Drugs/
GuidanceComplianceRegulatoryInformation/Guidances/UCM389370.pdf(accessed
11 September 2019).
FDA, 2017. Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-
Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System.
Guidance for Industry.https://www.fda.gov/downloads/Drugs/
GuidanceComplianceRegulatoryInformation/Guidances/UCM070246.pdf(accessed
11 September 2019).
FDA, 2018. Physiologically Based Pharmacokinetic Analyses - Format and Content.
Guidance for industry. https://www.fda.gov/ucm/groups/fdagov-public/@fdagov-
drugs-gen/documents/document/ucm531207.pdf(accessed 11 Septemeber 2019).
Feig, C., Gopinathan, A., Neesse, A., Chan, D.S., Cook, N., Tuveson, D.A., 2012. The
pancreas cancer microenvironment. Clin. Cancer Res 18, 4266–4276.
Feldman, M., Barnett, C., 1991. Fasting gastric pH and its relationship to true hypo-
chlorhydria in humans. Dig. Dis. Sci. 36, 866–869.
Fiorini, G., Bland, J.M., Hughes, E., Castelli, V., Vaira, D., 2015. A systematic review on
drugs absorption modifications after eradication in Helicobacter pylori positive pa-
tients undergoing replacement therapy. J. Gastrointestin. Liver Dis. 24, 95–100 101 p
following 100.
Fischer, J.H., Sarto, G.E., Hardman, J., Endres, L., Jenkins, T.M., Kilpatrick, S.J., Jeong,
H., Geller, S., Deyo, K., Fischer, P.A., Rodvold, K.A., 2014. Influence of gestational
age and body weight on the pharmacokinetics of labetalol in pregnancy. Clin.
Pharmacokinet. 53, 373–383.
Fischer, M., Fadda, H.M., 2016. The effect of sex and age on small intestinal transit times
in humans. J. Pharm. Sci. 105 (2), 682–686.
Fleisher, D., Li, C., Zhou, Y., Pao, L.H., Karim, A., 1999. Drug, meal and formulation
interactions influencing drug absorption after oral administration. Clinical implica-
tions. Clin. Pharmacokinet. 36, 233–254.
Ford, R.P., Menzies, I.S., Phillips, A.D., Walker-Smith, J.A., Turner, M.W., 1985. Intestinal
sugar permeability: relationship to diarrhoeal disease and small bowel morphology.
J. Pediatr. Gastroenterol. Nutr. 4, 568–574.
Freire, A.C., Basit, A.W., Choudhary, R., Piong, C.W., Merchant, H.A., 2011. Does sex
matter? The influence of gender on gastrointestinal physiology and drug delivery. Int.
J. Pharm 415, 15–28.
GAO, 2001. Drug Safety: Most Drugs Withdrawn in Recent Years Had Greater Health Risk
for Women. United States General Accounting Office, Washington.
Gelfond, D., Borowitz, D., 2013. Gastrointestinal complications of cystic fibrosis. Clin.
Gastroenterol. Hepatol. 11, 333–342 quiz e330-331.
Geliebter, A., Hashim, S.A., 2001. Gastric capacity in normal, obese, and bulimic women.
Physiol. Behav. 74, 743–746.
Gerards, C., Leodolter, A., Glasbrenner, B., Malfertheiner, P., 2001. H. pylori infection
and visceral hypersensitivity in patients with irritable bowel syndrome. Dig. Dis 19,
170–173. https://doi.org/10.1159/000050673.
Gesquiere, I., Darwich, A.S., Van der Schueren, B., de Hoon, J., Lannoo, M., Matthys, C.,
Rostami, A., Foulon, V., Augustijns, P., 2015. Drug disposition and modelling before
and after gastric bypass: immediate and controlled-release metoprolol formulations.
Br. J. Clin. Pharmacol. 80, 1021–1030.
Gesquiere, I., Hens, B., Van der Schueren, B., Mols, R., de Hoon, J., Lannoo, M., Matthys,
C., Foulon, V., Augustijns, P., 2016. Drug disposition before and after gastric bypass:
fenofibrate and posaconazole. Br. J. Clin. Pharmacol. 82, 1325–1332.
Ghobadi, C., Johnson, T.N., Aarabi, M., Almond, L.M., Allabi, A.C., Rowland-Yeo, K.,
Jamei, M., Rostami-Hodjegan, A., 2011. Application of a systems approach to the
bottom-up assessment of pharmacokinetics in obese patients: expected variations in
clearance. Clin. Pharmacokinet. 50, 809–822.
Ghosh, T., Lewis, D.I., Axon, A.T.R., Everett, S.M., 2011. Review article: methods of
measuring gastric acid secretion. Aliment. Pharmacol. Ther. 33, 768–781.
Glicksman, C., Pournaras, D.J., Wright, M., Roberts, R., Mahon, D., Welbourn, R.,
Sherwood, R., Alaghband-Zadeh, J., le Roux, C.W., 2010. Postprandial plasma bile
acid responses in normal weight and obese subjects. Ann. Clin. Biochem. 47,
482–484.
Goh, L.-H., Mohd Said, R., Go, K.-L., 2018. Lactase deficiency and lactose intolerance in a
multiracial Asian population in Malaysia. JGH Open 6 (2), 307–310.
Gonçalvesa, P., Martel, F., 2016. Regulation of colonic epithelial butyrate transport: Focus
on colorectal cancer. Porto Biomed. J. 1, 83–89. https://doi.org/10.1016/j.pbj.2016.
04.004.
Gotanda, Y., Akagi, Y., Kawahara, A., Kinugasa, T., Yoshida, T., Ryu, Y., Shiratsuchi, I.,
Kage, M., Shirouzu, K., 2013. Expression of monocarboxylate transporter (MCT)-4 in
colorectal cancer and its role: MCT4 contributes to the growth of colorectal cancer
with vascular endothelial growth factor. Anticancer Res 33, 2941–2947.
Gotch, F., Nadell, J., Edelman, I.S., 1957. Gastrointestinal water and electroyltes. IV. The
equilibration of deuterium oxide (D2O) in gastrointestinal contents and the propor-
tion of total body water (T.B.W.) in the gastrointestinal tract. J. Clin. Invest 36,
289–296.
Grasso, C., Jansen, G., Giovannetti, E., 2017. Drug resistance in pancreatic cancer: Impact
C. Stillhart, et al. European Journal of Pharmaceutical Sciences 147 (2020) 105280
23
of altered energy metabolism. Crit. Rev. Oncol. Hematol. 114, 139–152.
Greenblatt, D.J., Harmatz, J.S., Chow, C.R., 2018. Vortioxetine disposition in obesity:
potential implications for patient safety. J. Clin. Psychopharmacol. 38, 172–179.
Grimm, M., Koziolek, M., Kuhn, J.P., Weitschies, W., 2018. Interindividual and in-
traindividual variability of fasted state gastric fluid volume and gastric emptying of
water. Eur. J. Pharm. Biopharm. 127, 309–317.
Grimsrud, K.N., Sherwin, C.M.T., Constance, J.E., Tak, C., Zuppa, A.F., Spigarelli, M.G.,
Mihalopoulos, N.L., 2015. Special population considerations and regulatory affairs
for clinical research. Clin. Res. Regul. Aff. 32, 47–56.
Groer, C., Busch, D., Patrzyk, M., Beyer, K., Busemann, A., Heidecke, C.D., Drozdzik, M.,
Siegmund, W., Oswald, S., 2014. Absolute protein quantification of clinically relevant
cytochrome P450 enzymes and UDP-glucuronosyltransferases by mass spectrometry-
based targeted proteomics. J. Pharm. Biomed. Anal. 100, 393–401.
Grover, Z., De Nardi, A., Lewindon, P.J., 2017. Inflammatory bowel disease in adoles-
cents. Aust. Fam. Physician 46, 565–571.
Guimaraes, M., Statelova, M., Holm, R., Reppas, C., Symilllides, M., Vertzoni, M., Fotaki,
N., 2019. Biopharmaceutical considerations in paediatrics with a view to the eva-
luation of orally administered drug products - a PEARRL review. J. Pharm.
Pharmacol. 71 (4), 603–642.
Gulbake, A., Jain, A., Jain, A., Jain, A., Jain, S.K., 2016. Insight to drug delivery aspects
for colorectal cancer. World J. Gastroenterol. 22, 582–599.
Gutmann, H., Hruz, P., Zimmermann, C., Beglinger, C., Drewe, J., 2005. Distribution of
breast cancer resistance protein (BCRP/ABCG2) mRNA expression along the human
GI tract. Biochem. Pharmacol. 70 (5), 695–699.
Gurumurthy, P., Ramachandran, G., Hemanth Kumar, A.K., Rajasekaran, S.,
Padmapriyadarsini, C., Swaminathan, S., Bhagavathy, S., Venkatesan, P., Sekar, L.,
Mahilmaran, A., Ravichandran, N., Paramesh, P., 2004. Decreased bioavailability of
rifampin and other antituberculosis drugs in patients with advanced human im-
munodeficiency virus disease. Antimicrob. Agents Chemother. 48, 4473–4475.
Hanley, M.J., Abernethy, D.R., Greenblatt, D.J., 2010. Effect of obesity on the pharma-
cokinetics of drugs in humans. Clin. Pharmacokin. 49, 71–87.
Haro, C., Rangel-Zuniga, O.A., Alcala-Diaz, J.F., Gomez-Delgado, F., Perez-Martinez, P.,
Delgado-Lista, J., Quintana-Navarro, G.M., Landa, B.B., Navas-Cortes, J.A., Tena-
Sempere, M., Clemente, J.C., Lopez-Miranda, J., Perez-Jimenez, F., Camargo, A.,
2016. Intestinal microbiota is influenced by gender and body mass index. PLoS One
11 (5), e0154090.
Hartmanshenn, C., Scherholz, M., Androulakis, I.P., 2016. Physiologically-based phar-
macokinetic models: approaches for enabling personalized medicine. J.
Pharmacokinet. Phar. 43, 481–504.
Haskell, H., Andrews Jr., C.W., Reddy, S.I., Dendrinos, K., Farraye, F.A., Stucchi, A.F.,
Becker, J.M., Odze, R.D., 2005. Pathologic features and clinical significance of
"backwash" ileitis in ulcerative colitis. Am. J. Surg. Pathol. 29, 1472–1481.
Hasler, W.L., Coleski, R., Chey, W.D., Koch, K.L., McCallum, R.W., Wo, J.M., Kuo, B.,
Sitrin, M.D., Katz, L.A., Hwang, J., Semler, J.R., Parkman, H.P., 2008. Differences in
intragastric pH in diabetic vs. idiopathic gastroparesis: relation to degree of gastric
retention. Am. J. Physiol. Gastrointest. Liver Physiol 294, G1384–G1391.
Hatton, G.B., Madla, C.M., Rabbie, S.C., Basit, A.W., 2018. All disease begins in the gut:
Influence of gastrointestinal disorders and surgery on oral drug performance. Int. J.
Pharm. 548, 408–422.
Hatton, G.B., Madla, C.M., Rabbie, S.C., Basit, A.W., 2019. Gut reaction: impact of sys-
temic diseases on gastrointestinal physiology and drug absorption. Drug Discov.
Today 24, 417–427.
Hebert, M.F., Easterling, T.R., Kirby, B., Carr, D.B., Buchanan, M.L., Rutherford, T.,
Thummel, K.E., Fishbein, D.P., Unadkat, J.D., 2008. Effects of pregnancy on CYP3A
and P-glycoprotein activities as measured by disposition of midazolam and digoxin: a
University of Washington specialized center of research study. Clin. Pharmacol. Ther.
84, 248–253.
Hebert, M.F., Ma, X., Naraharisetti, S.B., Krudys, K.M., Umans, J.G., Hankins, G.D.,
Caritis, S.N., Miodovnik, M., Mattison, D.R., Unadkat, J.D., Kelly, E.J., Blough, D.,
Cobelli, C., Ahmed, M.S., Snodgrass, W.R., Carr, D.B., Easterling, T.R., Vicini, P., for
the Obstetric-Fetal Pharmacology Research Unit Network, 2009. Are we optimizing
gestational diabetes treatment with glyburide? The pharmacologic basis for better
clinical practice. Clin. Pharmacol. Ther 85, 607–614.
Heikkinen, T., Ekblad, U., Palo, P., Laine, K., 2003. Pharmacokinetics of fluoxetine and
norfluoxetine in pregnancy and lactation. Clin. Pharmacol. Ther. 73, 330–337.
Hendrickson, B.A., Gokhale, R., Cho, J.H., 2002. Clinical aspects and pathophysiology of
inflammatory bowel disease. Clin. Microbiol. Rev. 15, 79–94.
Heyes, N., Kapoor, P., Kerr, I.D., 2018. Polymorphisms of the multidrug pump ABCG2: A
systematic review of their effect on protein expression, function, and drug pharma-
cokinetics. Drug Metab. Dispos. 46, 1886–1899.
Heyman, M., Abed, J., Lebreton, C., Cerf-Bensussan, N., 2012. Intestinal permeability in
coeliac disease: insight into mechanisms and relevance to pathogenesis. Gut 61,
1355–1364.
Higgs, R.H., Ellis-Pegler, R.B., Lambert, H.P., 1975. Assessment of simple methods of
measuring intestinal transit times in children with gastroenteritis. Gut 16, 458–461.
Hlavata, I., Mohelnikova-Duchonova, B., Vaclavikova, R., Liska, V., Pitule, P., Novak, P.,
Bruha, J., Vycital, O., Holubec, L., Treska, V., Vodicka, P., Soucek, P., 2012. The role
of ABC transporters in progression and clinical outcome of colorectal cancer.
Mutagenesis 27, 187–196.
Hochleitner, B., Bösmüller, C., Nehoda, H., Steurer, W., Königsrainer, A., Margreiter, R.,
Frühwirt, M., Simma, B., Ellemunter, H., Hochleitner, E., 2001. Increased tacrolimus
levels during diarrhea. Transpl. Int. 14, 230–233.
Holt, P.R., 2018. Effects of aging upon intestinal absorption. In: Moment, G.B., Adelman,
R.C., Roth, G.S. (Eds.), Nutritional Approaches to Aging Research, first ed. CRC Press,
Boca Raton, pp. 151–170.
Horowitz, M., Cook, D.J., Collins, P.J., Harding, P.E., Hooper, M.J., Walsh, J.F.,
Shearman, D.J., 1982. Measurement of gastric emptying after gastric bypass surgery
using radionuclides. Br. J. Surg. 69, 655–657.
Hsueh, C.H., Hsu, V., Zhao, P., Zhang, L., Giacomini, K.M., Huang, S.M., 2018. PBPK
modeling of the effect of reduced kidney function on the pharmacokinetics of drugs
excreted renally by organic anion transporters. Clin. Pharmacol. Ther. 103, 485–492.
Hu, T., Li, Z., Gao, C.Y., Cho, C.H., 2016. Mechanisms of drug resistance in colon cancer
and its therapeutic strategies. World J. Gastroenterol. 22, 6876–6889.
Hughes, C.A., Tseng, A., Cooper, R., 2015. Managing drug interactions in HIV-infected
adults with comorbid illness. CMAJ 187, 36–43.
Hultman, B., Mahteme, H., Sundbom, M., Ljungman, M., Larsson, R., Nygren, P., 2014.
Benchmarking of gastric cancer sensitivity to anti-cancer drugs ex vivo as a basis for
drug selection in systemic and intraperitoneal therapy. J. Exp. Clin. Cancer Res. 33,
110.
Human Microbiome Project Consortium, 2012. Structure, function and diversity of the
healthy human microbiome. Nature 486, 207–214.
ICH, 1993. ICH harmonised tripartite guideline E7: Studies in support of special popu-
lations: Geriatrics. https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/
Guidelines/Efficacy/E7/Step4/E7_Guideline.pdf(accessed 11 September 2019).
ICH, 1997. ICH harmonised tripartite guideline E8: General considerations for clinical
trials. https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/
Efficacy/E8/Step4/E8_Guideline.pdf(accessed 11 September 2019).
ICH, 1998. ICH harmonised tripartite guideline: Ethnic factors in the acceptability of
foreign clinical data E5(R1). https://www.ich.org/fileadmin/Public_Web_Site/ICH_
Products/Guidelines/Efficacy/E5_R1/Step4/E5_R1__Guideline.pdf(accessed 11
September 2019).
ICH, 2000. ICH clinical investigation of medicinal products in the pediatric population
E11. https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/
Efficacy/E11/Step4/E11_Guideline.pdf.
ICH, 2008. Non-Clinical Safety Studies for the Conduct of Human Clinical Trials and
Marketing Authorization for Pharmaceuticalshttps://www.ema.europa.eu/
documents/scientific-guideline/ich-m-3-r2-non-clinical-safety-studies-conduct-
human-clinical-trials-marketing-authorization_en.pdf(accessed 11 September 2019).
Irving, A.B., Wood, C.G., Bennotti, N.P., Babu, E., Deshpande, A., Lent, R.M., Petrick, A.,
Gabrielsen, J., Strodel, W., Gerhard, S.G., Still, D.C., Ganapathy, V., Rolston, D.D.,
2016. Nutrient transporter expression in the jejunum in relation to body mass index
in patients undergoing bariatric surgery. Nutrients 8 (11), 683.
Jackson, S.J., Leahy, F.E., McGowan, A.A., Bluck, L.J.C., Coward, W.A., Jebb, S.A., 2004.
Delayed gastric emptying in the obese: an assessment using the non-invasive 13C-
octanoic acid breath test. Diabetes Obes. Metabol. 6, 264–270.
Jamei, M., Turner, D., Yang, J., Neuhoff, S., Polak, S., Rostami-Hodjegan, A., Tucker, G.,
2009. Population-based mechanistic prediction of oral drug absorption. AAPS J 11,
225–237.
Johnson, J.A., 1997. Influence of race or ethnicity on pharmacokinetics of drugs. J.
Pharm. Sci. 86, 1328–1333.
Johnson, T.N., Bonner, J.J., Tucker, G.T., Turner, D.B., Jamei, M., 2018. Development
and applications of a physiologically-based model of paediatric oral drug absorption.
Eur. J. Pharm. Sci. 115, 57–67.
Johnson, T.N., Tanner, M.S., Taylor, C.J., Tucker, G.T., 2001. Enterocytic CYP3A4 in a
paediatric population: developmental changes and the effect of coeliac disease and
cystic fibrosis. Br. J. Clin. Pharmacol. 51, 451–460.
Jones, H.M., Chen, Y., Gibson, C., Heimbach, T., Parrott, N., Peters, S.A., Snoeys, J.,
Upreti, V.V., Zheng, M., Hall, S.D., 2015. Physiologically based pharmacokinetic
modeling in drug discovery and development: a pharmaceutical industry perspective.
Clin. Pharmacol. Ther. 97, 247–262.
Joshi, G., Kumar, A., Sawant, K., 2014. Enhanced bioavailability and intestinal uptake of
Gemcitabine HCl loaded PLGA nanoparticles after oral delivery. Eur. J. Pharm. Sci.
60, 80–89.
Jost, W.H., 2010. Gastrointestinal dysfunction in Parkinson's Disease. J. Neurol. Sci. 289,
69–73. https://doi.org/10.1016/j.jns.2009.08.020.
Juvin, P., Fèvre, G., Merouche, M., Vallot, T., Desmonts, J.M., 2001. Gastric residue is not
more copious in obese patients. Anesth. Analg. 93, 1621–1622.
Kang, H., Kim, I., Park, J., Shin, Y., Ku, J., Jung, M., Yoo, B., Kim, H., Park, J., 2004.
Identification of genes with differential expression in acquired drug-resistant gastric
cancer cells using high-density oligonucleotide microarrays. Clin. Cancer Res. 10,
272–284.
Kar, P., Jones, K.L., Horowitz, M., Chapman, M.J., Deane, A.M., 2015. Measurement of
gastric emptying in the critically ill. Clin. Nutr. 34, 557–564.
Karkossa, F., Krueger, A., Urbaniak, J., Klein, S., 2017. Simulating different dosing sce-
narios for a child-appropriate valproate ER formulation in a new pediatric two-stage
dissolution model. AAPS PharmSciTech 18, 309–316.
Kashyap, P., Farrugia, G., 2010. Diabetic gastroparesis: what we have learned and had to
unlearn in the past 5 years. Gut 59, 1716–1726.
Ke, A.B., Greupink, R., Abduljalil, K., 2018. Drug dosing in pregnant women: challenges
and opportunities in using physiologically based pharmacokinetic modeling and si-
mulations. CPT Pharmacometrics. Syst. Pharmacol. 7, 103–110.
Kenney, W.L., Chiu, P., 2001. Influence of age on thirst and fluid intake. Med. Sci. Sports.
Exerc 33, 1524–1532.
Khan, M.S., Roberts, M.S., 2018. Challenges and innovations of drug delivery in older age.
Adv. Drug. Deliv. Rev. 135, 3–38.
Kim, D.H., Yun, H.Y., Song, Y.-J., Ryu, D.H., Han, H.-S., Han, J.-H., Kim, K.B., Yoon, S.M.,
Youn, S.J., 2017. Clinical features of gastric emptying after distal gastrectomy. Ann.
Surg. Treat. Res. 93, 310–315.
Kim, J.S., Sung, H.Y., 2015. Gastrointestinal autonomic dysfunction in patients with
Parkinson's Disease. J. Mov. Disord. 8, 76–82.
Kim, M.K., Osada, T., Barry, W.T., Yang, X.Y., Freedman, J.A., Tsamis, K.A., Datto, M.,
Clary, B.M., Clay, T., Morse, M.A., Febbo, P.G., Lyerly, H.K., Hsu, D.S., 2012.
C. Stillhart, et al. European Journal of Pharmaceutical Sciences 147 (2020) 105280
24
Characterization of an oxaliplatin sensitivity predictor in a preclinical murine model
of colorectal cancer. Mol. Cancer Ther. 11, 1500–1509.
Kitis, G., Lucas, M.L., Bishop, H., Sargent, A., Schneider, R.E., Blair, J.A., Allan, R.N.,
1982. Altered jejunal surface pH in coeliac disease: its effect on propranolol and folic
acid absorption. Clin. Sci. (London) 63, 373–380.
Klingmann, V., Linderskamp, H., Meissner, T., Mayatepek, E., Moeltner, A., Breitkreutz,
J., Bosse, H.M., 2018. Acceptability of multiple uncoated minitablets in infants and
toddlers: A randomized controlled trial. J Pediatr. 201, 202–207 e201.
Knutti, R., Rothweiler, H., Schlatter, C., 1981. Effect of pregnancy on the pharmacoki-
netics of caffeine. Eur. J. Clin. Pharmacol. 21, 121–126.
Kodidela, S., Kumar, S.S., Uppugunduri, C.R.S., 2017. Developmental pattern of hepatic
drug-metabolizing enzymes in pediatric population and its role in optimal drug
treatment. Arch. Med. Health Sci. 5 (1), 115–122.
Kohlmann, P., Stillhart, C., Kuentz, M., Parrott, N., 2017. Investigating oral absorption of
carbamazepine in pediatric populations. AAPS J 19, 1864–1877.
Kostewicz, E.S., Aarons, L., Bergstrand, M., Bolger, M.B., Galetin, A., Hatley, O., Jamei,
M., Lloyd, R., Pepin, X., Rostami-Hodjegan, A., Sjogren, E., Tannergren, C., Turner,
D.B., Wagner, C., Weitschies, W., Dressman, J., 2014. PBPK models for the prediction
of in vivo performance of oral dosage forms. Eur. J. Pharm. Sci. 57, 300–321.
Koziolek, M., Grimm, M., Becker, D., Iordanov, V., Zou, H., Shimizu, J., Wanke, C.,
Garbacz, G., Weitschies, W., 2015. Investigation of pH and temperature profiles in the
GI tract of fasted human subjects using the Intellicap((R)) system. J. Pharm. Sci. 104,
2855–2863.
Koziolek, M., Grimm, M., Garbacz, G., Kuhn, J.P., Weitschies, W., 2014. Intragastric
volume changes after intake of a high-caloric, high-fat standard breakfast in healthy
human subjects investigated by MRI. Mol. Pharm. 11, 1632–1639.
Krecic-Shepard, M.E., Barnas, C., Slimko, J., Jones, M., Schwartz, J.B., 2000. Gender-
specific effects on verapamil pharmacokinetics and pharmacodynamics in humans. J.
Clin. Pharmacol 40, 219–230.
Kuehl, C.J., Wood, H.D., Marsh, T.L., Schmidt, T.M., Young, V.B., 2005. Colonization of
the cecal mucosa by Helicobacter hepaticus impacts the diversity of the indigenous
microbiota. Infect. Immun. 73, 6952–6961.
Kuitunen, M., Savilahti, E., 1996. Gut permeability to human alpha-lactalbumin, beta-
lactoglobulin, mannitol, and lactulose in celiac disease. J. Pediatr. Gastroenterol.
Nutr. 22, 197–204.
Kumagai, T., Nagayama, H., Ota, T., Nishiyama, Y., Mishina, M., Ueda, M., 2014. Sex
differences in the pharmacokinetics of levodopa in elderly patients with Parkinson
Disease. Clin. Neuropharmacol. 37, 173–176.
Kumar, R., Lieske, J.C., Collazo-Clavell, M.L., Sarr, M.G., Olson, E.R., Vrtiska, T.J.,
Bergstralh, E.J., Li, X., 2011. Fat malabsorption and increased intestinal oxalate ab-
sorption are common after Roux-en-Y gastric bypass surgery. Surgery 149, 654–661.
Kumar, S., Tana, A., Shankar, A., 2014. Cystic fibrosis - What are the prospects for a cure?
Eur. J. Int. Med 25, 803–807.
Kuribayashi, R., Takishita, T., Mikami, K., 2016. Regulatory considerations of bioequi-
valence studies for oral solid dosage forms in Japan. J. Pharm. Sci. 105 (8),
2270–2277.
Lahner, E., Annibale, B., Della Fave, G., 2009. Systematic review: Heliocobacter pylori
infection and impaired drug absorption. Aliment. Pharmacol. Ther. 29, 379–386.
Lahner, E., Virili, C., Santaguida, M.G., Annibale, B., Centanni, M., 2014. Helicobacter
pylori infection and drugs malabsorption. World J. Gastroenterol. 20, 10331–10337.
Lang, C.C., Brown, R.M., Kinirons, M.T., Deathridge, M.A., Guengerich, F.P., Kelleher, D.,
O'Briain, D.S., Ghishan, F.K., Wood, A.J., 1996. Decreased intestinal CYP3A in celiac
disease: reversal after successful gluten-free diet: a potential source of interindividual
variability in first-pass drug metabolism. Clin. Pharmacol. Ther. 59, 41–46.
Lebwohl, B., Sanders, D.S., Green, P.H.R., 2018. Coeliac disease. Lancet 391, 70–81.
Lee, J.Y., Lee, I., Chang, W.J., Ahn, S.M., Lim, S.H., Kim, H.S., Yoo, K.H., Jung, K.S., Song,
H.N., Cho, J.H., Kim, S.Y., Kim, K.M., Lee, S., Kim, S.T., Park, S.H., Lee, J., Park, J.O.,
Park, Y.S., Lim, H.Y., Kang, W.K., 2016. MCT4 as a potential therapeutic target for
metastatic gastric cancer with peritoneal carcinomatosis. Oncotarget 7,
43492–43503.
Leke, A.Z., Dolk, H., Loane, M., Casson, K., Maboh, N.M., Maeya, S.E., Ndumbe, L.D.,
Nyenti, P.B., Armstrong, O., Etiendem, D., 2018. First trimester medication use in
pregnancy in Cameroon: a multi-hospital survey. BMC Pregnancy Childb 18, 450.
Li, H., He, J., Jia, W., 2016. The influence of gut microbiota on drug metabolism and
toxicity. Expert Opin. Drug Metab. Toxicol. 12, 31–40.
Li, R., Barton, H.A., 2018. Explaining ethnic variability of transporter substrate phar-
macokinetics in healthy Asian and Caucasian subjects with allele frequencies of
OATP1B1 and BCRP: A mechanistic modeling analysis. Clin. Pharmacokinet. 57,
491–503.
Lim, S.G., Lipman, M.C., Squire, S., Pillay, D., Gillespie, S., Sankey, E.A., Dhillon, A.P.,
Johnson, M.A., Lee, C.A., Pounder, R.E., 1993. Audit of endoscopic surveillance
biopsy specimens in HIV positive patients with gastrointestinal symptoms. Gut 34,
1429–1432.
Lin, C., Ng, H.L., Pan, W., Chen, H., Zhang, G., Bian, Z., Lu, A., Yang, Z., 2015. Exploring
different strategies for efficient delivery of colorectal cancer therapy. Int. J. Mol. Sci.
16, 26936–26952.
Linnebjerg, H., Park, S., Kothare, P.A., Trautmann, M.E., Mace, K., Fineman, M., Wilding,
I., Nauck, M., Horowitz, M., 2008. Effect of exenatide on gastric emptying and re-
lationship to postprandial glycemia in type 2 diabetes. Regul. Pept. 151, 123–129.
Lozoya-Agullo, I., Gonzalez-Alvarez, I., Gonzalez-Alvarez, M., Merino-Sanjuan, M.,
Bermejo, M., 2015. In situ perfusion model in rat colon for drug absorption studies:
Comparison with small intestine and Caco-2 cell model. J. Pharm. Sci. 104,
3136–3145.
Lu, P.-J., Hsu, P.-I., Chen, C.-H., Hsiao, M., Chang, W.-C., Tseng, H.-H., Lin, K.-H., Chuah,
S.-K., Chen, H.-C., 2010. Gastric juice acidity in upper gastrointestinal diseases.
World J. Gastroenterol. 16, 5496–5501.
Ludvigsson, J.F., Card, T.R., Kaukinen, K., Bai, J., Zingone, F., Sanders, D.S., Murray, J.A.,
2015. Screening for celiac disease in the general population and in high-risk groups.
United European Gastroenterol. J. 3, 106–120.
Ma, X., Wang, H., Zhang, P., Xu, L., Tian, Z., 2019. Association between small intestinal
bacterial overgrowth and toll-like receptor 4 in patients with pancreatic carcinoma
and cholangiocarcinoma. Turk. J. Gastroenterol. 30, 177–183.
Mahajan, V., Hashmi, J., Singh, R., Samra, T., Aneja, S., 2015. Comparative evaluation of
gastric pH and volume in morbidly obese and lean patients undergoing elective
surgery and effect of aspiration prophylaxis. J. Clin. Anesth. 27, 396–400.
Maharaj, A.R., Edginton, A.N., Fotaki, N., 2016. Assessment of age-related changes in
pediatric gastrointestinal solubility. Pharm. Res. 33, 52–71.
Maharaj, A.R., Edginton, A.N., 2016. Examining small intestinal transit time as a function
of age: is there evidence to support age-dependent differences among children? Drug
Metab. Dispos 44 (7), 1080–1089.
Mai, Y., Afonso-Pereira, F., Murdan, S., Basit, A.W., 2017. Excipient-mediated alteration
in drug bioavailability in the rat depends on the sex of the animal. Eur. J. Pharm. Sci.
107, 249–255.
Mai, Y., Dou, L., Madla, C.M., Murdan, S., Basit, A.W., 2019. Sex-dependence in the effect
of pharmaceutical excipients: polyoxyethylated solubilising excipients increase oral
drug bioavailability in male but not female rats. Pharmaceutics 11.
Mai, Y., Dou, L., Murdan, S., Basit, A.W., 2018a. An animal’s sex influences the effects of
the excipient PEG 400 on the intestinal P-gp protein and mRNA levels, which has
implications for oral drug absorption. Eur. J. Pharm. Sci. 120, 53–60.
Mai, Y., Murdan, S., Awadi, M., Basit, A.W., 2018b. Establishing an in vitro permeation
model to predict the in vivo sex-related influence of PEG 400 on oral drug absorption.
Int. J. Pharm. 542 (1–2), 280–287.
Malebranche, R., Arnoux, E., Guerin, J.M., Pierre, G.D., Laroche, A.C., Pean-Guichard, C.,
Elie, R., Morisset, P.H., Spira, T., Mandeville, R., et al., 1983. . Acquired im-
munodeficiency syndrome with severe gastrointestinal manifestations in Haiti.
Lancet 2, 873–878.
Marathe, C.S., Rayner, C.K., Jones, K.L., Horowitz, M., 2013. Relationships between
gastric emptying, postprandial glycemia, and incretin hormones. Diabetes Care 36,
1396–1405.
Matsuoka, H., Maeda, K., Katsuno, H., Tsunoda, A., Koda, K., Ohge, H., Oya, M.,
Yoshioka, K., Imazu, Y., Masaki, T., 2011. Recovery of upper gastrointestinal bowel
movement after rectosigmoid cancer surgery: a pilot transit analysis. Int. Surgery 96,
281–285.
McCreight, L.J., Bailey, C.J., Pearson, E.R., 2016. Metformin and the gastrointestinal
tract. Diabetologia 59, 426–435.
McDougall, C.J., Wong, R., Scudera, P., Lesser, M., DeCosse, J.J., 1993. Colonic mucosal
pH in humans. Digest. Dis. Sci. 38, 542–545.
McEwen, B.S., 2014. Sex, stress and the brain: interactive actions of hormones on the
developing and adult brain. 17(2), 18-25.
McGready, R., Stepniewska, K., Seaton, E., Cho, T., Cho, D., Ginsberg, A., Edstein, M.D.,
Ashley, E., Looareesuwan, S., White, N.J., Nosten, F., 2003. Pregnancy and use of oral
contraceptives reduces the biotransformation of proguanil to cycloguanil. Eur. J.
Clin. Pharmacol. 59, 553–557.
McGregor, A.J., Markowitz, J.S., Forrester, J., Shader, R.I., 2017. Joining the effort: the
challenges in establishing guidelines for sex- and gender-specific research design in
clinical therapeutic studies. Clin. Ther. 39, 1912–1916.
McIlleron, H., Rustomjee, R., Vahedi, M., Mthiyane, T., Denti, P., Connolly, C., Rida, W.,
Pym, A., Smith, P.J., Onyebujoh, P.C., 2012. Reduced antituberculosis drug con-
centrations in HIV-infected patients who are men or have low weight: implications
for international dosing guidelines. Antimicrob. Agents Chemother. 56, 3232–3238.
McKinley, M.J., Denton, D.A., Thomas, C.J., Woods, R.L., Mathai, M.L., 2006. Differential
effects of aging on fluid intake in response to hypovolemia, hypertonicity, and hor-
monal stimuli in Munich Wistar rats. Proc. Natl. Acad. Sci. 103, 3450–3455.
Mearin, F., de Ribot, X., Balboa, A., Salas, A., Varas, M.J., Cucala, M., Bartolomé, R.,
Armengol, J.R., Malagelada, J.R., 1995. Does Helicobacter pylori infection increase
gastric sensitivity in functional dyspepsia? Gut 37, 47–51.
Mehandru, S., Poles, M.A., Tenner-Racz, K., Horowitz, A., HOtherey, A., Hogan, C.,
Boden, D., Racz, P., Markowitz, M., 2004. Primary HIV-1 infection is associated with
preferential depletion of CD4+ T lymphocytes from effector sites in the gastro-
intestinal tract. J. Exp. Med. 200, 761–770.
Metcalf, A.M., Phillips, S.F., Zinsmeister, A.R., MacCarty, R.L., Beart, R.W., Wolff, B.G.,
1987. Simplified assessment of segmental colonic transit. Gastroenterology 92,
40–47.
Michielan, A., D'Incà, R., 2015. Intestinal permeability in inflammatory bowel disease:
pathogenesis, clinical evaluation, and therapy of leaky gut. Mediat. Inflamm. 2015,
628157.
Miller, A.D., Smith, K.M., 2006. Medication and nutrient administration considerations
after bariatric surgery. Am. J. Health-Syst. Pharm. 63, 1852–1857.
Miyaji, H., Azuma, T., Ito, S., Abe, Y., Ono, H., Suto, H., Ito, Y., Yamazaki, Y., Kohli, Y.,
Kuriyama, M., 1999. The effect of helicobacter pylori eradication therapy on gastric
antral myoelectrical activity and gastric emptying in patients with non-ulcer dys-
pepsia. Aliment. Pharmacol. Ther. 13, 1473–1480.
Miyauchi, E., Tachikawa, M., Declèves, X., Uchida, Y., Bouillot, J.-L., Poitou, C., Oppert,
J.-M., Mouly, S., Bergmann, J.-F., Terasaki, T., Scherrmann, J.-M., Lloret-Linares, C.,
2016. Quantitative atlas of cytochrome P450, UDP-glucuronosyltransferase, and
transporter proteins in jejunum of morbidly obese subjects. Mol. Pharm. 13,
2631–2640.
Mojaverian, P., Vlasses, P.H., Kellner, P.E., Rocci Jr., M.L., 1988. Effects of gender,
posture, and age on gastric residence time of an indigestible solid: pharmaceutical
considerations. Pharm. Res. 5, 639–644.
Mooij, M.G., de Koning, B.A., Huijsman, M.L., de Wildt, S.N., 2012. Ontogeny of oral drug
absorption processes in children. Expert Opin. Drug Metab. Toxicol. 8, 1293–1303.
C. Stillhart, et al. European Journal of Pharmaceutical Sciences 147 (2020) 105280
25
Mooij, M.G., De Koning, B.E.A., Lindenbergh-Kortleve, D.J., Simons-Oosterhuis, Y., Van
Groen, B.D., Tibboel, D., Samsom, J.N., De Wildt, S.N., 2016a. Human intestinal
PEPT1 transporter expression and localization in preterm and term infants. Drug
Metab. Dispos. 44, 1014–1019.
Mooij, M.G., Nies, A.T., Knibbe, C.A.J., Schaeffeler, E., Tibboel, D., Schwab, M., de Wildt,
S.N., 2016b. Development of human membrane transporters: drug disposition and
pharmacogenetics. Clin. Pharmacokinet. 55, 507–524.
Mooij, M.G., Van De Steeg, E., Van Rosmalen, J., Windster, J.D., De Koning, B.A.E., Vaes,
W.H.J., Van Groen, B.D., Tibboel, D., Wortelboer, H.M., De Wildt, S.N., 2016c.
Proteomic analysis of the developmental trajectory of human hepatic membrane
transporter proteins in the first three months of life. Drug Metab. Dispos. 44,
1005–1013.
Morinigo, R., Moize, V., Musri, M., Lacy, A.M., Navarro, S., Marin, J.L., Delgado, S.,
Casamitjana, R., Vidal, J., 2006. Glucagon-like peptide-1, peptide YY, hunger, and
satiety after gastric bypass surgery in morbidly obese subjects. J. Clin. Endocrinol.
Metab. 91, 1735–1740.
Mouly, S., Lloret-Linares, C., Sellier, P.O., Sene, D., Bergmann, J.F., 2017. Is the clinical
relevance of drug-food and drug-herb interactions limited to grapefruit juice and
Saint-John's Wort? Pharmacol. Res. 118, 82–92.
Mourad, F.H., Barada, K.A., Saade, N.E., 2017. Impairment of small intestinal function in
ulcerative colitis: role of enteric innervation. J. Crohns Colitis 11, 369–377.
Mudie, D.M., Murray, K., Hoad, C.L., Pritchard, S.E., Garnett, M.C., Amidon, G.L.,
Gowland, P.A., Spiller, R.C., Amidon, G.E., Marciani, L., 2014. Quantification of
gastrointestinal liquid volumes and distribution following a 240 mL dose of water in
the fasted state. Mol. Pharm. 11, 3039–3047.
Mullertz, A., Fatouros, D.G., Vertzoni, M., Reppas, C., 2013. Unravelling the ultra-
structure of ascending colon fluids from patients with ulcerative colitis by cryogenic
transmission electron microscopy. J. Pharm. Pharmacol. 65, 1482–1487.
Munoz-Torres, M., Varsavsky, M., Alonso, G., 2006. Lactose intolerance revealed by se-
vere resistance to treatment with levothyroxine. Thyroid 16, 1171–1173.
Murray, K., Hoad, C.L., Mudie, D.M., Wright, J., Heissam, K., Abrehart, N., Pritchard, S.E.,
Al Atwah, S., Gowland, P.A., Garnett, M.C., AMidon, G.E., Spiller, R.C., Amidon, G.L.,
Marciani, L., 2017. Magnetic resonance imaging quantification of fasted state colonic
liquid pockets in healthy humans. Mol. Pharm. 14 (8), 2629–2638.
Mustalahti, K., Catassi, C., Reunanen, A., Fabiani, E., Heier, M., McMillan, S., Murray, L.,
Metzger, M.H., Gasparin, M., Bravi, E., Maki, M., 2010. The prevalence of celiac
disease in Europe: results of a centralized, international mass screening project. Ann.
Med. 42, 587–595.
Näslund, I., Beckman, K.W., 1987. Gastric emptying rate after gastric bypass and gas-
troplasty. Scand. J. Gastroenterol. 22, 193–201.
Neal-Kluever, A., Fisher, J., Grylack, L., Kakiuchi-Kiyota, S., Halpern, W., 2019.
Physiology of the neonatal gastrointestinal system relevant to the disposition of orally
administered medications. Drug Metab. Dispos. 47 (3), 296–313.
Neff, K.J., Le Roux, C.W., 2014. Bariatric surgery: the indications in metabolic disease.
Digest. Surg. 31, 6–12.
Neff, K.J., Olbers, T., Le Roux, C.W., 2013. Bariatric surgery: the challenges with can-
didate selection, individualizing treatment and clinical outcomes. BMC Medicine
11, 8.
Nelson John, D., Shelton, S., Kusmiesz Helen, T., Haltalin Kenneth, C., 1972. Absorption
of ampicillin and nalidixic acid by infants and children with acute shigellosis. Clin.
Pharmacol. Therap. 13, 879–886.
Niwa, T., Yamamoto, S., Saito, M., Shiraga, T., Takagi, A., 2007. Effect of cyclosporine
and tacrolimus on cytochrome p450 activities in human liver microsomes. Yakugaku
Zasshi 127 (1), 209–216.
Norman, J.L., Fixen, D.R., Saseen, J.J., Saba, L.M., Linnebur, S.A., 2017. Zolpidem pre-
scribing practices before and after Food and Drug Administration required product
labeling changes. SAGE Open Med 5, 2050312117707687.
Nugent, S.G., Kumar, D., Rampton, D.S., Evans, D.F., 2001. Intestinal luminal pH in in-
flammatory bowel disease: possible determinants and implications for therapy with
aminosalicylates and other drugs. Gut 48, 571–577.
O'Sullivan, G.M., Bullingham, R.E., 1984. The assessment of gastric acidity and antacid
effect in pregnant women by a non-invasive radiotelemetry technique. Br. J. Obstet.
Gynaecol. 91, 973–978.
Oami, T., Hattori, N., Matsumura, Y., Watanabe, E., Abe, R., Oshima, T., Takahashi, W.,
Yamazaki, S., Suzuki, T., Oda, S., 2017. The effects of fasting and massive diarrhea on
absorption of enteral vancomycin in critically ill patients: A retrospective observa-
tional study. Front. Med. 4, 70.
Obuchi, W., Ohtsuki, S., Uchida, Y., Ohmine, K., Yamori, T., Terasaki, T., 2013.
Identification of transporters associated with Etoposide sensitivity of stomach cancer
cell lines and methotrexate sensitivity of breast cancer cell lines by quantitative
targeted absolute proteomics. Mol. Pharmacol. 83, 490–500.
Odstrcil, E.A., Martinez, J.G., Santa Ana, C.A., Xue, B., Schneider, R.E., Steffer, K.J.,
Porter, J.L., Asplin, J., Kuhn, J.A., Fordtran, J.S., 2010. The contribution of malab-
sorption to the reduction in net energy absorption after long-limb Roux-en-Y gastric
bypass. Am. J. Clin. Nutr. 92, 704–713.
Ohman, I., Beck, O., Vitols, S., Tomson, T., 2008. Plasma concentrations of lamotrigine
and its 2-N-glucuronide metabolite during pregnancy in women with epilepsy.
Epilepsia 49, 1075–1080.
Olesen, A.E., Brokjaer, A., Fisher, I.W., Larsen, I.M., 2013. Pharmacological challenges in
chronic pancreatitis. World J. Gastroenterol. 19, 7302–7307.
Orditura, M., Galizia, G., Sforza, V., Gambardella, V., Fabozzi, A., Laterza, M.M.,
Andreozzi, F., Ventriglia, J., Savastano, B., Mabilia, A., Lieto, E., Ciardiello, F., De
Vita, F., 2014. Treatment of gastric cancer. World J Gastroenterol 20, 1635–1649.
Padwal, R., Brocks, D., Sharma, A.M., 2010. A systematic review of drug absorption
following bariatric surgery and its theoretical implications. Obes. Rev. 11, 41–50.
Padwal, R.S., Gabr, R.Q., Sharma, A.M., Langkaas, L.A., Birch, D.W., Karmali, S., Brocks,
D.R., 2011. Effect of gastric bypass surgery on the absorption and bioavailability of
metformin. Diabetes Care 34, 1295–1300.
Pariente, G., Leibson, T., Carls, A., Adams-Webber, T., Ito, S., Koren, G., 2016. Pregnancy-
associated changes in pharmacokinetics: A systematic review. PLoS Med 13,
e1002160.
Park, J.Y., Mitrou, P.N., Luben, R., Khaw, K.T., Bingham, S.A., 2009. Is bowel habit linked
to colorectal cancer? - Results from the EPIC-Norfolk study. Eur. J. Cancer 45,
139–145.
Patti, M.E., Houten, S.M., Bianco, A.C., Bernier, R., Larsen, P.R., Holst, J.J., Badman,
M.K., Maratos-Flier, E., Mun, E.C., Pihlajamaki, J., Auwerx, J., Goldfine, A.B., 2009.
Serum bile acids are higher in humans with prior gastric bypass: potential con-
tribution to improved glucose and lipid metabolism. Obesity 17, 1671–1677.
Perez de, la, Cruz Moreno, M., Oth, M., Deferme, S., Lammert, F., Tack, J., Dressman, J.,
Augustijns, P., 2006. Characterization of fasted-state human intestinal fluids collected
from duodenum and jejunum. J. Pharm. Pharmacol 58, 1079–1089.
Perri, F., Pastore, M., Zicolella, A., Annese, V., Quitadamo, M., Andriulli, A., 2000. Gastric
emptying of solids is delayed in celiac disease and normalizes after gluten with-
drawal. Acta paed 89, 921–925.
Peter, S., Navis, G., de Borst, M.H., von Schacky, C., van Orten-Luiten, A.C.B.,
Zhernakova, A., Witkamp, R.F., Janse, A., Weber, P., Bakker, S.J.L., Eggersdorfer, M.,
2017. Public health relevance of drug-nutrition interactions. Eur. J. Nutr. 56, 23–36.
Peters, S.A., Jones, C.R., Ungell, A.L., Hatley, O.J., 2016. Predicting drug extraction in the
human gut wall: Assessing contributions from drug metabolizing enzymes and
transporter proteins using preclinical models. Clin. Pharmacokinet. 55, 673–696.
Petrini, E., Caviglia, G.P., Pellicano, R., Saracco, G.M., Morino, M., Ribaldone, D.G., 2019.
Risk of drug interactions and prescription appropriateness in elderly patients. Ir. J.
Med. Sci.
Pfeiffer, R.F., 1998. Gastrointestinal dysfunction in Parkinson's disease. Clin. Neurosc. 5,
136–146.
Pfeiffer, R.F., 2011. Gastrointestinal dysfunction in Parkinson's disease. Parkinsonism
Relat. D. 17, 10–15.
Phan, J., Benhammou, J.N., Pisegna, J.R., 2015. Gastric hypersecretory states: in-
vestigation and management. Curr. Treat. Options Gastroenterol. 13 (4), 386–397.
Pierantozzi, M., Pietroiusti, A., Brusa, L., Galati, S., Stefani, A., Lunardi, G., Fedele, E.,
Sancesario, G., Bernardi, G., Bergamaschi, A., Magrini, A., Stanzione, P., Galante, A.,
2006. Helicobacter pylori eradication and l-dopa absorption in patients with PD and
motor fluctuations. Neurology 66, 1824–1829.
Pierantozzi, M., Pietroiusti, A., Sancesario, G., Lunardi, G., Fedele, E., Giacomini, P.,
Frasca, S., Galante, A., Marciani, M.G., Stanzione, P., 2001. Reduced L-dopa ab-
sorption and increased clinical fluctuations in Helicobacter pylori-infected
Parkinson's disease patients. Neurol. Sci. 22, 89–91.
Pinheiro, C., Longatto-Filho, A., Scapulatempo, C., Ferreira, L., Martins, S., Pellerin, L.,
Rodrigues, M., Alves, V.A., Schmitt, F., Baltazar, F., 2008. Increased expression of
monocarboxylate transporters 1, 2, and 4 in colorectal carcinomas. Virchows Arch.
452, 139–146.
Poirier, A.A., Aube, B., Cote, M., Morin, N., Di Paolo, T., Soulet, D., 2016. Gastrointestinal
dysfunctions in Parkinson's disease: symptoms and treatments. Parkinsons Dis. 2016,
6762528.
Poles, M.A., Elliott, J., Taing, P., Anton, P.A., Chen, I.S., 2001. A preponderance of
CCR5(+) CXCR4(+) mononuclear cells enhances gastrointestinal mucosal suscept-
ibility to human immunodeficiency virus type 1 infection. J. Virol. 75, 8390–8399.
Pradhan, S., Shi, X., Hijrat, K.A., Liu, C.X., Maharjan, P., 2017. An analysis of possible risk
factors contributing to delayed gastric emptying after distal gastrectomy for gastric
cancer. J. Dig. Dis. 7.
Pye, G., Evans, D.F., Ledingham, S., Hardcastle, J.D., 1990. Gastrointestinal intraluminal
pH in normal subjects and those with colorectal adenoma or carcinoma. Gut 31,
1355–1357.
Rademaker, M., 2001. Do women have more adverse drug reactions? Am. J. Clin.
Dermatol 2, 349–351.
Rao, S.S.C., Kuo, B., McCallum, R.W., Chey, W.D., DiBaise, J.K., Hasler, W.L., Koch, K.L.,
Lackner, J.M., Miller, C., Saad, R., Semler, J.R., Sitrin, M.D., Wilding, G.E., Parkman,
H.P., 2009. Investigation of colonic and whole-gut transit with wireless motility
capsule and radiopaque markers in constipation. Clin. Gastroenterol. Hepatol. 7 (5),
537–544.
Rasool, M.F., Khalil, F., Laer, S., 2015. A physiologically based pharmacokinetic drug-
disease model to predict carvedilol exposure in adult and paediatric heart failure
patients by incorporating pathophysiological changes in hepatic and renal blood
flows. Clin. Pharmacokinet. 54, 943–962.
Riethorst, D., Mols, R., Duchateau, G., Tack, J., Brouwers, J., Augustijns, P., 2016.
Characterization of human duodenal fluids in fasted and fed state conditions. J.
Pharm. Sci. 105, 673–681.
Roberts, D.J., Hall, R.I., 2013. Drug absorption, distribution, metabolism and excretion
considerations in critically ill adults. Expert Opin. Drug Metab. Toxicol. 9,
1067–1084.
Rosen, M.J., Dhawan, A., Saeed, S.A., 2015. Inflammatory bowel disease in children and
adolescents. JAMA Pediatrics 169, 1053–1060.
Rubio-Tapia, A., Murray, J.A., 2010. Celiac disease. Curr. Opin. Gastroenterol 26,
116–122.
Russell, T.L., Berardi, R.R., Barnett, J.L., Dermentzoglou, L.C., Jarvenpaa, K.M., Schmaltz,
S.P., Dressman, J.B., 1993. Upper gastrointestinal pH in seventy-nine healthy, el-
derly, North American men and women. Pharm. Res. 10, 187–196.
Saint-Marcoux, F., Knoop, C., Debord, J., Thiry, P., Rousseau, A., Estenne, M., Marquet,
P., 2005. Pharmacokinetic study of tacrolimus in cystic fibrosis and non-cystic fi-
brosis lung transplant patients and design of Bayesian estimators using limited
sampling strategies. Clin. Pharmacokinet. 44, 1317–1328.
Sairenji, T., Collins, K.L., Evans, D.V., 2017. An update on inflammatory bowel disease.
C. Stillhart, et al. European Journal of Pharmaceutical Sciences 147 (2020) 105280
26
Primary care 44, 673–692.
Samant, T.S., Mangal, N., Lukacova, V., Schmidt, S., 2015. Quantitative clinical phar-
macology for size and age scaling in pediatric drug development: A systematic re-
view. J. Clin. Pharmacol. 55, 1207–1217.
Samsel, A., Seneff, S., 2013. Glyphosate, pathways to modern diseases II: Celiac sprue and
gluten intolerance. Interdiscip. Toxicol. 6, 159–184.
Santamaría, M.M., Villafranca, J.J.A., Abilés, J., López, A.F., Rodas, L.V., Goitia, B.T.,
Navarro, P.U., 2018. Systematic review of drug bioavailability following gastro-
intestinal surgery. Eur. J. Clin. Pharmacol. 74, 1531–1545.
Sanz, Y., De Pama, G., Laparra, M., 2011. Unraveling the ties between celiac disease and
intestinal microbiota. Int. Rev. Immunol. 30, 207–218.
Sarosiek, I., Selover, K.H., Katz, L.A., Semler, J.R., Wilding, G.E., Lackner, J.M., Sitrin,
M.D., Kuo, B., Chey, W.D., Hasler, W.L., Koch, K.L., Parkman, H.P., Sarosiek, J.,
McCallum, R.W., 2010. The assessment of regional gut transit times in healthy con-
trols and patients with gastroparesis using wireless motility technology. Aliment.
Pharmacol. Ther. 31, 313–322.
Scarpello, J.H., Greaves, M., Sladen, G.E., 1976. Small intestinal transit in diabetics. BMJ
2, 1225–1226.
Schiller, C., Frohlich, C.P., Giessmann, T., Siegmund, W., Monnikes, H., Hosten, N.,
Weitschies, W., 2005. Intestinal fluid volumes and transit of dosage forms as assessed
by magnetic resonance imaging. Aliment. Pharmacol. Ther. 22, 971–979.
Schiller, L., 1999. Secretory diarrhea. Curr. Gastroenterol. Rep 1, 389–397.
Schlender, J.F., Vozmediano, V., Golden, A.G., Rodriguez, M., Samant, T.S., Lagishetty,
C.V., Eissing, T., Schmidt, S., 2018. Current strategies to streamline pharmacotherapy
for older adults. Eur. J. Pharm. Sci. 111, 432–442.
Seaman, J.S., Bowers, S.P., Dixon, P., Schindler, L., 2005. Dissolution of common psy-
chiatric medications in a Roux-en-Y gastric bypass model. Psychosomatics 46,
250–253.
Sekirov, I., Finlay, B.B., 2009. The role of the intestinal microbiota in enteric infection.
The J. Physiol. 587, 4159–4167.
Sharpstone, D., Neild, P., Crane, R., Taylor, C., Hodgson, C., Sherwood, R., Gazzard, B.,
Bjarnason, I., 1999. Small intestinal transit, absorption, and permeability in patients
with AIDS with and without diarrhoea. Gut 45, 70–76.
Shelton, M.J., Akbari, B., Hewitt, R.G., Adams, J.M., Morse, G.D., 2000. Eradication of
Helicobacter pylori is associated with increased exposure to delavirdine in hypo-
chlorhydric HIV-positive patients. J. Acquir. Immune Defic. Syndr. 24, 79–82.
Shelton, M.J., Hewitt, R.G., Adams, J.M., Cox, S.R., Chambers, J.H., Morse, G.D., 2003.
Delavirdine malabsorption in HIV-infected subjects with spontaneous gastric hy-
poacidity. J. Clin. Pharmacol. 43, 171–179.
Sheppard, J.J., Mysak, E.D., 1984. Ontogeny of infantile oral reflexes and emerging
chewing. Child Dev 55, 831–843.
Simon, K., 2016. Colorectal cancer development and advances in screening. Clin. Interv.
Aging 11, 967–976.
Simonen, M., Dali-Youcef, N., Kaminska, D., Venesmaa, S., Kakela, P., Paakkonen, M.,
Hallikainen, M., Kolehmainen, M., Uusitupa, M., Moilanen, L., Laakso, M., Gylling,
H., Patti, M.E., Auwerx, J., Pihlajamaki, J., 2012. Conjugated bile acids associate with
altered rates of glucose and lipid oxidation after Roux-en-Y gastric bypass. Obes.
Surg. 22, 1473–1480.
Simons, C.C., Schouten, L.J., Weijenberg, M.P., Goldbohm, R.A., van den Brandt, P.A.,
2010. Bowel movement and constipation frequencies and the risk of colorectal cancer
among men in the Netherlands Cohort Study on Diet and Cancer. Am. J. Epidemiol.
172, 1404–1414.
Singh-Manoux, A., Gueguen, A., Ferrie, J., Shipley, M., Martikainen, P., Bonenfant, S.,
Goldberg, M., Marmot, M., 2008. Gender differences in the association between
morbidity and mortality among middle-aged men and women. Am. J. Public Health
98, 2251–2257.
Sjoberg, A., Lutz, M., Tannergren, C., Wingolf, C., Borde, A., Ungell, A.L., 2013.
Comprehensive study on regional human intestinal permeability and prediction of
fraction absorbed of drugs using the Ussing chamber technique. Eur. J. Pharm. Sci.
48, 166–180.
Slavik, T., 2012. Human immunodeficiency virus-related gastrointestinal pathology: a
southern Africa perspective with review of the literature (part 2: neoplasms and
noninfectious disorders). Arch. Pathol. Lab. Med. 136, 316–323.
Smit, C., De Hoogd, S., Brüggemann, R.J.M., Knibbe, C.A.J., 2018. Obesity and drug
pharmacology: a review of the influence of obesity on pharmacokinetic and phar-
macodynamic parameters. Expert Opin. Drug Metab. Toxicol. 14, 275–285.
Smith, A., Henriksen, B., Cohen, A., 2011. Pharmacokinetic considerations in Roux-en-Y
gastric bypass patients. Am. J. Health-Syst. Pharm. 68, 2241–2247.
Smith, C.D., Herkes, S.B., Behrns, K.E., Fairbanks, V.F., Kelly, K.A., Sarr, M.G., 1993.
Gastric acid secretion and vitamin B12 absorption after vertical Roux-en-Y gastric
bypass for morbid obesity. Ann. Surg. 218, 91–96.
Soldin, O.P., Mattison, D.R., 2009. Sex differences in pharmacokinetics and pharmaco-
dynamics. Clin. Pharmacokinet. 48 (3), 143–157.
Soldner, A., Christians, U., Susanto, M., Wacher, V.J., Silverman, J.A., Benet, L.Z., 1999.
Grapefruit juice activates P-glycoprotein-mediated drug transport. Pharm. Res 16,
478–485.
Somani, A.A., Thelen, K., Zheng, S., Trame, M.N., Coboeken, K., Meyer, M., Schnizler, K.,
Ince, I., Willmann, S., Schmidt, S., 2016. Evaluation of changes in oral drug ab-
sorption in preterm and term neonates for Biopharmaceutics Classification System
(BCS) class I and II compounds. Br. J. Clin. Pharm. 81, 137–147.
Spak, E., Bjorklund, P., Helander, H.F., Vieth, M., Olbers, T., Casselbrant, A., Lonroth, H.,
Fandriks, L., 2010. Changes in the mucosa of the Roux-limb after gastric bypass
surgery. Histopathology 57, 680–688.
Spiller, R., 2006. Role of motility in chronic diarrhoea. J. Neurogastroenterol. Motil. 18,
1045–1055.
Standing, J.F., 2017. Understanding and applying pharmacometric modelling and
simulation in clinical practice and research. Br. J. Clin. Pharmacol. 83, 247–254.
Stappaerts, J., Annaert, P., Augustijns, P., 2013. Site dependent intestinal absorption of
darunavir and its interaction with ketoconazole. Eur. J. Pharm. Sci. 49, 51–56.
Stein, J., Makowiec, F., Starlinger, R.M., Caspary, W.F., 1999. Crohn´s Disease. In:
Caspary, W.F., Stein, J. (Eds.), Darmkrankheiten. Springer Verlag, Berlin, pp.
439–464.
Stewart, K.D., Johnston, J.A., Matza, L.S., Curtis, S.E., Havel, H.A., Sweetana, S.A.,
Gelhorn, H.L., 2016. Preference for pharmaceutical formulation and treatment pro-
cess attributes. Patient Prefer. Adherence 10, 1385–1399.
Su, A., Gandhy, R., Barlow, C., Triadafilopoulos, G., 2017. A practical review of gastro-
intestinal manifestations in Parkinson's disease. Parkinsonism Relat D 39, 17–26.
Su, Y.C., Wang, W.M., Wang, S.Y., Lu, S.N., Chen, L.T., Wu, D.C., Chen, C.Y., Jan, C.M.,
Horowitz, M., 2000. The association between Helicobacter pylori infection and
functional dyspepsia in patients with irritable bowel syndrome. Am. J. Gastroenterol.
95, 1900–1905.
Suchy, F.J., Brannon, P.M., Carpenter, T.O., Fernandez, J.R., Gilsanz, V., Gould, J.B., Hall,
K., Hui, S.L., Lupton, J., Mennella, J., Miller, N.J., Osganian, S.K., Sellmeyer, D.E.,
Wolf, M.A., 2010. National institutes of health consensus development conference:
lactose intolerance and health. Ann. Intern. Med. 152, 792–796.
Sundaram, S.S., Bove, K.E., Lovell, M.A., Sokol, R.J., 2008. Mechanisms of disease: Inborn
errors of bile acid synthesis. Nature clinical practice. Gastroenterol. Hepatol. 5,
456–468.
Suri, A., Chapel, S., Lu, C., Venkatakrishnan, K., 2015. Physiologically based and popu-
lation PK modeling in optimizing drug development: A predict-learn-confirm ana-
lysis. Clin. Pharmacol. Ther. 98, 336–344.
Takagi, T., Ramachandran, C., Bermejo, M., Yamashita, S., Yu, L.X., Amidon, G.L., 2006.
A provisional biopharmaceutical classification of the top 200 oral drug products in
the United States, Great Britain, Spain, and Japan. Mol. Pharm. 3, 631–643.
Tamargo, J., Rosano, G., Walther, T., Duarte, J., Niessner, A., Kaski, J.C., Ceconi, C.,
Drexel, H., Kjeldsen, K., Savarese, G., Torp-Pedersen, C., Atar, D., Lewis, B.S.,
Agewall, S., 2017. Gender differences in the effects of cardiovascular drugs. Eur.
Heart J 3, 163–182.
Tamboli, AM, Todkar, P, Zope, P, FJ, S., 2010. An overview on bioequivalence: regulatory
consideration for generic drug products. J. Bioequiv. Availab. 2, 86–92.
Tamura, A., Shiomi, T., Hachiya, S., Shigematsu, N., Hara, H., 2008. Low activities of
intestinal lactase suppress the early phase absorption of soy isoflavones in Japanese
adults. Clin. Nutr. 27, 248–253.
Tang, L., Fatehi, M., Linsdell, P., 2009. Mechanism of direct bicarbonate transport by the
CFTR anion channel. J. Cyst. Fibros. 8, 115–121.
Tannergren, C., Bergendal, A., Lennernas, H., Abrahamsson, B., 2009. Toward an in-
creased understanding of the barriers to colonic drug absorption in humans: im-
plications for early controlled release candidate assessment. Mol. Pharm. 6, 60–73.
Tatsuta, M., Iishi, H., Okuda, S., 1990. Gastric emptying in patients with fundal gastritis
and gastric cancer. Gut 31, 767–769.
Thaiss, C.A., Levy, M., Grosheva, I., Zheng, D., Soffer, E., Blacher, E., Braverman, S.,
Tengeler, A.C., Barak, O., Elazar, M., Ben-Zeev, R., Lehavi-Regev, D., Katz, M.N.,
Pevsner-Fischer, M., Gertler, A., Halpern, Z., Harmelin, A., Aamar, S., Serradas, P.,
Grosfeld, A., Shapiro, H., Geiger, B., Elinav, E., 2018. Hyperglycemia drives intestinal
barrier dysfunction and risk for enteric infection. Science 359, 1376–1383.
Thakkar, N., Salerno, S., Hornik, C.P., Gonzalez, D., 2017. Clinical Pharmacology Studies
in Critically Ill Children. Pharm. Res. 34, 7–24.
Thompson, C.M., Johns, D.O., Sonawane, B., Barton, H.A., Hattis, D., Tardif, R., Krishnan,
K., 2009. Database for physiologically based pharmacokinetic (PBPK) modeling:
physiological data for healthy and health-impaired elderly. J. Toxicol. Env. Heal. B
12, 1–24.
Thompson, T., Lee, M.G., Clarke, T., Mills, M., Wharfe, G., Walters, C., 2012. Prevalence
of gastrointestinal symptoms among ambulatory HIV patients and a control popula-
tion. Ann. Gastroenterol. 25, 243–248.
Thor, P., Lorens, K., Tabor, S., Herman, R., Konturek, J.W., Konturek, S.J., 1996.
Dysfunction in gastric myoelectric and motor activity in Helicobacter pylori positive
gastritis patients with non-ulcer dyspesia. J. Physiol. Pharmacol. 47, 469–476.
Tilg, H., Moschen, A.R., 2014. Microbiota and diabetes: an evolving relationship. Gut 63,
1513–1521.
Tistaert, C., Heimbach, T., Xia, B., Parrott, N., Samant, T.S., Kesisoglou, F., 2019. Food
effect projections via physiologically based pharmacokinetic modeling: predictive
case studies. J. Pharm. Sci 108, 592–602.
Tosetti, C., Corinaldesi, R., Stanghellini, V., Pasquali, R., Corbelli, C., Zoccoli, G., Di Febo,
G., Monetti, N., Barbara, L., 1996. Gastric emptying of solids in morbid obesity. Int. J.
Obes. Relat. Metab. Disord. 20, 200–205.
Touw, D., Mouton, J., Vinks, A., Horrevorts, A., Heijerman, H., 2000. Antibiotic treatment
in cystic fibrosis: Part 1: Introduction: Clinical pharmacokinetics and toxicology.
Antimicrob. Infect. Dis. Newslett. 18, 25–29.
Tran, T.H., Smith, C., Mangione, R.A., 2013. Drug absorption in celiac disease. Am. J.
Health-Syst. Pharm. 70, 2199–2206.
Trumpi, K., Emmink, B.L., Prins, A.M., van Oijen, M.G., van Diest, P.J., Punt, C.J.,
Koopman, M., Kranenburg, O., Rinkes, I.H., 2015. ABC-transporter expression does
not correlate with response to irinotecan in patients with metastatic colorectal
cancer. J. Cancer 6, 1079–1086.
Usai-Satta, P., Oppia, F., Lai, M., Cabras, F., 2018. Motility disorders in celiac disease and
non-celiac gluten sensitivity: the impact of a gluten-free diet. Nutrients 10.
Vaarala, O., Atkinson, M.A., Neu, J., 2008. The "perfect storm" for type 1 diabetes: the
complex interplay between intestinal microbiota, gut permeability, and mucosal
immunity. Diabetes 57, 2555–2562.
Van Den Abeele, J., Rayyan, M., Hoffman, I., Van de Vijver, E., Zhu, W., Augustijns, P.,
2018. Gastric fluid composition in a paediatric population: Age-dependent changes
relevant for gastrointestinal drug disposition. Eur. J. Pharm. Sci. 123, 301–311.
C. Stillhart, et al. European Journal of Pharmaceutical Sciences 147 (2020) 105280
27
van der Galiën, R., Ter Heine, R., Greupink, R., Schalkwijk, S.J., van Herwaarden, A.E.,
Colbers, A., Burger, D.M., 2019. Pharmacokinetics of HIV-integrase inhibitors during
pregnancy: mechanisms, clinical implications and knowledge gaps. Clin.
Pharmacokinet. 58, 309–323.
van Groen, B.D., van de Steeg, E., Mooij, M.G., van Lipzig, M.M.H., de Koning, B.A.E.,
Verdijk, R.M., Wortelboer, H.M., Gaedigk, R., Bi, C., Leeder, J.S., van Schaik, R.H.N.,
van Rosmalen, J., Tibboel, D., Vaes, W.H., de Wildt, S.N., 2018. Proteomics of human
liver membrane transporters: a focus on fetuses and newborn infants. Eur. J. Pharm.
Sci. 124, 217–227.
Van Hartesveldt, C., Joyce, J.N., 1986. Effects of estrogen on the basal ganglia. Neurosci.
Biobehav. Rev. 10, 1–14.
van Oosterhout, J.J., Dzinjalamala, F.K., Dimba, A., Waterhouse, D., Davies, G., Zijlstra,
E.E., Molyneux, M.E., Molyneux, E.M., Ward, S., 2015. Pharmacokinetics of anti-
tuberculosis drugs in HIV-positive and HIV-negative adults in Malawi. Antimicrob.
Agents Chemother. 59, 6175–6180.
Van Orten-Luiten, A.C.B., 2017. Food for the Aging Population, Food-Drug Interactions in
Elderly, second ed. Woodhead Publishers.
van Rongen, A., Brill, M.J.E., Vaughns, J.D., Välitalo, P.A.J., van Dongen, E.P.A., van
Ramshorst, B., Barrett, J.S., van den Anker, J.N., Knibbe, C.A.J., 2018. Higher mid-
azolam clearance in obese adolescents compared with morbidly obese adults. Clin.
Pharmacokin. 57, 601–611.
Van Thiel, D.H., Gavaler, J.S., Joshi, S.N., Sara, R.K., Stremple, J., 1977. Heartburn of
pregnancy. Gastroenterology 72, 666–668.
Varela, J.E., Hinojosa, M., Nguyen, N., 2009. Correlations between intra-abdominal
pressure and obesity-related co-morbidities. Surg. Obes. Relat. Dis. 5, 524–528.
Vertzoni, M., Goumas, K., Soderlind, E., Abrahamsson, B., Dressman, J.B., Poulou, A.,
Reppas, C., 2010. Characterization of the ascending colon fluids in ulcerative colitis.
Pharm. Res. 27, 1620–1626.
Very, N., Lefebvre, T., El Yazidi-Belkoura, I., 2018. Drug resistance related to aberrant
glycosylation in colorectal cancer. Oncotarget 9, 1380–1402.
Vet, N.J., Brussee, J.M., de Hoog, M., Mooij, M.G., Verlaat, C.W., Jerchel, I.S., van Schaik,
R.H., Koch, B.C., Tibboel, D., Knibbe, C.A., de Wildt, S.N., Skic, 2016. Inflammation
and organ failure severely affect midazolam clearance in critically ill children. Am. J.
Respir. Crit. Care Med. 194, 58–66.
Vilela, E.G., Torres, H.O., Ferrari, M.L., Lima, A.S., Cunha, A.S., 2008. Gut permeability to
lactulose and mannitol differs in treated Crohn's disease and celiac disease patients
and healthy subjects. Braz. J. Med. Biol. Res. 41, 1105–1109.
Villiger, A., Stillhart, C., Parrott, N., Kuentz, M., 2016. Using physiologically based
pharmacokinetic (PBPK) modelling to gain insights into the effect of physiological
factors on oral absorption in paediatric populations. AAPS J 18, 933–947.
Virally-Monod, M., Tielmans, D., Kevorkian, J.P., Bouhnik, Y., Flourie, B., Porokhov, B.,
Ajzenberg, C., Warnet, A., Guillausseau, P.J., 1998. Chronic diarrhoea and diabetes
mellitus: prevalence of small intestinal bacterial overgrowth. Diabetes Metab 24,
530–536.
Wagner, C., Zhao, P., Arya, V., Mullick, C., Struble, K., Au, S., 2017. Physiologically based
pharmacokinetic modeling for predicting the effect of intrinsic and extrinsic factors
on darunavir or lopinavir exposure coadministered with ritonavir. J. Clin. Pharmacol.
57, 1295–1304.
Wang, G., Agenor, K., Pizot, J., Kotler, D.P., Harel, Y., Van Der Schueren, B.J., Quercia, I.,
McGinty, J., Laferrere, B., 2012. Accelerated gastric emptying but no carbohydrate
malabsorption 1 year after gastric bypass surgery (GBP). Obes. Surg 22, 1263–1267.
Wangboonskul, J., White, N.J., Nosten, F., ter Kuile, F., Moody, R.R., Taylor, R.B., 1993.
Single dose pharmacokinetics of proguanil and its metabolites in pregnancy. Eur. J.
Clin. Pharmacol. 44, 247–251.
Webber, L., Divajeva, D., Marsh, T., McPherson, K., Brown, M., Galea, G., Breda, J., 2014.
The future burden of obesity-related diseases in the 53 WHO European-Region
countries and the impact of effective interventions: a modelling study. BMJ open 4,
e004787.
Wegener, M., Borsch, G., Schaffstein, J., Luerweg, C., Leverkus, F., 1990. Gastrointestinal
transit disorders in patients with insulin-treated diabetes mellitus. Dig. Dis. 8, 23–36.
Whitehead, E.M., Smith, M., Dean, Y., O'Sullivan, G., 1993. An evaluation of gastric
emptying times in pregnancy and the puerperium. Anaesthesia 48, 53–57.
Wisen, O., Johansson, C., 1992. Gastrointestinal function in obesity: motility, secretion,
and absorption following a liquid test meal. Metabolism 41, 390–395.
Witkamp, R.F., van Norren, K., 2018. Let thy food be thy medicine....when possible. Eur.
J. Pharmacol. 836, 102–114.
Wolking, S., Schaeffeler, E., Lerche, H., Schwab, M., Nies, A.T., 2015. Impact of genetic
polymorphisms of ABCB1 (MDR1, P-glycoprotein) on drug disposition and potential
clinical implications: update of the literature. Clin. Pharmacokinet. 54, 709–735.
Wollmer, E., Klein, S., 2017. A review of patient-specific gastrointestinal parameters as a
platform for developing in vitro models for predicting the in vivo performance of oral
dosage forms in patients with Parkinson's disease. Int. J. Pharm. 533, 298–314.
Won, C.S., Oberlies, N.H., Paine, M.F., 2012. Mechanisms underlaying food-drug inter-
actions: inhibition of intestinal metabolism and transport. Pharmacol. Ther. 136 (2),
186–201.
Wu, H.F., Hristeva, N., Chang, J., Liang, X., Li, R., Frassetto, L., Benet, L.Z., 2017.
Rosuvastatin pharmacokinetics in asian and white subjects wild type for both
OATP1B1 and BCRP under control and inhibited conditions. J. Pharm. Sci. 106,
2751–2757.
Xavier, R.J., Podolsky, D.K., 2007. Unravelling the pathogenesis of inflammatory bowel
disease. Nature 448, 427–434.
Yang, Y., Carlin, A.S., Faustino, P.J., Motta, M.I, Hamad, M.L., He, R., Watanuki, Y.,
Pinnow, E.E., Khan, M.A., 2009. Participation of women in clinical trials for new
drugs approved by the food and drug administration in 2000-2002. J. Womens
Health 18, 303–310.
Yoon, D.Y., Mansukhani, N.A., Stubbs, V.C., Helenowski, I.B., Woodruff, T.K., Kibbe,
M.R., 2014. Sex bias exists in basic science and translational surgical research.
Surgery 156, 508–516.
Yu, B., Xie, J., 2016. Identifying therapeutic targets in gastric cancer: the current status
and future direction. Acta Biochim. Biophys. Sin. 48, 90–96.
Yung, D., Douglas, S., Hobson, A.R., Giannakou, A., Plevris, J.N., Koulaouzidis, A., 2016.
Morpho-functional evaluation of small bowel using wireless motility capsule and
video capsule endoscopy in patients with known or suspected Crohn's disease: pilot
study. Endosc. Int. Open 4, E480–E486.
Zacchi, P., Mearin, F., Humbert, P., Formiguera, X., Malagelada, J.R., 1991. Effect of
obesity on gastroesophageal resistance to flow in man. Dig. Dis. Sci. 36, 1473–1480.
Zahorska-Markiewicz, B., Jonderko, K., Lelek, A., Skrzypek, D., 1986. Gastric emptying in
obesity. Hum. Nutr. Clin. Nutr. 40, 309–313.
Zanger, U.M., Schwab, M., 2013. Cytochrome P450 enzymes in drug metabolism: reg-
ulation of gene expression, enzyme activities, and impact of genetic variation.
Pharmacol. Therap. 138, 103–141.
Zevin, A.S., McKinnon, L., Burgener, A., Klatt, N.R., 2016. Microbial translocation and
microbiome dysbiosis in HIV-associated immune activation. Curr. Opin. HIV AIDS 11,
182–190.
Zhong, H.J., Yuan, Y., Xie, W.R., Chen, M.H., He, X.X., 2016. Type 2 diabetes mellitus is
associated with more serious small intestinal mucosal injuries. PLoS One 11,
e0162354.
Zimmermann, M., Zimmermann-Kogadeeva, M., Wegmann, R., Goodman, A.L., 2019.
Mapping human microbiome drug metabolism by gut bacteria and their genes.
Nature 570, 462–467.
Zimmermann, T., Laufen, H., Yeates, R., Scharpf, F., Riedel, K.D., Schumacher, T., 1999.
The pharmacokinetics of extended-release formulations of calcium antagonists and of
amlodipine in subjects with different gastrointestinal transit times. J. Clin.
Pharmacol. 39, 1021–1031.
Zoppi, G., Andreotti, G., Pajno-Ferrara, F., Njai, D.M., Gaburro, D., 1972. Exocrine pan-
creas function in premature and full term neonates. Pediatr. Res. 6, 880–886.
C. Stillhart, et al. European Journal of Pharmaceutical Sciences 147 (2020) 105280
28
